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Patients with cystic fibrosis often have chronic pulmonary
infection caused by mucoid, alginate producing Pseudomonas aeruginosa.
These bacteria are difficult to eradicate and are indicati ve of cystic
fibrosis. The hypothesis that the production of alginate confers a
selective advantage on the mucoid form of P.aeruginosa by impairing
the host's immune response was examined. Alginate obtained from
a mucoid strain of P.aeruginosa inhibited the phagocytosis of an
isogenic non-mucoid revertant by rat alveolar macrophages. The
phagocytosis of Staphylococcus albus and the binding of unopsonised bact¬
eria were also inhibited in a dose-dependent fashion. Inhibition
occurred when the macrophages were pre-treated with alginate and
when the alginate was added with the bacteria to the macrophage mono¬
layers. The inhibition was reduced when the macrophages were washed
vigorously after alginate treatment and phagocytosis returned to control
levels when the macrophages were re-incubated in normal serum after
alginate treatment. The binding of antibody sensitised sheep erythro¬
cytes (EA_,) to Pc receptors and the nonspecific uptake of latex particles
was also inhibited by pseudomonas alginate in a dose-dependent fashion.
Alginic acid, a polysaccharide purified from seaweed, which is
structurally similar to alginate also inhibited the phagocytosis of
non-mucoid P.aeruginosa by rat alveolar macrophages. This indicated
that the observed effects of alginate were not due to bacterial toxins
contaminating the material. Alginate inhibited the opsonisation of
the non-mucoid revertant with a non-agglutinating immune serum. At
high alginate concentrations, the observed inhibition reached 100%.
These results suggest that the alginate acts as a barrier, surrounding
the macrophage or bacteria, to prevent the attachment of bacteria and
other particles to the macrophage membrane and inhibit opsonisation.
The importance of this impairment of the host's immune response by
pseudomonas alginate is discussed.
Mucoid P.aeruginosa are rarely eradicated from the lung, even
with extensive antibiotic therapy. One of the reasons for this may
be that only low levels are attained in the cystic fibrosis lung.
The further possibility that antibiotics may affect alveolar macro¬
phages, in which function is already impaired by alginate was examined.
Three antibiotics, azlocillin, ticarcillin and tobramycin, that are used
in the treatment of P, aeruginosa lung infections in cystic fibrosis
patients were studied at low concentrations for their effect on rat
alveolar macrophages, Azlocillin, a semi-synthetic penicillin inhibited
the phagocytosis of opsonised non-mucoid P.aeruginosa and the binding
of antibody sensitised sheep erythrocytes when added with the indicator
cells to the macrophage monolayers. However, no effect was observed
when the macrophages were pre-treated with azlocillin for 30 minutes.
Ticarcillin, a semi-synthetic penicillin that is less active as an
antimicrobial agent in vitro than azlocillin,had no effect on alveolar
macrophages at the concentrations used in this study. Tobramycin,
a highly active aminoglycoside inhibited the phagocytosis of opsonised
non-mucoid P.aeruginosa and the binding of unopsonised bacteria and
enhanced Ec receptor expression when the macrophages were pretreated
with antibiotic. These effects were dose, temperature and time-
dependent. Inhibition of both phagocytosis ana binding of EA^ was
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observed when tobramycin was co-incubated with the macrophage mono¬
layers and indicator cells.
Tobramycin and azlocillin had no effect on opsonised P.aeruginosa
or sensitised sheep erythrocytes, except that the phagocytosis of
EA^ was increased after treatment of the erythrocytes with tobramycin.
Culture supernatants prepared from macrophages treated with
tobramycin inhibited the binding of EA„ to macrophage monolayers.
The inhibition was directly proportional to the amount of supernatant
added to the red cells and was greatest when the supernatant had been
prepared from macrophages incubated with the antibiotic for one hour.
When macrophage monolayers were incubated for one hour with supernatants
from tobramycin treated macrophages subsequent binding of EA_, was
increased. The supernatants also caused the agglutination of antibody
sensitised erythrocytes. This activity was lost after the supernatants
had been absorbed against formalised EA^. The supernatants were
further analysed by polyacrylamide gel electrophoresis. Those from
antibiotic treated macrophages contained more material compared to
control supernatants at two bands of approximately US,000 and 66,000
daltons. It is proposed that the supernatants contain released Fc
receptors and that tobramycin causes an increase in the shedding of
Fc receptors from the macrophage membrane. The mechanism of action
of tobramycin and the in vivo relevance of these results is discussed.
Studies on human peripheral blood monocytes were also carried
out. Azlocillin enhanced the binding of EA^ to monocytes when co-
incubated with the erythrocytes and monocyte monolayers while ticar-
cillin had no effect. Tobramycin inhibited the binding of EA^ to Fc
receptors when added with the erythrocytes to the monolayers. When
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results from different individuals were pooled, pre-treatment with tobra¬
mycin had no effect on Fc receptor expression. However when monocytes
were taken from the same individual on different days, tobramycin
inhibited or enhanced Fc receptor expression according to the
individual studied. Therefore a longitudinal study may give different
results than when results from different individuals are pooled. These
results indicate the necessity for further work on human cells and
their significance is discussed.
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Cystic fibrosis (CP) is currently the most common fatal hereditary
disease of Caucasian populations. The incidence is one per 2,000 live
births and it is inherited as an autosomal recessive trait. Clinically
CP is characterised by elevated sweat electrolytes, chronic obstructive
pulmonary infection and pancreatic insufficiency. However the main
cause of death, is progressive pulmonary deterioration with character¬
istic intermittent exacerbations of chronic bacterial infection.
The earliest known reference to CP comes from the German folklore,
which literally translated states "The child will soon die, whose brow
tastes salty when kissed" (Wood _et al. , 1976). In 1938, Dorothy
Andersen distinguished CP from coeliac disease and described the
destructive lesion of the pancreas associated with CP. Initially CP
was considered to involve the pancreas as the sole target organ, but it
soon became apparent that CP patients had a generalised disorder of mucus
secretion. This was shown to affect most exocrine glands and other organs
particularly the lung. Today, pancreatic insufficiency and its compli¬
cations can be effectively overcome, by addition of pancreatic supple¬
ments to the diet. The high mortality of these patients is new a result
of chronic pulmonary infection, and effective treatment is the
main problem of CP today.
When CP was first recognised, few patients reached adolescence as
the disease was invariably and rapidly fatal. With improved diagnosis
and early patient care, 50% of all patients survive to 20 years of age
(Warwick, 1982). This has resulted in an increasing adolescent and
adult population, so that CP is no longer a strictly paediatric disease.
3.
1.1 'The Bacteriology of Cystic Fibrosis
Staphylococcus aureus, Haemophilus influenzae and Pseudomonas
aeruginosa are the three main pathogens that have been involved in
CP pulmonary infection. However as survival has improved, a changing
pattern of infection has been observed.
In 19U6, Staph, aureus was the most common etiological agent isolated
from the sputum of CP patients (di Sant 'Agnese and Andersen, 19U6). With
the advent of effective antistaphylococcal antibiotics, infection with
Staph, aureus decreased significantly, while infection with P.aeruginosa
began to increase (Mearns et al., 1972). The importance of Staph, aureus
as a cause of mortality in CP patients has continued to decrease and is
now minimal (Hj6iby, 1982). In 1963> Iacocca et al. , reported that
Staph.aureus remained predominant, but that the incidence of P.aeruginosa
and H.influenzae were increasing. 5.influenzae is also a significant
pathogen, but can be treated effectively with appropriate antibiotics
(McCrae and Raeburn, 197U)-
P.aeruginosa is presently the predominant bacterial pathogen in CP,
particularly in older patients and occurs in 70-90% of CP cases (isles
et al. , I98I4.). Following primary colonisation with classic non-mucoid
forms of P.aeruginosa, mucoid, alginate producing forms of the same micro¬
organism emerged and came to predominate with a corresponding increase
in pulmonary deterioration (Doggett et al., 1966; Doggett, 1969; Hoiby,
1975). In 1982, it was reported that non-mucoid forms of P.aeruginosa
appeared to be of no major significance, further indicating that the
mucoid form is associated with a poor prognosis (Henry et al., 1982).
Although P.aeruginosa, Staph.aureus and H.influenzae are often
isolated simultaneously from the same individual (Mearns, 1980), there
is a lower prevalence of the two latter bacterial species in patients
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with P.aeruginosa infection (H^iby, 1982).
A recent report has shown that the prevalence of P.cepacia in CP
has increased from ^01/o in 1971 to 18% in 1981, while; that of P.aeruginosa
has remained unchanged. P.cepacia is uniformly resistant to all commonly
used anti-pseudomonal agents and infected patients have greater impair¬
ment of pulmonary function than those infected with P.aeruginosa
(isles et al. , 1981+).
Although P.cepacia may become a problem in the future, at present
mucoid P.aeruginosa is the predominant pathogen and cause of death in
patients with CP (H^iby, 1982).
5.
2.0 THE IMMUNE SYSTEM IN CYSTIC FIBROSIS
A considerable amount of work has been performed to determine
whether or not an immunological defect is involved in CP. Such a
defect could be either generalised or localised to the bronchial tree.
However while CP patients are characteristically highly susceptible to
respiratory tract bacterial infection, they are no more susceptible than
normal individuals to infection at other sites, such as the skin, gut,
urinary tract or central nervous system, and bacteraemia occurs rarely.
This implies a defect in local rather than systemic defense mechanisms
(Hodson, 1980). Both systems will be reviewed, to give a clear picture
of the immunological state of the chronically infected CP patient.
2.1.0 The systemic humoral immune response
The total serum concentrations of IgG, IgA and IgM are normal to
elevated in CP and tend to parallel the observed chronic infection
(Schwartz, 1966; Wallwork et al., 197b)- The majority of CP patients
have high levels of serum antibody against bacterial outer membrane
proteins and bacteria infecting their lungs (Speert et al. , 1981;). This
may play a role in keeping the infection localised and explain the rarity
of systemic infections observed in these patients (H^iby and Wilk, 1975)-
However, 2C^ of CP patients under the age of ten have hypogammaglobu11 inemia
(Matthews et_ al., 1980). This condition is only found in patients with
a low incidence of pulmonary infection as age-matched CP patients with
chronic infection were shown to have high levels of serum antibody. It
was thus suggested that an initial failure to recognise antigen when
it crosses the gut or respiratory mucosa is followed by a hyperimmune
response to the infecting organism (Matthews et al., 1980).
Serum precipitins are demonstrably increased after the emergence
of mucoid P.aeruginosa (Doggett and Harrison, 1972) and their presence
is closely associated with a poor prognosis (H^iby et al., 1975)*
Antibody production has been investigated at the cellular level
by a haemolytic plaque forming cell (PPC) assay (Gotz et al., 1981).
The ability of peripheral mononuclear cells obtained from patients with
CP to form PPC upon stimulation with pokeweed mitogen was significantly
decreased compared to healthy controls. However, there was no corre¬
lation between the level of serum IgG and the number of PPC cells, so
this observation may be of no relevance in vivo (Gotz et al., 1982).
Other studies showed that the formation of spontaneous PFC that indicate
in vivo activation of B cells was significantly higher in CP patients
in good physical condition than controls, but depressed in patients with
a bad prognosis, where suppression of antibody response may occur in
vivo (Harper et al. , I98O; Sorensen et al. , "1983)•
There is a high prevalence of autoantibodies in the serum and
sputum of CP patients. IgG rheumatoid factor has been detected in 88%
of patients and is not dependent on infection with P. aeruginosa (Schi<zftz
et al., 1979b). Antinuclear autoantibodies have also been detected and
are probably associated with the tissue damage that accompanies prolonged
respiratory infection (H^iby and Wilk, 1975).
2.1.1 Complement
There was no functional difference between CP patients and control
subjects in any of the complement components, whole complement or C^
inactivator, when a haemolytic complement assay was employed (Conover
et al., 1973). Similarly, there were no differences observed between
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C1a, C3,Cl4. and total haemolytic complement in patients infected with
mucoid P.aeruginosa and those that had no infection (Sch/itz et al.,
1977). However using radial immunodiffusion C3 serum levels were
found to be higher in CP than normal (Conover et al., 1973)
decreased in P.aeruginosa infected patients (Gotz and Lubec, 1978).
However, these defects may represent secondary changes as total comple¬
ment levels were similar in CP and normal.
2.1.2 neutrophilis
There does not appear to be any inherent defect in neutrophils
(PMN) from patients with CP (Hill et al., 197U). In fact they have
been shown to be hyperfunctional when not in contact with autologous
serum (Holland et al., 1981).
Chemotactic activity of PMN obtained from CP patients was found
to be normal in one study that used the agarose plate method (Church
et al. , 1980), but significantly depressed .in another study that used
modified Boyden chambers (Zielinski et al., 1982). These contra¬
dictory results may be due to differences in the techniques employed
for measuring chemotaxis and indicate that an inherent neutrophil
defect is unlikely.
2.1.3 Lymphocytes
Absolute numbers of T and B lymphocytes in the blood increase
with pulmonary infection, although the percentage of each cell type
remains normal (Ejzfiby and Mathieson, 197U). The ratio between helper
(OKTij.) and suppressor (0KT8) T cells has also been found to be normal
(van Geffel et al., 1982; Wilson and Pudenberg, 1982), although increased
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levels of suppressor T cells have been reported during chronic pulmonary
infection in CF (Sorensen et al. , 1980).
CP patients in good clinical condition have normal lymphocyte
responses to P.aeruginosa (Sorensen et al., 1981a, 1981b). B cell
transformation in response to poke weed mitogen or whole Staph.aureus
was significantly impaired in CP patients in vitro and was not a result
of increased suppression by T cells (Sorensen et al., 1983)-
These lymphocyte abnormalities in CP probably arise as a result
of pulmonary infection, as immunoglobulin levels are high and patients
who are free from infection have normal responses. However any change
in lymphocyte function may contribute to the establishment and patho¬
genicity of chronic pulmonary infection.
2.2 Pulmonary immune defense
The normal immune defense mechanisms of the lung have been exten¬
sively reviewed (Kaltreider, 1976; Green et al., 1977; Reynolds, 1978).
This section will concentrate on immune function in CP and how it differs
from that observed in the normal lung. Mucociliary transport is impaired
in CP (Wood et al., 1975). However ciliary beat frequency in vitro
is normal, suggesting that the abnormality is present in the mucus
secretion (Rutland and Cole,1981).
2.2.1 Humoral immune response
The pulmonary humoral antibody response has been extensively
studied in CF and a deficiency in total concentration of IgG, S-IgA
or IgM has not been observed (review by Talamo et al., 1976). Pre¬
cipitating antibodies to dietary proteins, allergens, body fluids
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(McFarlane _et al. , 1975) and. to the infecting organism are present
(Schiotz, 1981).
Although the IgA antibody titre is higher in the sputum than the
serum of chronically infected patients with CF, indicating local anti¬
body production in the pulmonary tissue (Schijz5tz et al. , 1977), IgG
is the predominant immunoglobulin in the secretion during infection
due to passive transudation from the serum (Schi^tz, 1981).
Secretory IgA in the lung appears to be ineffective in CF against
bacterial colonisation. However the only evidence for a structural
abnormality of this immunoglobulin is the presence of free J chains
in CF sputum (Wallwork _et al., 197U) which may have no relevance in
vivo. P.aeruginosa appears to be adequately opsonised as strains of
bacteria isolated from CF sputa were shown to be coated with antibodies,
predominantly of the IgA class (Hann and Holsclaw, 1976). However,
the possibility that observations obtained from sputa may not reflect
the in vivo situation in the lung, should be considered.
2.2.2 Pulmonary comulement
Complement components have been demonstrated in the lung (Reynolds
and Newball, 197U), but may be associated with inflammation and trans¬
udation from the serum as opposed to local production (SchijzStz et_ al. ,
1979a). However infection with P.aeruginosa has been shown to increase
the synthesis of and by guinea-pig alveolar macrophages (Alpert
et al. , 198I4.) indicating that complement components can be produced in
the lung. An increase in complement activation would enhance the
inflq.mma.tory response and facilitate the recruitment of intravascular,
cellular and humoral mediators.
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2.2.3 Alveolar macrophages
One of the main functions of the alveolar macrophage is the
phagocytosis and elimination of foreign particles including bacteria
(Green and Kass, 196U) • As mucociliary clearing mechanisms are
impaired in the CP lung (Wood et al. , 1975) > "the alveolar macrophage
may be more important in bacterial clearance in OP than normal individuals.
Many studies have been performed to examine the possibility that
the alveolar macrophage may be defective in CP. Results however have
been contradictory and vary with the age of the patient and the technique
used. However alveolar macrophages are obtained by bronchopulmonary
lavage, so that the cells studied may not be the predominant cell-type
or representative of the cell population within the lung.
Ultrastructural studies have shown that alveolar macrophages from
CF patients are morphologically normal, although not heavily engaged
in phagocytosis (Thomassen at al., 1980). Furthermore the phagocytic
properties of cells isolated from CP adults were found to be normal in
the presence of normal serum indicating the absence of any intrinsic
defect of the cell. Alveolar macrophages obtained from CP patients
were shown to contain intracellular bacteria that were capable of pro¬
liferation so that killing may be impaired in these cells (Hodson and
Warner, 1981;). Non-specific phagocytic activity as measured by yeast
uptake was increased in alveolar macrophages from CP patients and was
similar to that observed in control patients with respiratory infection
(Cassino et al., 1980). Therefore the increase observed in phagocytic
activity was a result of the infection and consequent activation of the
macrophages and was not directly associated with CP. A study in
children by the same workers showed a marked decrease in the "phagocytic
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work" of alveolar macrophages from CF patients with pulmonary infection,
while alveolar macrophages from non-CP patients with other forms of
respiratory disease showed an increase in "phagocytic work" (Sordelli
et al., 1982). These results were obtained by employing Michaelis
Menten kinetics and were not dependent on the presence of autologous
serum. The different methods employed to measure phagocytosis in
these two studies may account for the apparent contradictory results.
It has been postulated that CF is the result of an inherent defect
in the monocyte-macrophage (Wilson and Fudenberg, 1982). T lymphocytes
and macrophages from CF homozygotes and obligate heterozygote carriers
synthesize CF specific ciliary dyskinesia factors (CDF) that are not
present in cultures of macrophages from healthy controls (Wilson and
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Bahm, 1980). These factors were first discovered in serum (di Sant'
Agnese and Davis, 1976; Wood et_ al., 1976) and have been shown to
markedly increase the ciliary beat, cause excessive mucus production
by goblet cells and the destruction of ciliary epithelium (Czegledy-
Nagy and Sturgess, 1976; Wilson ejfc al. , 1977; Conover and Conod, 1978).
Hyperproduction of both CDF and normal inflammatory mediators was shown
to occur in CF macrophages (Wilson and Bahm, 1980). This metabolic
defect appeared to be linked with an abnormality of CF alpha-2-
macroglobulin, a regulating glycoprotein produced by macrophages
(Mosher ejt al. 1977) • These observations led Wilson and Fudenberg
(1982) to postulate that the production of CDF by CF macrophages was
responsible for the pathophysiology observed in CF patients and that
the macrophage defect was genetically inherited. However this view
is not widely accepted, as it is possible that the macrophage abnormal¬
ities are secondary to infection. Moreover macrophages from hetero-
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ozygote carriers produce CDF "but this does not result in chronic
obstructive lung disease (Wilson and Bahrft 1980; Wilson et al., 1981)
2.3 Serum - Inhibitory factors
An early report by Biggar et al., (1971) showed that sera from
CP patients supported normal phagocytosis by neutrophils but not by
alveolar macrophages suggesting a dysfunction of the alveolar macro¬
phages. Later phagocytosis by rabbit alveolar macrophages was found
to be inhibited by fresh CP sera but not normal sera, while that of
peripheral phagocytes was unaffected (Boxerbaum et al., 1973) and. a
serum opsonin defect for alveolar macrophage function in CP patients
with frequent infections was discovered (Cole, 1979). CP serum has
high opsonic activity for P.aeruginosa when neutrophils are studied
(LeBlanc et al., 1982) but less than that of nonimmune sera or saline
when alveolar macrophages are studied (Pick and Reynolds, 1980, 1983)>
indicating the presence of a serum inhibitory factor. Such an inhib¬
itory factor had been indicated earlier as normal serum failed to
overcome the inhibitory effect of CP serum on alveolar macrophages
(Thomassen et_ al., 1979)- The inhibitory factor was shown to
specifically inhibit the phagocytosis of P.aeruginosa by alveolar
macrophages, and it was suggested that the factor was a "blocking
antibody" (Thomassen et_ al., 1979)- Moreover the blocking antibody
only occurs in CP patients with P.aeruginosa infection and was shown
to have a defective Pc portion in the molecule (Pick and Reynolds, 1983)-
Thus the antibody coats the bacteria via its Pab portion, but attach¬
ment to the macrophage via the Pc portion is impaired. This molecular
alteration of the Pc portion also occurs in the lung, where it is caused
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by a metallo-proteinase, produced by P.aeruginosa, which enzymatically
degrades immunoglobulin (Pick and Reynolds, "1983)•
The blocking antibody has been shown to protect autologous
P.aeruginosa strains from the bactericidal action of serum (Hizfiby
and Oiling, 1977; Thomassen and Lemko, 1981) and is present as IgA
in sputum (Schiller and Millard, 1983)* The specificity of the
inhibitory activity for alveolar macrophages has not been explained,
but may be a result of an undetermined receptor difference between
alveolar macrophages and monocytes (Thomassen et al. , 1982).
A recent report has indicated that this blocking antibody is an
IgG antibody against naturally occurring bactericidal IgM antibody
specific for the strain of P.aeruginosa infecting the patient (Penketh
at al. , 1983)• The presence of these blocking antibodies may partly
explain the inability of the pulmonary defense mechanisms to clear
P.aeruginosa from the lungs, and may further exacerbate respiratory
pathology.
Human respiratory tract ciliary motility is unaffected by factors
in CP serum (Rutland at al., 1983a, 1983b) that disrupt rabbit tracheal
ciliary activity (Spock et_ al., 1967).
2.k Immune complexes in Cystic Fibrosis
Patients chronically infected with P.aeruginosa have high levels
of immune complexes in their serum (SchijzStz et al. . 1977; Moss and
Lewiston, 1980; Pitcher-Wilmott, 1982) and sputum (McParlane
et_ al., 1975). Circulating immune complexes are composed of
P.aeruginosa antigens ana serum precipitins, especially against LPS
antigens (Moss and Lewiston, 1980; Berdischewsky et al., 1980).
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The infecting strain of P.aeruginosa was shown to account for the
antigenic specificity of the antibodies in immune complexes (Moss
and Hsu, 1982), but not to be the sole antigenic stimulus (Manthei
et al., 1982).
The presence of circulating immune complexes did not correlate
with the initial severity of the lung disease or the clinical status
of the patient (Pitcher-Wilmott et al., 1982). It was therefore
postulated that immune complexes did not play a major role in pul¬
monary pathology but simply reflected the extent of lung tissue
damage (Manthei et al., 1982). However this study was performed in
children, where chronic infection may not be established. Circulating
immune complexes are more common in advanced CF and occur at a higher
frequency in chronically infected patients (Schi^tz et al., 1978).
Immune complexes affect histamine release and activate complement
with a resulting increase in vascular permeability and infiltration
of peripheral neutrophils and monocytes (H^iby and Schidtz, 1982).
Subsequently neutrophils are trapped and release lysosomal enzymes
which cause tissue damage. Coagulation, kinin and fibrinolytic systems
are also activated. Moreover immune complexes act as regulators of both
cellular and humoral immune responses by virtue of their capacities to
interact with antigen receptor-bearing lymphocytes and subpopulations
of T and B cells, as well as with lymphocytes and macrophages that
possess Fc and complement receptors (reviewed by Theofiiopoulos and
Dixon, 1979). Immune complexes may also suppress or enhance immune
function, depending on the molar ratio of antigen to antibody, the
epitope density of the complex and the class and affinity of antibody
(review by Theofilopouos, 1980). For example enzymatic digestion of
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immune complexes by macrophages results in Fc sub-fragments being
released which non-specifically activate B cells (Morgan and Weigle,
1980).
Although immune complex formation is secondary to bacterial
infection, it seems possible that their formation may lead to further
tissue damage, by enhancing the immune response in hyperimmune patients.
However, there is no direct evidence that immune complexes cause pul¬
monary damage in CF. The host may benefit as immune complexes are
designed to eliminate and neutralise the antigens that are detrimental
to the host.
2.5 .Animal model systems for Cystic Fibrosis
The difficulties and limitations of working with humans have led
to the search for a practical animal model to study CF. At present,
no single animal model exists that exhibits all the aberrations present
in the CF patient. However there are models that have been used to
study particular aspects of CF and these will be briefly reviewed here.
A rat model of chronic respiratory infection has been described
by Cash et_ al.,(1979)• ?.aeruginosa are enmeshed in agar beads and
injected intratracheally into the lung. The agar beads protect the
bacteria from the immune system that would otherwise eliminate them.
Histologic examination of the infected lungs revealed lesions resembling
those seen in the lung tissue of CF patients. This model is used in
the investigation of the interactions between microbial virulence
factors and host defense mechanisms. A similar model has been
described in guinea-pigs (Blackwood and Pennington, 1981) and cats
(Winnie et al., 1982).
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A recent study has shown that P.aeruginosa only required to be mixed
with the agar beads to replicate and produce chronic respiratory
infection in rats (Naccucchio e_t al. , 198k). However other workers
did not find that this procedure worked (Govan et al., unpublished
results).
Rats and mice treated with high doses of reserpine have been used
as a model for CP (Sordelli et al., 1978; Martinez et al., 1979)* These
animals have a disturbed secretory function of the respiratory tract
and altered exocrine gland function. However the relevance of this
model to CP is debatable as the reserpine affects the sympathetic nervous
system and the animals become very ill as a result of the treatment.
The autosomal recessive cribriform degeneration mutation (cri)
in DBA/2J mice was first described in 1972 by Green et al. Several
studies since then have suggested that mice homozygous for the cri-
gene might serve as an animal model for CP. Characteristics of the
animals that resemble those of CP, include: increased salinity of the
saliva, diminished ability to clear Staph.aureus from the lung and
inflammation of the lung (Pivetta et al., 1977; Pivetta et al., 1981).
It is intersting that kinetic studies have revealed decreased phagocytic
capacity in alveolar macrophages and neutrophils from these animals
(Cerquetti et al., 1983).
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3.0 PSEUDOMONAS AERUGINOSA
P.aeruginosa is a gram negative "bacillus which can survive in
almost any reasonably moist environment. It can multiply in distilled
water and antiseptic solutions, utilising the trace elements provided
"by dissolved carbon dioxide and organic matter.
The organism is an opportunistic pathogen and causes severe and
debilitating infections in a variety of immunocompromised patients
including those with OF. Conditions predisposing to P.aeruginosa
infection include: natural immunologic deficiency (agammaglobulinemia);
immunologic immaturity (premature infants); immunologic suppression
(granulocytopenia); patients with extensive burns, underlying disease
or undergoing respiratory procedures such as catheterisation
or tracheostomy and patients with CP (Wood, 1976). During the last
thirty years there has been a significant increase in the incidence of
P.aeruginosa infection, particularly of nosocomial origin. The
increased use of antibiotics, cytostatic and immunosuppressive drugs and
more radical therapeutic and surgical practices may partly explain this
increase (Prjzfland, 1981).
3.1 Products and virulence factors
P.aeruginosa produces many biologically active substances (reviewed
by Woods and Iglewski, 1983)• These include:
1) Lipo-polysaccharide, that has endotoxic activity (Greer and
Milazzo, 1976), but is less toxic than other gram negative
lipopolysaccharides and is not a primary virulence factor
(Kostiala, 1980).
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2) Exotoxin A, which inhibits protein synthesis by ribosylation
in mammalian cells (iglewski et al., 1977).
3) Several proteases and haemolysins that cause tissue damage
(Liu et al., 1961; Kostiala, 1980).
k) A slime layer containing a leukotoxic glycolipoprotein (Lynn
et al., 1977).
3-1.1 Effects on the immune system
A variety of studies on animals have shown that toxins produced
by P.aeruginosa affect the immune system.
Supernatant from P.aeruginosa cultures, as well as living and
killed bacteria have been shown to suppress cell mediated responses and
cause prolongation of skin grafts in mice (Ploersham et al., 1971)-
This immunosuppression was transferred by spleen cells and peritoneal
macrophages from treated mice, and it was postulated that a product
derived from P.aeruginosa altered macrophages and T lymphocyte activities
by increasing the number of T suppressor cells (Petit et al., 1982).
Some strains of P.aeruginosa produce an extracellular high molecular
weight compound that inhibits the phagocytic and killing activities of
rabbit neutrophils (Eonoyama et al., 1979; Kamimura et al., 1980).
This substance is toxic and has been given the term neutrophil inhibitor.
High concentrations of heat-killed P.aeruginosa are toxic to cultured
neutrophils and monocytes (Garzelli at al., 1982). This is a result
of the neutrophil inhibitor and other bacterial products.
Exotoxin A is toxic to human peripheral monocytes (Pollack and Anderson,
1978) and inhibits protein synthesis in mouse peritoneal macrophages
(iglewski et al., 1977). The exotoxin does not affect phagocytosis
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but reduces the bactericidal activity of human neutrophils by
inactivating complement (Weber et al. , 1982). This product would
appear to be an important virulence factor as purified preparations,
injected intra-tracheally into rats produced histopathologic changes
that resembled infection with the whole bacteria (Cash et al. , "l983) •
A similar effect was also observed with proteases.
Alkaline protease and elastase have been shown to inhibit
myeloperoxidase mediated chemiluminescence, a major antimicrobial
system of human neutrophils (Kharazmi et al., 1981;). Antibodies
against the different toxins are produced in CP patients (Klinger et al.,
1978) so that the toxins may be inactivated and their contribution to
the pathogenesis of tissue damage in CP is at present uncertain.
3.1.2 Slime
The extracellular slime layer of P.aeruginosa is characteristic
of the species and contains high molecular weight glycolipoprotein
(GLP). In mice, the slime layer was shown to make a significant
contribution to the pathogenesis of the bacteria, with GLP being
the active component (Dimitracopoulos and Bartell, 1980).
The slime acts as a protective antigen and will cause leuko¬
penia and death when injected intraperitoneally into mice (Limitracopoulos
et al., 197U; Lynn et al., 1977). Neutropenia is induced by the GLP,
which binds to the neutrophils to form a complex that localises in the
liver and is subsequently removed from the circulation. In animals
that are immune to the organism, antibody binds to the GLP and inhibits
its attachment to the neutrophils (Lynn et al., 1977).
Slime is antiphagocytic (Sensakovic and Bartell, 197U) and impairs
the in vitro motility, endocytosis and phagosome formation of human
neutrophils (Laharrague et al., 198U)• The carbohydrate moiety of
the GLP molecule is responsible for its antigenic specificity and
inhibition of phagocytosis, whereas the lipid moiety is associated
with the leucopenic and lethal effects (Sensakovic ana Bartell, 1975).
This profound impairment of neutrophil function, without alteration of
viability may contribute to the virulence of the organism.
3.2 Mucoid Pseudomonas aeruginosa
Clinical and bacteriological studies of patients with CP have
indicated that initial colonisation or infection occurs with a typical non™
mucoid strain of P.aeruginosa. Once colonized the gradual emergence
of the mucoid form is almost inevitable and is associated with clinical
deterioration and a poor prognosis (Doggett and Harrison, 1972;
Hgfiby et al. , 1975) • The mucoid form is a mutant of the non-mucoid
strain and produces large quantities of an alginate-like exopolysaccaride
in vivo and on broth culture in vitro. The properties of alginate
will be reviewed in a later section. Despite the wide range and
variety of infection due to P.aeruginosa, the mucoid form is seldom
encountered except in patients with CP (Doggett, 1969). Moreover
the association between mucoid P.aeruginosa and CP became so characteristic
that it was suggested to be diagnostic of CP (Reynolds et al., 1976).
3y the time of post mortem examination,Kulczycki et al. , (1978) observed
that almost 1OO^o of patients who died of pulmonary tract complications
had cultures positive for P.aeruginosa, 90% of which were the mucoid form.
Mucoid P.aeruginosa are infrequently isolated from non CP patients where
they are either associated with chronic lung infection (Hjzslby, 1975) or
obstruction of the airways (Clarke et al., 1981).
3.2.1 The role of mucoid P.aeruginosa in cystic fibrosis
The association between mucoid P.aeruginosa and CP has not yet
been adequately explained. The factors that may be involved in the
emergence of the mucoid form in CP will be discussed here.
The fact that the CP lung is already obstructed by viscid macus
and that mucociliary clearance is impaired (Rutland and Cole, 1981)
may be an important factor in the emergence of mucoid P.aeruginosa
and mucus excess may help to keep the infection localised. Host
P.aeruginosa isolates from CP patients are capable of mutation to the
mucoid form if the correct medium is used (Lam et al., 1980). However
the environment of the lung does not switch on mutation but acts as
a selective environment for the establishment of the mucoid form
(Govan et al., 1979)* In vitro, although the mutation is easily
observed, the environment of most culture media, favours the growth
of non-mucoid revertants, so that mucoidy may be lost in culture but
not in the CP lung. Further evidence that the CP lung may be conducive
for mucoid variants of bacteria, was obtained by the isolation of
mucoid strains of E.coli from CP sputa (Hacone et al.,1981).
Levels of calcium are elevated in CP and concentrations as high as
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0.002 mg ml have been documented in CP respiratory secretions (Kilbourn,
1978). In the absence of suitable electrolytes Pseudomonas alginate
is produced as an extracellular slime and is easily removed by washing.
In the presence of calcium ions, however, the cells become embedded
in a protective matrix or microcolony surrounded by their own alginate.
Thus these elevated calcium levels may provide a positive selective
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pressure for the emergence of the mucoid phenotype.
The continuous use of antibiotics may contribute to the persistence
of P.aeruginosa and the appearance of the mucoid strains (Kulczyki et
al. , 1978), however this seems unlikely to be the sole explanation as
mucoid P.aeruginosa have been isolated from patients with no history of
antimicrobial therapy (Doggett and Harrison, 1969)• In early studies
mucoid variants were reported to be more resistant in vitro to B-lactam
and aminoglycoside antibiotics than related non-mucoid strains (Govan.
and Fyfe, 1978). Later studies showed that some mucoid strains were
extremely sensitive to antibiotics such as carbenicillin (Govan et al.,
1983). This apparent contradictory finding is explained by the demon¬
stration of an independent mutation responsible for hypersensitivity to
antibiotics, which overcomes the slight enhancement of resistance due
to the mucoid layer (Govan et al. , 1983; jtyfe and Govan, I98I4.). The
fact that mucoid strains are hypersensitive to antibiotics yet persist
after antibiotic therapy, may be a result of the microcolony mode of
growth as the alginate matrix may protect the bacteria from the anti¬
biotic. Alternatively antibiotic hypersensitivity in vivo may be an
adaptation to the environment, by providing enhanced permeability and
uptake of essential nutrients through an otherwise impermeable alginate
matrix (Govan, 1983)•
The formation of microcolonies surrounded by alginate, renders
the bacteria resistant to immune clearance (Gosterton et al. , 1983). Mucoid
P.aeruginosa are also resistant to opsonisation by antibody directed
against the immunotype specific antigen (Baltimore and Shedd, 1983)-
However, even if opsonisation had taken place, a large microcolony,
surrounded by alginate would probably resist phagocytosis by macrophages.
A microcolony mode of growth would also protect the bacteria
from the bactericidal action of serum. This would explain the
in vitro observation that mucoid strains are more serum sensitive
when compared with non-mucoid forms (Thomassen and Demko, 1981).
Tissue damage due to pseudomonas toxins would also be enhanced by
microcolony formation since the concentration of the bacteria within
a matrix would act to localise toxins and reduce the diluting effect
of body fluids.
Alginate production and hypersensitivity to antibiotics are both
associated with advanced chronic infection and are due to bacterial
mutations of non-mucoid P.aeruginosa that initially colonised the
patient. Therefore CP patients may be more susceptible to initial
colonisation with P.aeruginosa than normal. CP patients have raised
levels of salivary proteases and P.aeruginosa were shown to adhere to
a greater extent to buccal cells from CP patients than to similar cells
from control subjects (Woods et al., 1980). Previous studies
(johanson _et al., 1979) had shown that control cells behaved similarly
to CP cells if their normal coating of fibroaectin was reduced by
treatment with the proteolytic enzyme, trypsin. Therefore the raised
levels of proteases reduce the level of fibroaectin that leads to
increased binding of P.aeruginosa (Woods et al., 1983)• Non-mucoid
bacteria adhered better than mucoid bacteria to buccal cells. Adhesion
to the buccal cells was mediated by hair-like pili on the bacterial
surface which was masked by the presence of alginate. However in the
lower respiratory tract, only mucoid P.aeruginosa adhered in significant
numbers (Baker and Marcus, 1982). Mucoid bacteria adhered in the form
of microcolonies rather than as individual cells. Mucoid bacteria are
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metabolically less efficient (Mian, 1978) yet supersede non-mucoid bacteria
in CP. The emergence and persistance of mucoid P.aeruginosa in CP is
probably a result of many inter-related factors, although in large
part may be a result of the microcolony mode of growth and protection
of the bacteria within an alginate matrix.
3.2.2 Heterogeneity
Mucoid P.aeruginosa are often thought to be a homogenous class
of species possessing basic common properties. However physiological
and genetic studies have revealed heterogeneity within this form of
the species (irvin et al., 1981; Govan et al., 1983)- A heterogenous
population of mucoid variants are often found within sputum taken from
individual CP patients and this is not explained by simultaneous
infection with more than one strain. The heterogeneity may involve
forms that are indistinguishable in colonial appearance, yet show
differences in the synthesis and chemical structure of alginate and
hundred fold differences in susceptibility to B-lactam antibiotics
(Govan et al., 1983). This heterogeneity serves to illustrate the
complexity of the natural history of P.aeruginosa chronic pulmonary
infection that occurs in CP.
3-3 Pseudomonas alginate
The extracellular exopolysaccharide produced by mucoid variants
of P.aeruginosa is quite distinct from the slime material characteristi¬
cally secreted by non-mucoid strains (Doggett et_ al. , 19&0 and referred
to earlier. This material has been referred to as alginate, giyco-
calyx, mucoid material or slime. Confusion has often arisen in the
literature, as the term slime has been used to describe extracellular
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substance from mucoid (Evans and Linker, 1973) and from non-mucoid
strains (Bartell et al., 1970). The term alginate has been used in
this thesis to distinguish the material produced by mucoid forms of
P. aeruginosa from the characteristic slime of the species.
Alginate is a polyuronide composed of D-mannuronic acid and
L-guluronic acid linked by 0-acetyl groups (Linker and Jones, 1966).
The structure is similar to alginate produced by the bacterial species
Aaotobacter vinelandii and by marine algae, except the algal alginate
is non-acelylated. The relative amounts of the two monomers and their
physiological properties are dependent on the calcium ions present in
the nutrients (Doggett et al., 1971; Govan et al., 19^3)-
3.3-1 Physical -properties
Pseudomonas alginate has a molecular weight of 10,000 daltons or more
(Speert et al. ,1981+) and is highly viscous in nature. The polysaccharide
is produced extracellularly in the form of a loosely associated peri¬
pheral capsule as opposed to a distinct, cell-bound bacterial capsule
(Costerton et al., 1981; Marty et al., 1981). The degree of viscosity
or rheological properties are significantly influenced by divalent cations
which link the negatively charged carboxylic acid moieties and are
increased in the presence of calcium ions (Pier et al., 1983)-
In contrast to Pseudomonas slime (Liu, 1979)? the purified alginate
is nontoxic when injected intraperitoneally into mice (J.R.W. Govan,
personal communication).
3.3.2 Bios?/nthesis
Pseudomonas alginate is synthesised initially as a homopolymer of
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mannuronic acid, subsequently a proportion of the mannuronic acid residues
are converted to guluronic acid by a C5 epimerisation (rotation around
the C bond) (Sutherland, 1977; Fyfe and Govan, 1983)•
X X
OH - C - H H - C - OH
polymannuronate
epimerase
The acetyl groups are added from acetyl CoA before the polymer is
secreted into the medium. Fortions of the polymer containing O-acetyl
mannuronic acid may then be protected from epimerisation. The degree
of acetylation of the alginate is proportional to the viscosity of the
polymer (Piggott, 1979). Individual mucoid strains differ considerably
in the amount of alginate produced, the ratio of the two monomers, the
degree of acetylation and the optimal conditions for synthesis of the
alginate (Evans and Linker, 1973).
3.3-3 Effects on the immune system
As mucoid producing strains of P.aeruginosa are seldom eradicated,
once established in the CP lung, it would seem that the production of
alginate may confer a selective advantage on the bacteria. One advantage
might be that the alginate protects the bacteria from the hosts immune
responses and thus plays an important role in the establishment and
chronicity of the infection. The advantage conferred by the micro-
colony mode of growth in this way has previously been discussed.
A report by Schwartzmann and Boring (1971) showed that Pseudomonas
alginate inhibited the phagocytosis of E.coli, Staph.aureus and
P.aeruginosa. However no distinction was made between phagocytosis and
intracellular killing in the assay performed, as cells were lysed and
colony counts performed to determine the percentage of killed bacteria
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in treated and untreated cells. Mucoid forms were shown to resist
phagocytosis "by cultured rat and guinea-pig alveolar macrophages
(Ruhen et al., 1980). Cell free alginate was also shown to inhibit
phagocytosis of the non-mucoid variant when added with the "bacteria.
However this was in the form of a preliminary report and did not
include details of the procedures employed.
Mucoid P.aeruginosa strains that produced moderate amounts of
alginate were shown to be killed by human neutrophils, whereas high
producing strains were ineffectively killed (Roe and Jones, ^lb),
indicating that alginate protected the bacteria from microbicidal
mechanisms. A later study reported that mucoid strains were in¬
effectively opsonised with antibody specific for the non-mucoid
revertant (Baltimore and Mitchell, 1980). It was concluded from
these observations that the immunodeterminant for opsonic antibody
was blocked in the mucoid form by alginate. However in the same
study a crude alginate extract had no effect on the opsonisation of
the non-mucoid revertant, when added to a mixture of antibody and
bacteria. This latter result appears to contradict the former and may
be a result of the alginate purification technique.
Alginate has been shown to inactivate the classical complement
pathway by primary inactivation of C2, which results in poor opsonic
activity and impaired killing of Staph.aureus by human neutrophils
(Speert et al., 1981).
The contradictory results that are sometimes obtained in different
studies may be explained by differences in techniques. Por example,
after washing, mucoid ?.aeruginosa are no longer mucoid, as during
centrifugation most of the alginate remains in the culture supernate
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(Personal Observation). In the course of a short experiment there
would be little prospect for alginate synthesis in vivo (Govan, 1983).
There was no difference observed in the pulmonary clearance of mucoid
and non-mucoid P.aeruginosa inoculated intratracheally into guinea-
pigs, when the organisms were washed (Blackwood and Pennington, 1981).
Similarly no differences were observed in the opsonic requirements and
phagocytosis of mucoid and non-mucoid strains when studied with an
assay using radio-labelled bacteria that involved washing the bacteria
(Meshulam et al., 1982). However increased pulmonary survival of
mucoid P.aeruginosa was observed in rats killed three and six hours
after intra-tracheal inoculation with unwashed bacteria (Govan et al.,
1983)- This effect did not occur when the bacteria were washed prior
to inoculation.
Thus the alginate may render mucoid P.aeruginosa less susceptible
than non-mucoid forms to normal pulmonary bactericidal mechanisms. This
action together with mechanical obstruction, microcolony mode of growth,
ana rheological properties in the presence of calcium may partly explain
the persistance of the mucoid form and its association with a poor
prognosis. Farther actions of the alginate on pulmonary immune defenses
will be described in this thesis.
3.3'b Immunogenicity
Until recently, it was generally accepted that alginate was non-
i Tnmunogenie, as humoral or cellular responses against the alginate were
not observed (H^iby et al., 1975; Lam et al., 1980). However in 1981,
Macone et_ al. reported that rabbits immunised with mucoid P.aeruginosa
produced high titres of antibody, specific for the alginate. The
activity was absorbed with mucoid, but not non-mucoid organisms and
the immune serum reacted specifically with purified alginate. One
factor that possibly interferred with the search for an anti-alginate anti¬
body in CP patients, may have been the lack of a reliable and sensitive
procedure for its detection. This was overcome by Bryan erfc al. , (1983)
and later by Speert et_ al. , (1981;) by the development of an enzyme-
linked immunosorbent assay (ELISA), with alginate as the antigen. This
technique allowed low levels of anti-alginate antibody to be detected in
the sera of several patients with CP, demonstrating that the alginate was
immunogenic. At the same time another group of workers discovered anti-
alginate antibody by performing a haemagglutination assay (Pier _et al.,
1983). The mucoid antigen from one strain was found to be composed
predominantly of a single serologic epitope, that was shared with forty
other chemical isolates. In addition to the common epitope, alginate
from some strains also possessed a serotype-specific determinant. CP
patients colonised with P.aeruginosa had higher antibody titres than
patients who were not colonised and antibody was absent in healthy controls
(Speert et al. , I98I4). The antiserum was shown to cross-react with
seaweed alginate, but not other bacterial polysaccharides.
The anti-alginate antibody produced by CP patients appears to be
an ineffective opsonin, as mucoid strains persist and are rarely erad¬
icated. The reason for this could be that the antibody does not reach
the lung or is "mopped-up" by an excess of alginate (Lam et al., 1980).
Alternatively opsonisation could take plane but the sheer size of the
Pseudomonas microcolony enclosed within an alginate gel frustrates
phagocytosis (Govan, 1983)* -be formation of alginate antibody may
even be harmful, if it participates in an arthus reaction in the
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lung (Zavala et al. , 1975) ox forms part of the immune complexes that
occur in CP sera and sputum (Manthei at al. , 1982).
3.I+ Pseudomonas aeruginosa vaccines
Although several P.aeruginosa vaccines have been developed, it
would seem unlikely that active immunisation would be of use to those
CP patients who already have chronic pulmonary infection and high anti¬
body titres in the serum and sputum. Such patients might be considered
to be already hyperimmune. Patients with CP immunised with a multivalent
P.aeruginosa LPS vaccine were shown to have increased serum antibody titres
(Pennington et al., 1975)* However the clinical course was unchanged
and P.aeruginosa was not eradicated from the sputum. Patients immunised
intranasally with the same vaccine, showed a slight increase in serum
antibody titres, although sputum levels remained the same. On the other
hand, intranasal application of the vaccine to rabbits led to a rise in
the antibody titre in the lung and serum (Wood at al. , 1983)- Another
study showed that serum antibodies against envelope proteins did not pro¬
tect CP patients from further pulmonary infection with P.aeruginosa
(Pernandes et al., 1981).
Prophylactic immunisation against P.aeruginosa may be effective in
preventing initial colonisation, the emergence of mucoid P.aeruginosa
and the establishment of chronic infection. Vaccination of mice with
a high molecular weight polysaccharide from mucoid P.aeruginosa, protected
them against a challenge with the organisms (Pier at al., 1978).
Similarly a polyvalent cell wall extract protected guinea-pigs from
pneumonia, following challenge with ?.aeruginosa (Pennington and Miller,
1979)5 and the polyvalent vaccine (PEV-01) protected rats against an
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intra-tracheal challenge of P.aeruginosa in agarose beads (Klinger
et al., 1983)* Protection in the rats may have been a result of immun¬
isation against toxic exoproducts, as although lung inflammation was
minimal, the bacterial numbers in the lungs were no different in treated
and untreated rats. At present, no study on prophylactic immunisation
in CP patients has been reported.
Vaccines against P.aeruginosa have been shown to be effective in
non-pulmonary infections in animals and man. A ribosomal vaccine
produced active immunity in mice against intra-peritoneal injection of
P.aeruginosa (Lieberman et al., 1979). A study in India reported that
a polyvalent vaccine decreased the mortality due to systemic P.aeruginosa
infection (Jones et_ al., 1979) and a high molecular weight polysaccharide
from slime has been shown to be an effective vaccine against burn
infections (Pollack et al. , I98I4.). Rabbit antisera produced against
the polysaccharide was shown to passively protect mice from
infection .
As P.aeruginosa antibody produced by chronically infected CP patients
may be functionally inefficient (Pick et al. , 1981+), qualitative
replacement of specific IgG anti-Pseudomonas antibody may be more approp¬
riate than prophylatic vaccination .Prom the previous discussion it can
be seen that many factors are likely to be involved in the predisposition
of CP patients to lung infection with P.aeruginosa, so that prophylatic
vaccination may be of little use.
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1+.0 MACROPHAGES
Macrophages are derived from peripheral blood monocytes, reside
in the tissues and are part cf the mononuclear phagocyte system
(van Furth, 1982). The maturation of monocytes into macrophages occurs
without cell division, but with a more than three fold increase in cell
volume (Gordon and Cohn, 1973). Monocytes are a mobile, functionally
diverse group of cells that may be recruited to tissues and stimul ated
to a high degree of metabolic activity. Monocytes are chemotactically
attracted to an infected focus, where they may differentiate into macro¬
phages. Many substances are chemotactic for monocytes and they include
bacteria and their products, immune complexes, complement components,
kallekrein and lymphokines released by activated T lymphocytes (Wilkinson,
1976). Macrophages are also able to accumulate and remain at an infected
focus under the influence of a migration inhibition factor (MIE) released
by T lymphocytes (Racklin _et al., 1980). Macrophages have a marked
capacity for endocytosis and the ability to adhere tenaciously to glass
or plastic surfaces. They also secrete various enzymes, including
lysozyme, complement components, prostaglandins and other substances
that may mediate or modulate tissue damage and repair (Hopper et al.,
1979). Macrophages are also very important effector cells in cell
mediated immunity and act as accessory cells for many T lymphocyte
functions. Other functions ascribed to macrophages include numerous
homeostatic functions unrelated to host defence, such as removal of
senescent red blood cells,turnover of lung surfactant and bone remodell¬
ing and resorption (Douglas, 1980; Silverstein, 1982). Macrophage
heterogeneity may be detected between populations from different sites
or between macrophages within a population obtained from a particular
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site (reviewed "by Dougherty and McBride, 1981+)• There are many general
reviews concerning the macrophage (Hopper et al., 1979; Lasser, 1983;
van Furth, 19^3)- This discussion will concentrate on the alveolar
macrophage and emphasize the ways in which these macrophages differ
from other macrophage populations, especially peritoneal macrophages.
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5.0 ALVEOLAR MACROPHAGES
The alveolar macrophage is the resident mononuclear phagocyte
and the most prominant inflammatory and immune effector cell in the
lung (Crapo et al., 1982). Bronchoalveolar lavage fluid taken from
a normal adult contains 93% - 3% macrophages, 7% - 1% lymphocytes and
less than 1% neutrophils, eosinophils or "basophils (Hunninghake
et al. , 1979)' Their main function is in the primary defence against
inhaled particulate matter (Green and Kass, I96I4.) 30 thai the lung is
maintained as a clean and sterile surface suitable for gas exhange.
The phagocytes function primarily on alveolar surfaces rather than
within tissues, and move around on the alveolar surface within the
liquid lining layer (.Burri, 1983)* Alveolar macrophages display most
of the typical macrophage traits but also exhibit certain unique
characteristics that are discussed below.
5.1 Origin and kinetics
Alveolar macrophages are derived from progenitors in the bone
marrow. A bone marrow monoblast divides to give rise to two promonocytes
which divide once to give rise to two monocytes. The monocytes
leave the bone marrow and enter the circulation where they remain (in
man the half-life is seventy-one hours) unless they migrate into the
tissues where they differentiate into macrophages (van Furth, 1981).
In animals given lethal whole-body irradiation, followed by an
infusion of donor bone marrow cells the alveolar macrophage population
has been shown to be substantially replaced with cells of donor origin
(Blusse van oud Alblas and van Furth, 1979)- Human alveolar macrophages
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have also "been shown to "be derived from the hone marrow (Thomas et al. ,
1976). Monocytes differentiate into morphologically typical alveolar
macrophages within a few hours of entering the alveolar air spaces
(Blusse van oud Alhlas et al., 1983a). These workers preclude the
existence of an interstial pool of dividing precursor cells. However
a dual mechanism of monocyte differentiation into macrophages has "been
postulated (Adamson and Bowden, 1980; Bowden and Adamson, 1980). The
monocytes either cross the interstitium without dividing and differ¬
entiate into alveolar macrophages or "become interstitial cells that
subsequently divide and migrate to the alveoli to become macrophages.
Thus the lung interstitium may be an intermediate environment between
the blood and alveolar space. Genetic markers have shown that blood
monocytes do populate the interstitial and alveolar compartments of
the lung (Johnson et al., 1980b). Therefore the monocytes may
develop functional and metabolic features of the alveolar macrophage
in the interstitium, prior to their efflux into the alveoli. Using
Ec receptor avidity as a marker, alveolar macrophages have been shown
to be more stimulated than peripheral blood monocytes (Holt et_ al.,
1982).
Alveolar macrophages are continually renewed to balance the loss
of cells through the airways and lymphatic channels (Bertalanffy, 1961+).
However, whether the population is sustained wholly by monocyte efflux
into the lung or by local division of resident alveolar macrophages is
controversial.
Rodent alveolar macrophages have the capacity to proliferate in vivo
(Haum, 1975) and nitrous oxide is a potent stimulator of alveolar macro¬
phage proliferation (Evans et al., 1973)* Similarly hamster alveolar
macrophages
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will proliferate and form colonies in soft gel agar (Lin et al., 1975).
Human alveolar macrophages are also capable of replication (Golde et_
al., 197U)• However the in vivo importance of this capacity for
replication is uncertain. In mice it has been demonstrated that 70%
of the alveolar macrophage population is supplied by monocyte influx
into the lung and 30% by local division of immature monocytes originat¬
ing from the bone marrow (31usse van oud Alblas at al., 1983b). These
workers claim that the maintenance of the alveolar macrophage popul¬
ation is dependent on the influx of circulating monocytes and only to
a minor degree on local division. They also postulate that the
increase in the alveolar macrophage population during local inflammation
is a result of an increased influx of peripheral monocytes as opposed
to an increase in division of the resident population (Blusse van oud
Alblas et_ al., 1983a, van Furth and Blusse van oud Alblas, 1983)-
However no evidence is presented to show that the dividing population
of alveolar macrophages are solely new monocytes recently recruited
into the lung. Although these workers now admit that a dividing
alveolar macrophage population exists, they claim it is unimportant
in sustaining the population. They argue that other workers who claim
that the dividing population may be important have not used adequate
techniques for identifying the alveolar macrophage from other pulmonary
macrophages (van Purth and Blusse van oud Alblas, 1982).
Contrary to these views is the proposal that alveolar macrophages
are a self-sustaining population (Coggle and Tarling, 1983)- These
workers showed that the labelling pattern of alveolar macrophages was
only altered after lung irradiation and that it did not change after
bone marrow irradiation. Macrophage numbers remained constant despite
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a severe depression in the numbers of peripheral monocytes. Flash
labelling studies also revealed that 30% of the resident alveolar
macrophage population were involved in DNA synthesis. Previously it
had been reported that patients with acute leukemia, maintained their
alveolar macrophage population despite prolonged periods of monocyto-
pernia (Golde et al., 197U). Therefore it would appear that under
certain conditions the alveolar macrophage population can be self-
sustaining.
Cellular transformation can be modelled in vitro. Human mono¬
cytes and alveolar macrophages have different enzyme patterns, however
after culture, monocytes have been shown to display the alveolar macro¬
phage pattern (Radzun et al., 1983)*
Thus whilst studies definitely show that that alveolar macrophage
is originally derived from the blood monocyte, controversy remains over
the more important mechanism (monocyte influx or local cell division)
involved in sustaining the alveolar macrophage population, once it is
established. The macrophages apparently have the capacity to divide,
but whether this is limited to a population of newly differentiated mono¬
cytes is open to question. The system may be adaptable, so that under
certain conditions, for example, monocytopenia, local macrophage
division would increase as opposed to monocyte influx to maintain
the alveolar macrophage population.
$.2 Characteristics
Alveolar macrophages differ from other macrophages in structural,
biochemical and functional properties (Sorokin, 1979; Hocking and
Golde 1979; Hunninghake et_ al., 1979)- Monoclonal antibodies have
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also indicated antigenic differences between alveolar and peritoneal
macrophages (Rumpold et al., 1981).
Alveolar macrophages vary in size from fifteen to fifty microns
in diameter and have a nucleus to cytoplasmic ratio of approximately
one to three. When attached to glass they have an elongated and
flat or spherical appearance with a raised central area. They attach
readily to glass and this is accomplished by lamellipodia and filapodia
(Hocking and Golde, 1979)- They contain large numbers of mitochondria
and an increased content of mitochondrial enzymes, compared to other
macrophages. Similarly they have more numerous and larger cytoplasmic
inclusions containing lysosomal hydrolytic enzymes, and produce substan¬
tially higher amounts of acid phosphatase, B-glucuronidase (Hearst et al.,
1980) and prostaglandins (Morley et al., 1979)-
5.3 Oxidative Metabolism
The aerobic environment of the alveolus has led the alveolar macro¬
phage to develop special metabolic adaptations (Simon et_ al. ,1977) • At
rest they have a higher 114.G—1 -glucose metabolism (Paper Master-Bender
et al., 1980) and phosphatase activity (Hearst et al., 1980) than peri¬
toneal macrophages. The respiratory rate of the alveolar macrophage
is greater than that of any other mammalian phagocytic cell. For
phagocytosis to occur, a higher level of energy supplied through oxidative
phosphoylation is required than for comparable numbers of peritoneal
macrophages (Karnovsky et al. , 1970). Resident alveolar macrophages
show high levels of glucose and oxygen consumption, with only slight
changes during phagocytosis, when production of toxic metabolites is low,
compared to that of peritoneal macrophages (Oren et al., 1963)-
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Incubation of alveolar macrophages under anaerobic conditions
will inhibit phagocytosis and particle ingestion is decreased in the
presence of inhibitors of glycolysis or oxidative metabolism (Ouchi
et al., 19^5; Cohen and Chovaniec, 1978). In contrast to other
phagocytes, alveolar macrophages depend on both oxidative and glyco¬
lytic metabolism for phagocytosis to occur.
The activities of oxygen metabolising enzymes of either peritoneal
or alveolar macrophages can vary depending on whether they are maintained
in an aerobic or anaerobic environment. For example, when alveolar
macrophages are incubated in vitro under anaerobic conditions, they
exhibit an enzymatic pattern similar to that of peritoneal macrophages
(Simon et al., 1977).
Alveolar macrophages usually depend on an oxygen tension that is
greater than 25 nim Hg. for normal phagocytosis (Cohen and Cline, 1971).
The differences observed between alveolar and peritoneal macrophage
function may therefore sometimes be a result of the culture technique
employed. Alveolar macrophages may function optimally when cultured
on coverslips, where oxygen tension is high, whereas peritoneal macro¬
phages nay be more suitably studied in suspension under anaerobic
conditions (Hearst et al., 1980).
Unlike peritoneal macrophages, the alveolar macrophage has low
amounts of myelo-peroxidase mediated antimicrobial activity. However
high concentrations of catalase are also observed after ingestion and
it is this enzyme that functions primarily as a peroxidase in these
cells (Stossel et_ al. , 1972; Mauel, 1982).
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5.1+ Role in immunity
The principal role of the alveolar macrophage is in the primary
defense of the lung against inhaled bacteria and inert particles (Green
and Kass, 1961+; Goldstein et al. , 197U)- They also participate in
specific immunological reactions, such as antigen presentation and cell
mediated immunity and interact with other components of the immune
system acting as accessory cells (Nichols, 1980).
5«1+. 1 Surveillance and phagocytosis
Alveolar macrophages are dispersed throughout the alveoli, so that
they intercept bacteria within minutes of their entry into the lung.
Bacteria are then ingested, inactivated and degraded in two to four
hours (Jakab, 1981). Rats infected intratracheally with Staph.aureus
cleared 76.9% of the bacteria in five hours and 87.1% were found to
be intracellular within five hours (Goldstein et al., 1971+)• The
efficiency of this phagocytic mechanism maintains the sterility of the
lung, under normal conditions, despite the constant influx of bacteria
and other particles. However during pulmonary infection, the role of
the alveolar macrophage is augmented by an influx of blood monocytes
and neutrophils and antibody production.
Human alveolar macrophages in vitro have been shown to exhibit
a slight decrease in chemotaxis, phagocytosis and microbial killing
compared to similar numbers of peripheral blood monocytes (Territo and
Golde, 1979). A later study showed that the ability to phagocytose
Staph.aureus and E.coli was greater for human alveolar macrophages
than blood monocytes, although the bactericidal activity of the latter
was greater (Eoidal et al., 1981). In Swiss mice alveolar macrophages
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have a greater phagocytic capacity than peritoneal macrophages (Hearst,
1980)j itfhile in Sprague-Dawley rats the reverse is observed (Personal
observation).
5.I4..2. General immune functions
Alveolar macrophages are cytotoxic for virus-infected cells
(Stott et al., 1975) produce interferon (Acton and Myrvik, 1966) and
are important in antitumour immunity (Sone and Pidler, 1980).
They produce a colony stimulating factor that induces granulocyte
and monocyte stem cell replication in vitro (Golde e_t al. , 1972) release
factors chemotactic for monocytes and neutrophils (Hunninghake et al.,
1979) mediate the amplification of neutrophil bactericidal mechanisms
(Pennington et al., 1983)• Thus the alveolar macrophage has the
potential to stimulate the production of neutrophils and monocytes by
the bone marrow, induce their migration to the lung and sites of infection
and subsequently amplify their immune responses. The alveolar macrophage
is clearly an important effector cell during a pulmonary infection arid
may initiate the inflammatory response. Alveolar macrophages do not
form spontaneous rosettes with untreated sheep erythrocytes, but they
do form high numbers of rosettes with Candida (Hearst et al., 1980).
They are efficient at cleaning yeast from the lung, due to the presence
of a lectin-like receptor specific for mannan phosphate (Sung et al.,
1983). These cells are unique among macrophages in their ability to
inhibit the expression of natural killer (UK) cell activity (Bordignon
et al. , 1982). HK activity is low in the lung and may serve to protect
the pulmonary tissue from damage.
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5.5 Accessory cell function
Alveolar macrophages are not purely scavenger or surveillance
cells, but act as accessory cells in the induction and expression of
humoral and cell-mediated immune responses (Unanue, 1978).
As they are located on the surface of the alveoli, alveolar macro¬
phages are in an ideal position to recognise and bind antigens and sub¬
sequently present them to T lymphocytes. It has been shown that
antigen inoculated intratracheally into guinea-pigs can induce a
primary immune response and selectively recruit specific T lymphocytes
to the lung (Lyons and Lipscomb, 19^3). Alveolar macrophages are
capable of interacting with antigen in a manner analogous to that of
other macrophages. However they appear to be relatively inefficient
in presenting antigen for the initiation of an immune response (Ullrich
and Herscowitz, 1980). There are marked species differences in the
accessory immune function of alveolar macrophages which may be related
to the number of la positive cells in the population.
5.5•1 Animal studies
Murine alveolar macrophages have been shown to be capable of
supporting PHA induced lymphoproliferation (Holt, 1980). Another
study found that murine alveolar macrophages inhibited the splenocyte
response to Con.A as a result of prostaglandin release that caused the
cytostasis of lymphocytes (Sestini et_ al., 1982). Other observations
are contradictory, for on the one hand murine alveolar macrophages
did not support proliferation of lymphocytes to soluble antigen
(Ullrich and Herscowitz, 1980) while on the other they were shown to
be as potent as spleen cells at presenting alloantigen or soluble
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protein antigen to cloned. T cell hybridomas (Daughety et al., 1983) »
but less effective accessory cells than similar numbers of peritoneal
macrophages (Weinburg and Unanue, 1981; Shellito et al., 1983)- The
latter study also showed that interleukin 1 production was lower and
that fewer lymphocytes were bound by alveolar macrophages than peritoneal
macrophages. Differences between the studies may be related to the
different strains of mice used in each experiment. 30% of murine
alveolar macrophages are la positive and proliferation of primed T
cells propagated in vitro is induced by cells that possess functional
products of IA and IE subregions (Daughety et_ al. , 1983). When
antigen presentation assays are carried out with murine alveolar macro¬
phages they can be shown to be dose-dependent, antigen specific and
genetically restricted (Weinburg and IJnanue, 1981).
Hat alveolar macrophages suppress mitogen-stimulated lympho-
proliferation, are cytostatic and only support lew levels of T cell
activation (Holt, 1979a, 1980; Zaltreider, 1982). The percentage
of la positive alveolar macrophages in the rat is low, 10% in Sprague-
Dawley (Personal observation) and may account for the observed ineffective
accessory cell activity of these cells. A study on sub-populations of
rat alveolar macrophages, separated according to density, showed that
cells from the lowest and highest density fractions had a minimal effect
on mitogenesis, while cells from the intermediate density fractions
caused suppression (Shellito and Kaltreider, 198J4). Therefore these
cells exhibit differences in their ability to act as accessory cells,
depending on the degree of cell maturation.
Guinea-pig alveolar macrophages were shown to support PHA induced
lymphoproliferation and to present soluble antigen, with a response
greater than that observed with peritoneal macrophages (Holt and Batty,
1980; Ealtreider, 1982). These cells fail to suppress lymphoprolif-
eration even at high ratios. Their efficiency as accessory cells
may be a result of the high percentage (80%) of la positive cells in
the population (Lipscombe et al., 1981).
Studies on rabbit alveolar macrophages on the other hand have been
contradictory and confusing. The macrophages have been shown to inhibit
PHA induced lymphoproliferation (Holt, 1980). However in one study
low alveolar macrophage to lymphocyte ratios(l:100) were shown to
enhance the lymphocyte response to Con.A and sheep erythrocytes, while
high ratios (1:1) caused suppression of the response (Pennline and
Herscowitz, 1981). In another study high alveolar macrophage to
lymphocyte ratios (1:2, 2:1) supported Con.A induced lympho-proliferation
while suppression of the response occurred when the ratio of macrophages
was increased to I4.: 1 (Schuyler and Todd, 1981). These discrepancies
may be due to the fact that macrophage depletion of the lymphocyte
population was not carried out in the former study but that sephadex
G10 columns were used in the second study for macrophage depletion.
Canine alveolar macrophages may suppress lymphcproliferation
(Kaltreider, 1982) or function as accessory cells in cultures of
thymocytes stimulated with Con.A (Wulff et al., 1983). Antigen
presentation was shown to be genetically restricted as the la positive




At low concentrations (1%) human alveolar macrophages suppressed
the proliferation of peripheral blood lymphocytes, both to mitogens
and antigens (McCombs et al., 1982). This suppression was greater
with T cells than B cells and appeared to be due to prostaglandin
synthesis as indomethacin reversed the inhibition. Another study
showed that human alveolar macrophages enhanced mitogen stimulated
but not antigen stimulated lymphocyte proliferation and that they
are less effective than autologous monocytes when the optimal concen¬
tration of PHA was used (Ettensohn and Roberts, 1983). Human blood
monocytes were shown to promote T lymphocyte responses when present at
low concentrations and suppress proliferation when they comprised more
than 30% of the total cell concentration (Twomey et al., 1983). In
the same study alveolar macrophages showed a similar pattern but were
less efficient as accessory cells and caused suppression at a lower cell
concentration than blood monocytes. Generally alveolar macrophages
appear to be inferior to peripheral blood monocytes in supporting
antigen-induced proliferation.. However it was shown that in some
individuals the alveolar macrophages had the same activity as mono¬
cytes, other individuals possessed alveolar macrophages that suppressed
lymphocyte responses, while others had cells that exhibited 1%% of the
activity of the monocytes (Toews et al., 1981+). Therefore some
alveolar macrophages present antigen, some cause suppression and some
remain inert. The factors that determine which function is expressed
in vivo may determine the pulmonary response to inhaled antigen. A
high proportion of human alveolar macrophages (80X>) express HLA-DR
antigens, therefore they would be expected to be capable of antigen
presentation (Mason et al., 1982).
The majority of studies support the concept that the alveolar
macrophage is not simply a scavenger cell but is capable of participat¬
ing in cell-mediated immunologic reactions in the lung. As the first
cell in the lung to contact antigen, its role as an accessory cell would
be important in the modulation of the host response to antigenic exposure.
5.6. Activation
There is evidence that an effective cell-mediated immune response
depends on the recruitment of peripheral blood monocytes into the
alveolar spaces (Truitt and Mackaness, 1971) and the activation of
the resident alveolar macrophage population (Johnson et al. , 1975)- Tbe state
of macrophage activation is characterised by increased spreading of the
cell on glass surfaces, increased numbers of mitochondria and enzymes
and an increase in the metabolic activity, phagocytic capacity and
intracellular killing by the macrophage (Lasser, 1983)- Activation
of the alveolar macrophage can be induced directly by appropriate
stimuli in vivo, such as bacterial lipopolysaccharide (Sone and Fiddler,
1980), Bacillus Calmette-Guerin (BCG), (Schuyler and Steinberg, 1982)
or Freunds adjuvant (Arend and Mannik, 1973)> or indirectly by T lympho¬
cytes (Moore and Myrvik, 1977). In vivo macrophage activation results
from interaction with lymphokines that are products of stimulated T cells.
Intratracheal inoculation of hamsters with Freuruisadjuvant (Zwilling and
Campolito, 1981) or rabbits with BCG (Schuyler and Steinberg, 1982) was
shown to increase the number of alveolar macrophages that possess comple-
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ment and IgG receptors and the avidity of the receptors on individual
cells. These activated macrophages were also shown to increase in
size, exhibit an increased phagocytic capacity and become tumoricidal.
During pulmonary infection, alveolar macrophages become activated with
a concomitant increase in the clearance of the organism from the lungs.
5-7 Alveolar-lining material
The cell-free portion of broncho-pulmonary lavage fluid has been
termed the alveolar-lining material of the lung. This material is
important in promoting the bactericidal activity of the alveolar
macrophage (LaPorce et al., 1973)» can produce directional migration
of the macrophage ana may aid in lung clearance (Schwartz and Christman,
1979)* The factor responsible for this activity is a lipid related
to surfactant and is not present in the serum (juers et al., 1976).
The lipid material coats the organisms and after phagocytosis has
occurred, undergoes peroxidation to produce a bactericidal environment
within the phagocytic vesicles (Mason et al., 1972; LaPorce et al.,
1973; Robertson, 1980). In vitro studies have indicated that alveolar
macrophage function is severely impaired in the absence of this
material (Skornik et al., 1973; Juers et al., 1976).
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6.0 SURFACE RECEPTORS ON ALVEOLAR MACROPHAGES
The macrophage membrane has been shown to express more than
thirty different receptors, including receptors for immunoglobulins,
complement components, hormones and other particles. This study
concentrates on the non-immune "lectin-like" receptor and the Fc
receptor for IgG and only these receptors will be reviewed.
6.1 Lectin-like receptors
Lectin-like receptors have the specific ability to bind unopson-
ised bacteria by means of their cell wall sugars. They are present
on mouse peritoneal and alveolar macrophages, human monocytes and
neutrophils and a wide range of phagocytes from different species
(Glass et al., 1981). Lectin-like receptors are among a group of
receptors that recognise carbohydrates, especially sugars,which have
been described over the last few years (reviewed by Weir, 198U; Weir
et al. , 198U; Sharon, 1982+).
Lectin-like receptors were first recognised in studies on the
interaction between Corynebacterium parvum and mouse peritoneal macro¬
phages. Magnesium and calcium ions are essential for binding of the
bacteria to the macrophage, which is inhibited by various sugars
(Ogmundsdottir and Weir, 1976). The ability of a particular sugar
to inhibit bacterial binding was further found to be directly related
to its presence on the bacterial cell-wall lipopolysaccharide (Freimer
et al., 1978). The lectin-like receptor is capable of binding tumour
cells and proliferating mouse embryo fibroblasts as their attachment is
inhibited by various monosaccharides (Weir et al., 1979). The receptor
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is susceptible to proteolytic and glycolytic enzymes, including trypsin,
pronase and B galactosidase and also to periodate, although bacterial
binding is increased by neuraminidase (Ogmundsdottir et al., 1978).
The action of trypsin was found to be reversible with bacterial binding
returning to normal levels after a few hours. The sensitivity of the
receptor to these enzymes, indicates that it is a glycoprotein.
Conversely bacteria may bind to macrophages via a lectin present on
the bacterial cell wall. C.parvum contains a mannose specific lectin
that binds to macrophages that possess mannose on their cell membrane
(Bagg et_ al., 1981). However sugars do not inhibit binding when
incubated with bacteria (Ogmundsdottir, PhD thesis, 1979)-
6.1.1 Function
The binding of bacteria to macrophages is an essential process
for the initiation of phagocytosis and antigen presentation (Unanue,
1978). The sugar recognising lectin-like receptor is involved with
other binding mechanisms (Capo et al., 1981) in the initial binding
of unopsonised bacteria to phagocytes prior to the involvement of Fc
or 03 receptors and antibody production. Therefore these receptors
are possibly important in the recognition and destruction of unopsonised
bacteria before an immune response is initiated. An in vivo study
has shown that peritoneal macrophages from diabetic mice bind fewer
bacteria than macrophages from non-diabetic mice (Weir et_ al., 1981).
These results indicated that sugar molecules were blocking lectin-like
receptors on the macrophages of the mice, that were subsequently more
susceptible to bacterial infection. The lectin-like receptor may
also be important in antigen presentation as it has been shown to be
50.
associated or identical with IA antigens (Stewart et al. , 1983)-
Various monoclonal antibodies to IA antigens were shown to inhibit
the binding ox bacteria to macrophages. Further evidence of a role
for this receptor in antigen presentation comes from studies on mice
with alloxan-induced diabetes. Peritoneal macrophages of these mice
were less efficient at binding Staph.albus and at antigen presentation
than macrophages from untreated mice. However Fc receptor expression
was not altered in the diabetic mice, arguing against a general mal¬
function of the macrophages from these animals (E J Glass, personal
communication).
Lectin-like receptors may also be involved in macrophage recognition
of altered self, including transformed cells (Weir et al., 1979) and
effete red blood cells (Kolb and Kolb Bachofen, 1978).
6.1.2 Regulation
In vitro exposure of mouse peritoneal macrophages to chemotactic
agents, F Met Leu Phe and casein, and in vivo exposure to oyster
glycogen and C.parvum inhibited bacterial binding activity (Glass et
al., 1982, 1983)- Similar findings were observed for the receptor
on mouse macrophages specific for mannose, fucose and N-acetylgluco-
samine (Ezekowitz and Gordon, 1982; Imber et al., 1982). 3CG and
G. parvum activated peritoneal macrophages showed reduced binding and
uptake of radio-labelled mannose.
Pseudomonas alginate has been shown to inhibit the binding of
P.aeruginosa and Staph.albus to mouse peritoneal and pulmonary macrophages
(Oliver and Weir, 1983)• Further studies on the lectin-like receptor
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will be described in this thesis.
6.2 Fc receptors
Fc receptors bind the Fc portion of immunoglobulin and are usually
identified by rosette formation with antibody labelled red blood cells.
Fc receptors have been identified on a number of different cells,
including B lymphocytes (Dickler and Kunkler, 1972), monocytes
(Abramson et al., 1970a^and neutrophils (ishizaka et al., 1970).
Human promonocytes and bone marrow monocytes, progenitors of the tissue
macrophage also possess Fc receptors (van Furth et al., 1979).
Alveolar macrophages possess receptors for the Fc portion of
IgG (Reynolds at al. , 1975 a; Boltz-Nitulescu et al. , 1981) and IgE
(Boltz-Nitulescu and Spiegelberg, 1982), but not IgM. Human alveolar
macrophages are capable of phagocytosis of bacteria opsonised with IgA,
indicating the presence of an Fc receptor for this immunoglobulin
(Reynolds et al., 1975a). A study on mice has shown that 1i$ of their
alveolar macrophages possess an Fc receptor for IgA, that increases
to 30% on activation (Gauldie et al., 1983)- This is not surprising
as IgA is the principal immunoglobulin in the normal lung.
6.2.1 Avidity
The avidity of Fc receptors increases as monocytes differentiate
into macrophages in culture, although the response initially drops
between one and three days of culture (Newman et al., 1980). The
avidity of Fc receptors increases as macrophages become activated and
this change may be used to differentiate macrophages into subpopulations
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(Moore and McBride, 1980). The cells with the highest avidity Fc
receptors are identified as the most highly activated cells in the
population. The mean avidity may also differ between populations of
macrophages at different sites within an animal. For example guinea-
pig peritoneal macrophages have a Fc receptor avidity three times that
of their alveolar macrophages (Rhodes, 1975)- Similarly rat and
murine alveolar macrophages have low avidity Fc receptors when compared
to peritoneal macrophages (personal observation), although subpopulations
within the lung may possess very high Fc receptor avidity (Zwilling et_
al. , 1982).
The degree of adherence of soluble complexes to Fc receptor bearing
cells was shown to be directly correlated with the affinity of the re¬
ceptor site and not the absolute number of receptors (Arend and Marnik,
1973)- This suggests that the receptors may vary in their availability
or accessibility on the cell membrane and that this may be influenced
by their orientation with respect to adjacent surface proteins. An
intact covalently bound Fc fragment is essential for binding and
requires the presence of the CH2 domain (Diamond et al., 1979;
Dorrington and Klein, 1982).
6.2.2 Turnover
Receptor mediated phagocytosis leads to a selective and largely
irreversible removal of Fc receptors from the macrophage plasma mem¬
brane. Interiorised Fc receptors are rapidly and selectively degraded.
In resting cells, receptor turnover has a half life of ten hours.
However after phagocytosis more than 50% of the receptors are
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degraded and the half life is reduced to two hours (Mailman et al.,
1983).
6.2.3 Function
The main function of the Fc receptor is to augment the phagocytic
uptake of viable bacteria when they are specifically coated with
antibody (Reynolds et al., 1979a). In monocytes and macrophages,
the Fc receptor facilitates the phagocytosis of foreign (Reynolds
et al., 197U) and autologous material (Kay, 1975)- The receptor
is also able to mediate antibody dependent cell mediated cytotoxicity
(ADCC)(Haskill and Fett, 1976; Shen and Fanger, 1981), stimulate
superoxide anion production (Goldstein et al., 1975) and the release
of many other factors, including prostaglandins (Bonney et al., 1980).
6.2.1+ Specificity and type
The most detailed studies have been carried out on murine Fc
receptors and three distinct IgG Fc receptors have been described.
FcRI binds monomeric and aggregated IgG2a with high affinity and is
sensitive to trypsin, cytochalasin B and the cold (1+°C) while FcRII
binds aggregated IgG2b and antigen bound IgG1 and is resistant to
trypsin, cytochalosin B and the cold (Diamond et al., 1978). FcRIII
binds IgG3 and is similar to FcRII in that it is resistant to trypsin,
cytochalasin B and the cold (Diamond and Burshstein, 1981). The
receptor for IgG3 appears to be a separate receptor as IgG1, IgG2a
and IgG2b aggregates do not compete with IgG3 aggregates for binding.
All three receptors mediate phagocytosis and ADCC of opsonised sheep
erythrocytes (Unkeless et al., 1979; Diamond et al., 1978; Ralph
54.
et al., 1983)- Similarly rat macrophages have at least two distinct
IgG Fc receptors. One receptor is specific for IgG2a and is
resistant to trypsin, while the other receptor reacts with IgG1,
IgG2b and heterologous IgG and is sensitive to trypsin (Boltz-
Nitulescu et al., 1981). These receptors mediate phagocytosis and
lysis.
Human IgG3 consistantly "bound to human alveolar macrophages more
than the other subclasses, IgG1, IgG2 and IgGlj., indicating the presence
of a specific Fc receptor for IgG3 on these cells (Naegel et al. , 1981).).
6.2.9 Number/cell
3 6
There are between 10 and 10 Fc receptors per mononuclear phago¬
cyte although the number varies between species (Unkeless and Eisen,
1973? Alexander et al., 1978) and activated macrophages may have more
receptors as a result of increased cell size (Newman et al., 1980).
Heavily stimulated rabbit alveolar macrophages were found to possess
g2.16 x 10 receptor sites for IgG per cell, almost double the number
g(1.21 x 10 ) found in unstimulated cells (Arend and Mannik, 1973;
Newman et al., 1980). A comparative study showed that guinea-pig
peritoneal macrophages had fifty times the number of Fc receptors
(10^/cell) than neutrophils (2 x 10^/cell) (Coupland and Leslie, 1983)-
6.2.6 Isolation and characterisation
Two polypeptide chains from a mouse macrophage cell line have
been isolated with molecular weights of approximately 60,000 and I;7,000
daltons that recognised IgG2a and IgG2b respectively (Mellman and
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Unkeless, 1980). Similarly two receptors have been isolated from
thioglycollate stimulated macrophages (Lane et al., 1980). One
protein had FcRI activity and a molecular weight of 67,000 daltons
while the second had FcR-II activity, and a molecular weight of
5U,000 daltons. An FcR-like protein was isolated from rabbit
alveolar macrophages with the use of sepharose affinity columns
(Kulczycki et al., 1980). However the molecular weight of the
compound varied with the gel, being 90,000 - 70,000 daltons in 6-6%
acrylamide gel and 39?000-55»000 daltons in 9% acrylamide gel.
An Fc receptor protein isolated from the human cell line U937
formed two bands on polyacrylamide gel of molecular weights 72,000
and 1+0,000 (Anderson, 1982). The former protein bound IgG1 but
not IgG2. The predominant Fc receptor isolated from plastic-
adherent human blood monocytes was shown to have a molecular weight
of 60,000 - 68,000 daitons by SDS-polyacrylamlde gel electrophoresis
(Cohen et al., 1983)*
6.2.7 Regulation
The number of IgG receptors on rabbit alveolar macrophages was
shown to increase after intratracheal injection of complete Freuds
adjuvant (Arend and Mannik, 1973) BOG (Montarraso and Myrvik, 1978)
into the lung. Similarly IgG2b receptor expression was found to be
slightly increased in thioglycollate stimulated mouse macrophages and
markedly increased in C.uarvum activated macrophages (Glass _et al.,
1983). Incubation of peritoneal macrophages with lung lining material
causes the cells to lose their Fc receptors (Zeligs et al. , 1981+).
Thus the environment can influence the expression of macrophage Fc
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receptors.
Modulation of Fc receptors on rat alveolar macrophages and human
monocytes by antibiotics is investigated in this thesis.
6.3 Complement receptors
Receptors for C3b and C3d, the third components of complement are
present on bone marrow monocytes (van Furth et al., 1979)» monocytes
and most normal alveolar macrophages (Daughaday and Douglas, 1976;
Warr and Martin, 1977)> However alveolar macrophages from Sprague-
Dawley, Long Svans ana Fisher rats were shown to lack receptors for
C1 , C2 or C3 although they were present on Lewis-Wist.ar strains
(Coonrad and Rehm, 1982). Peritoneal macrophages from these strains
of rats were shown to possess receptors for C1 and C3 and were able
to bind bacteria opsonised with complement. The reason for the lack
of receptors on the alveolar macrophage is unknown, however peritoneal
macrophages treated with rat lung lavage fluid exhibited a loss in
complement receptor function (Coonrad and Yoneda, 1983)- This effect
was reversible and it was postulated that lipids in the alveolar lining
material affected alveolar macrophage membrane and receptor functions.
Swiss mice have also been shown to lack C1 and C3 receptors on their
alveolar macrophages (Hearst et al., 1980).
Complement levels are low in the lung (Reynolds and Thompson, 1973)
so that alveolar macrophage C3 receptors may not be functionally
important in vivo. The early phase of killing of Pneumococci in
human alveoli does not require complement (Rehm and Coonrad, 1982).
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Phagocytosis of complement coated sheep erythrocytes was low in
human monocytes, although peritoneal macrophages did ingest a high
proportion of the erythrocytes, indicating that "binding via 03
receptors may only cause phagocytosis by activated macrophages
(Newman et al., 1980). Human alveolar macrophages were able to
phagocytose bacteria opsonised with activated C3 in the absence of
IgG (Richards et al., 198I+). C3b and Pc receptors may act synergist-
ically, for although adhesion of particles to the C3b receptor does
not necessarily result in phagocytosis (Pearon, 1931;) adhesion may





Phagocytosis is an endocytic mechanism and involves the uptake
of large particles (71 micron) such as micro-organisms, latex beads
and oil droplets by an active receptor-mediated process. Phagocytosis
is clearly distinguished from pinocytosis, an endocytic mechanism that
involves the uptake of small particles or soluble material such as
ferritin, macromolecules and low molecular weight solutes. Pinocytosis
is a mainly passive process that occurs by membrane invagination, the
concentration gradient determining the rate of particle transfer
(Chapman-Andersen, 1977).
Phagocytosis can be divided into two distinct events, attachment or
adhesion of a particle to the cell surface, which is followed by ingest¬
ion. While the first process occurs in the cold and does not require
metabolic energy, ingestion is temperature dependent and requires active
cellular metabolism to occur (Eabinovitch, 1967; Ito et al., 1981).
7.1.1 Attachment
The initial event of the phagocytic process is the contact and
adhesion of particles to the cell surface. Adherence may occur as
a result of nonspecific interactions between the particle and the cell
(Bongrand et al. , 1982) or specific receptor-mediated interactions.
Adhesion of positively charged particles is stronger than that of
negatively charged particles on account of repulsive forces (Weiss,
1969) and is enhanced by the removal of negative ions from a particle,
such as an erythrocyte (Capo et al., 1979). However electrostatic
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forces do not play a main role in particle adhesion as "bacteria
and macrophages are often "both negatively charged (Beveridge, 1980).
Adhesion of latex, oil droplets and ghutaraldehyde-fixed cells to
macrophages takes place by means of "unspecific binding sites
(Stossel, 1975; Vogel et al., 1980; Benoliel et al., 1980).
In many cases this unspecific binding seems to be a result of the
hydrophobicity of the particles or molecules (Wilkinson, 1976;
van Oss, 1978). High interfacial tension between the particle and
surrounding medium, but low interfacial tension against the phago¬
cytic cell favours binding (van Oss, 1978). Cationic substances
enhance adhesion as they favour the formation of large contact
areas between the particle and phagocytes (Capo et al., 1981).
Specific receptors that mediate attachment include "lectin-
like" receptors, Fc and complement receptors and have been discussed.
7.1.2 Ingestion
Ingestion involves the formation of membrane extensions that
surround and finally fully enclose the particle in a phagocytic
vacuole. This process is rapid at optimum conditions and may
occur within 10-30 seconds after the initial contact of the particle
(Bowers, 1980; MacRae et al., 1980). It is temperature dependent
(Silverstein et al., 1977)» requires metabolic energy and is promoted
by calcium ions (Stossel, 1975; Bartwig et al., 1980).
7.2 Mechanism
The "zipper" mechanism of phagocytosis proposed by Griffin et al.,
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(1975b) involves the ligand-mediated circumferential spreading of
the plasma membrane around a particle. Phagocytosis will only
occur if macrophage membrane receptors, that were not involved in
the initial attachment process, bind to ligands over the whole
surface of the particle (Griffin et al., 1975b, 1976). Following
attachment of a particle to the Fc receptor, thin lamellipodia
form and remain tightly apposed to the particle surface throughout
the engulfment process (Stossel and Hartwig, 1976; Silverstein
et al., 1977). Pseudopods that form around the particle form a
large depression, termed the phagocytic cup. This gives rise to
a phagosome upon closure of the membrane and fuses with lysosomes
to form secondary lysosomes in which internalised material is di¬
gested by acid hydrolases (review by Silverstein et al., 1977)-
However the "zipper" mechanism has not been shown for all receptors
(Kaplan, 1977; MacRae et_ al. , 1980; Ryter and Hellio, 1980).
Ingestion will occur when contact areas are randomly located along
pseudopods or filapods (MacRae et al.,1980; McNeil et al., 1981)
and 03 receptors establish discontinuous contacts (Kaplan, 1977)«
7.2.1 Contractile Mechanism
Cytoplasmic contractile elements provide the locomotive force
for advancing pseudopods (filapodia or lamellipodia). The submem-
brane region adjacent to the particle being ingested contains a
thick network of filaments, from which cytoplasmic organelles are
excluded (Griffin et al., 1976). This network contains actin,
myosin and an actin-binding protein (Stendahl et_ al., 1980; Valerius
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et al. , 1981). Purified actin and actin "binding protein from
alveolar macrophages form gel lattices at low calcium concentrations,
while myosin, in the presence of magnesium ions and ATP causes
isometric contraction of the actin filaments (Stossel and Hartwig,
1976). A calcium dependent regulator protein, gelsolin, has been
identified and shown to control the formation of the actin - actin
binding protein lattice (Yin and Stossel, 1980). Contraction of the
actin filaments that are attached to the membrane leads to the mem¬
brane being pinched upwards and outwards, to form a pseudopod
(Hartwig et al., 1977). An increase in the calcium concentration
in the presence of gelsolin results in the dissolution of actin -
actin binding protein lattice. Thus as the region of rigid membrane
moves round the particle, it is followed by a secondary wave of
relaxation. A gradient is maintained, with rigidity being maximal
in the tip of the advancing pseudopodium. Throughout the process
fresh insertion of the membrane takes place, to keep pace with the
process of internalisation (Ryter and De Chastellier, 1977)-
7-3. Triggering mechanism
The mechanism that triggers the contractile protein mobilisation
is not clearly understood. The stimulus to phagocytose a bound
particle does not result in the ingestion of other particles that
are attached to the membrane surface (Griffin and Silverstein, 197U;
Griffin et al., 1975a). The response of the membrane is confined
to that segment of membrane immediately adjacent to the particle
initiating the stimulus, so that the signal for phagocytosis is
restricted to that particle. It has been proposed (Griffin at al. ,
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1976) that in the case of IgG coated particles, the ligand-receptor
interaction generates the release of actin-binding protein from the
plasma membrane. The protein is then believed to initiate poly¬
merization and aggregation of contractile proteins which leads to
the extension of phagocytic pseudopods. Pseudopod extension causes
further receptor-ligand interaction, which consequently generates
further contractile protein association. However this hypothesis
cannot account for the many cases in which contacts between a particle
and the phagocytic membrane are loose and discontinuous (MacRae et al.,
1980). It is therefore likely that the signal triggering contractile
protein mobilisation can propagate in the absence of a progressive
and permanent contact between particle and phagocyte. The factors
triggering the dissociation of the filament network., once internal-
isation has occurred, also remain unknown (Ryter and De Chastellier,
1983). It appears that phagosome closure is not a prerequisite for
local microfilament network dissociation (De Chastellier and Ryter,
1982).
After heavy phagocytic activity, phagocytes enter a refractory
period, during which particle uptake is markedly suppressed (Werb
and Cohn, 1972). Cells round up and are incapable of further phago¬
cytosis for several hours. This refractory period appears to be due
to the time required to replace the interiorised pla.sma membrane
(Low, 1975).
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8.0 ANTIBIOTICS DT CYSTIC FIBROSIS
The improvement in the prognosis of CP patients can to a large
extent be ascribed to the introduction and development of more
potent antibiotics since the 19U0's. Por example, penicillin and
streptomycin in the 19U0's, tetracycline, chloramphenicol and
erythromycin in the 1950's, ampicillin, carbenicillin and genta-
micin in the 1960's; tobramycin and a range of second and third
generation cephalosporine and ureidopenicillins in the 1970*3 and
1980"s (H^iby et al., 1982).
The principal beneficiaries of antimicrobial therapy are normally
healthy people who have an acute bacterial infection, whereas patients
with CP who have chronic respiratory infection are rarely cured by
antimicrobial therapy. In the latter situation, antibiotics may
control the infection, but therapy is often frequent and prolonged.
Therefore any effect that an antibiotic may have on the host, other
than an antimicrobial one, may be clinically important.
Three antibiotics used extensively in the therapy of CP patients,
namley azlocillin, ticarcillin and tobramycin have been studied for
their effects on the alveolar macrophage. These antibiotics all
improve the clinical status of the patients but mucoid P.aeruginosa
are rarely eradicated (Marks et al., 1976). Their structure and anti¬
microbial activity are discussed below.
8.1 Azlocillin
Azlocillin is a semi-synthetic B-lactam derived from ampicillin.
It possesses an acyl ureido derivative alteration at the amino group
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of the ampicillin molecule (Diagram 2).
8.1.1 ■Antibacterial activity
As a B-lactam, azlocillin inhibits the growth of bacteria by-
blocking the action of transpeptidases essential for the crosslinking
of the bacterial cell wall (Tipper and Strominger, 19^5) so that the
bacteria must be multiplying for the antibiotic to exert its bacteri¬
cidal activity. Recently several additional enzymes, termed penicillin-
binding proteins (PBP), essential for cell wall synthesis have been
found to be inhibited by B-lactams. P.aeruginosa possess eight
PBPs (Prince and Neu , 1981). The binding affinity of an antibiotic
for the receptor protein will in part determine the inhibitory
concentration of a particular B-lactam. The possession of an
acyl ureido group gives azlocillin an increased affinity for critical
penicillin-binding proteins, particularly the enzyme, septal murein
synthetase. The enzyme is responsible for septal formation during
bacterial growth and cell division. Inhibition of the enzyme results
in the formation of nonviable and readily lysed filamentous bacterial
cells.
The high activity of azlocillin is due to the antibiotics1
ability to pass through the outer bacterial cell wall and bind to the
target proteins with such high affinity that the penicillinase
enzymes cannot degrade it rapidly enough (Prince and Neu, 1983)-
Azlocillin is more active in vitro against P.aeruginosa than
ticarcillin (Coppens and Klastersky, 1979) or carbenicillin (Hodson
















Diagram \ Structure of the three antibiotics used in this study.
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Azlocillin is not normally used as a single agent for the
treatment of P.aeruginosa infection because of the risk of resistance
(Michalsen and Bergan, 1980; NpSrrby, 1981).
8.2 Ticarcillin
Ticarcillin is an d- carboxy-3-thienyl methyl penicillin and
lacks a ureido group (Diagram 2).
8.2.1 Antibacterial activity
The antibacterial mechanism of action of ticarcillin is similar
to that already described for azlocillin, although it is less active
in vitro than azlocillin as ticarcillin lacks a ureido group. How¬
ever its activity against P.aeruginosa exceeds that of carbenicillin
by two to four fold (Comber et al., 1977)*
Using electron microscopy it was found that azlocillin and
ticarcillin at similar concentrations initially caused the formation
of filaments by P.aeruginosa (Elliott and Greenwood, 1983). On
further incubation deposits of dense intracellular material were
observed with subsequent lysis of the filaments. Azlocillin caused
breakages at a restricted number of sites on the cell wall, while
ticarcillin caused breakage at many points. Therefore, ticarcillin
may act more rapidly and be more efficient at causing bacterial lysis
than azlocillin. The MIC of ticarcillin for P.aeruginosa is in the
range 11.2-62.1+ (Coppens and Klastersky, 1979).
8.3 Tobramycin
Tobramycin is an aminoglycoside and contains amino sugars
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glycosidically linked to aminocyclitols (Diagram f ).
8.3.1 Antibacterial activity
Tobramycin is rapidly bactericidal and acts on the
ribosomal subunit to block bacterial protein synthesis. It is
highly active against P.aeruginosa being four times more active
it
than gentamicin, thatfhas generally superseded in the treatment
of P.aeruginosa infections (Norrby, 1981). Tobramycin remains
active against strains with acquired resistance to gentamicin
(Hyams et al., 1973; Hodson and Batten, 1981) and the susceptibility
of this antibiotic has remained unchanged compared to gentamicin
(Blessing et al., 1981). Although tobramycin can eliminate non-
mucoid P.aeruginosa, mucoid forms are only reduced in number
(Hoogkamp-Xorstanje and van aer Laag, 1983).
Tobramycin is fairly resistant to the inactivating bacterial
enzymes, such as phosphorylases, adenylases and acetylases that
occur in P.aeruginosa strains and this may account for its high
anti-pseudomonal activity. The MIC against P.aeruginosa is in
the range 0.25-U mg/l (Rolston at al. , 1981+).
Tobramycin acts synergistically with the B-lactam antibiotics
and helps to prevent the development of P.aeruginosa resistance to
the B-lactams, such as azlocillin (Hoogkamp-Korstanje et al., 1981).
The phenomenon of synergy between aminoglycosides and B-lactam
antibiotics against P.aeruginosa can be explained by the activity
of the B-lactam on the cell wall, facilitating the penetration of
the aminoglycoside. Synergism requires that both the antibiotics
in combination are present at optimal concentrations at the site
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of an infection (Zak, 1980).
8.1}. Antibiotic therapy in Cystic Fibrosis
Antibiotic treatment of mucoid P.aeruginosa pulmonary infection
in CP patients is usually ineffective as the organisms are rarely
eradicated (Kulczycki et al«, 1978). In fact it has been claimed
that the continuous use of antistaphylococcal antibiotics in CP
has contributed to the increasing isolation of P.aeruginosa
(Kulczycki et al., 1978).
Although the levels of anti-staphylococcal and anti-haemophilus
antibiotics achieved in the CP lung are able to inhibit bacterial
growth, it is thought that adequate levels of anti-pseudomonal drugs
are rarely achieved (Raeburn, 1975). Pour hours after an intra¬
venous infusion, azlocillin was only detected in 3k out of 111 sputum
samples, where the concentration range (0.5-U ^g/l) was below the MIC
range for P.aeruginosa. However the antibiotic concentration in
serum was markedly higher (32-11+2 mg/ml) (Levy et al., 1982). Another
study showed that the sputum antibiotic concentrations were low
(1.5-28 mg/ml) after a large intravenous injection of azlocillin
(Malmborg et al., 1981). Similar studies with tobramycin have
shown the concentration in sputum to be below the MIC (0.1 - 0.1+ mg/l)
after intravenous injection of large doses (Malmborg et al., 1981).
Tobramycin was shown to penetrate slowly into the sputum but to give
fairly constant levels of up to 13% of peak serum level (0.57-0.68 mg/l)
(Hoogkamp-Korstanje and van der Laag, 1983). Treatment of patients
was most successful in whom the highest peak sputum concentration of
tobramycin was obtained, as opposed to the absolute dose given
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(McCrae et_ al., 1976). High doses of tobramycin were shown to
eradicate P.aeruginosa from four out of seventeen patients. However
the concentration of B.lactam antibiotics in sputum did not predict
the outcome of the treatment, as high levels did not correlate with
elimination of the bacteria (Malmborg et al., 1981). Inhalation of
tobramycin resulted in a higher percentage of eradication than intra¬
venous treatment (Stephens et al., 1983)- However, in this study
the observed suppression of P.aeruginosa in the sputum did not
correlate with the clinical response to treatment. This response
did not differ between the two groups and eradication of the bacteria
was only temporary with inhalation studies. These results illustrate
the complexicity of the problems involved in the treatment of
P.aeruginosa infection in CP.
Although many factors are involved in the persistent P.aeruginosa
infection observed in CP, the low levels of antibiotics attained in
the lungs of these patients may in part account for the ineffective
eradication of this organism. As previously discussed, CP patients
with chronic infection may be immunocompromised or hyper-immune, so
that antibiotic therapy may be less efficient and quite different for
CP than normal individuals. Information on the effective antibioxic
concentration at the site of infection, distribution and half-life in
pulmonary secretions is limited, making treatment difficult. Concen¬
trations of antibiotic in the sputum may not reflect the concentration
at the site of infection. Similarly sputum cultures and bacterial
numbers do not always correlate with that obtained from lung culture
(Doershuk et al., 1976).
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Purulent material such as pus may inactivate antibiotics or
they may bind pus or P.aeruginosa alginate and become ineffective
(Bryant and Eammond, 197U)- Diffusion of aminoglycosides, though
not B.lactams has been shown to be retarded in vitro by P.aeruginosa
alginate and sodium alginate (Slack and Nichols, 1981). It was
postulated that this result was due to the negatively charged
alginate acting as a cation exchanger to inhibit the diffusion of
positively changed antibiotics, such as the aminoglycosides.
Antibiotics are eliminated more rapidly in CP patients than
normal individuals (Marks, 1981; Kelly et al., 1982) so for serum
levels to be maintained, higher doses than those prescribed may be
required for the CP patient (Smith, 1980). Pharmacokinetic studies
have demonstrated altered deposition, increased excretion and low
peak serum levels of antibiotics in CP patients treated with conven¬
tional doses of semisynthetic penicillins (Prince and Neu, 1980) and
aminoglycosides (Pinkelstein and Hall, 1979)•
Improvement in pulmonary function does not always correlate
with the bacteriologic response of the patient. Factors, other
than intravenous antibiotic therapy, may contribute to the beneficial
response observed during hospitalisation (McLaughlin et al., 1983)-
Antibiotics may be prescribed intermittently to treat specific
exacerbations identified clinically and by sputum bacteriology or
prophylactically and continuously (Miller and Hpfiby, 1981). Both
regimens have disadvantages as there is a fall in the efficacy of
an antibiotic when antipseudomonal treatment is repeated. Prophylactic
treatment may result in a reduced capacity to resist secondary bacterial
challenge and the emergence of resistant strains (North et al., 1981).
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9.0 THE EFFECT OF ANTIBIOTICS ON THE IMMUNE RESPONSE
Since chemotherapy became established, the direct effect of
antimicrobial substances on bacteria have been extensively studied,
with little attention being given to the effects on the hosife
immune defense system. Conventional antimicrobial sensitivity
testing only considers the interaction between the drug and the
microorganism, ignoring the possible effects of humoral and cellular
factors on this relationship. Yet for antibiotic treatment to be
effective in the long term, an adequate host immune response is
essential (Peterson, 1982). Antibiotics alone do not eliminate
bacteria, they either kill or retard their growth, leaving the host
to clear the organisms and toxic products from the body.
Subinhibitory concentrations of antibiotics have been shown to
induce morphological and biochemical changes in bacteria (Lorian,
1975) and render them more susceptible to phagocytosis and killing
(Gemmell et al., 1981; Milatovic, 1982). The effect of these low
antibiotic concentrations may be important as drug levels achieved
in the tissues may not attain the MIC of the target organism, as
previously discussed.
Adverse effects of an antibiotic on the immune system may be
difficult to identify as the effect may be transient, easily reversed
or attributable to the primary infection (Haeburn, 1982). During
an acute bacterial infection, any disadvantageous effect of an
antibiotic would be likely to be outweighed by the benefits of the
drug in eliminating the organisms. Therefore the relevance of many
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observations is probably doubtful as antimicrobial therapy is usually
short-lived. However treatment of chronic bacterial infections
such as those that occur in CP require continuous or intermittant
therapy. In this case any effect that an antibiotic may have on
the host immune response may be important and influence the progress
of an infection. Immune mechanisms play an integral part in the
pathogenesis of CP and are important for recovery. Any immuno-
modulating effect of an antibiotic may have therpeutic significance
and an awareness of potential effects on the immune system could be
important. The many effects that antibiotics have on the immune
system have been reported and reviewed (Hauser and Remington, 1982a,b;
Mandell, 1982; Milatovic, 1983; Oleske, 198I4.) and will be discussed
below. Observations at concentrations that exceed those achieved
therapeutically are unlikely to have clinical significance (Pinch, 1980)
and will not be considered in this review.
9.1 Neutrophils
Initially neutrophils are the first cells to migrate and concentrate
at the site of bacterial infection, therefore any interaction with
antibiotics may be very important (Raeburn et al., 1980). Many
studies have been performed on the neutrophil as opposed to the
macrophage, possibly because neutrophils are easily obtained from human
peripheral blood (review by Mandell, 1982).
8.1.1 Tetracyclines and others
Tetracyclines have been shown to inhibit neutrophil chemotaxis
(Forsgren and ochmelling, 1977; Belsheim and Gnarpe, 1981),
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phagocytosis (Forsgren et al., 197U; Gnarpe and Belsheim, 1981),
intracellular killing (Welch et al., 1981) and adherence to glass
(Gnarpe and Belsheim, 1981). Rifampicin and trimethoprim were also
shown to depress neutrophil chemotaxis (Forsgren et al., 1980; Welch
et al. , 1981), chemiluminescence (Siegel and Hemington, 1982) and
intracellular killing (Easmon, 1979; Welch et al., 1981).
9.1.2 B.lactams
Generally the penicillin and cephalosporin antibiotics have
not been shown to have any effect on neutrophil function (Forsgren
and Schmelling, 1977; Ma.jesky et al. , 1978; Gnarpe and Belsheim,
1981; Hawkey et al., 1983)- However, there are a few exceptions.
At concentrations below the MIC, carbenicillin and sulbenicillin
were shown to increase the phagocytosis and intracellular killing
of P.aeruginosa by rabbit neutrophils (Nishida et al., 1976). In vivo
ampicillin depressed while cefaclor enhanced the myeloperoxidase
activity and phagocytosis of Staph.aureus by human neutrophils
(Kowclik et al., 1982; Grant et al., 1983).
Ceftazidine was shown to increase neutrophil adherence to nylon
wool in vitro (Gnarpe et al. , 198I+) and in vivo to increase the
chemiluminescence of human neutrophils stimulated with opsonised
zymosan, but not opsonised Staph.aureus (Cullen et_ al., 1983). A
new semisynthetic cephalosporin, AC 1370, has been found to augment
the chemotaxis, NBT reduction, phagocytosis and intracellular killing
in murine and human neutrophils (Ohnishi et al., 1983)-
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9.1.3 Aminoglycoside s
Results from studies of this group of antibiotics on the immune
response have been contradictory and confusing. Using Boyden
chambers, aminoglycosides including gentamicin were shown to inhibit
the migratory activity of neutrophils (Goodhart, 1977; Belsheim and
Gnarpe, 1981), while with studies using an agarose plate method,
these antibiotics had no effect on chemotaxis (Foragren and Schmelling,
1977; Forsgren _et al., 1980). Similarly other studies have shown
that aminoglycosides have no effect on phagocytosis (Welch et al.,
1981; LeMoli et al., 1983) intracellular killing by rabbit
(Uishida et al., 1976) or human neutrophils (Welch et. al. , 1981).
Gentamicin however inhibited the intracellular killing of bacteria
when added to the neutrophils after ingestion had occurred (Easmon,
1979) but had no effect when added prior to ingestion (Nishida et al.,
1976). Seckleki et. al., (1978) studied neutrophil migration and
adherence in the presence of varying concentrations of amikacin,
kanamycin, gentamicin, tobramycin and netilmicin, in vitro. Bacterial
chemotactic factor-induced chemotaxis was inhibited by each of the
aminoglycosides and was dependent on the continual presence of the
antibiotic. Adherence of neutrophils to rnylon fibres was moderately
increased, while phagocytosis and NBT reduction were unaffected by
the antibiotics. Neutrophils incubated with various aminoglycosides
including tobramycin, prior to the addition of Candida, exhibited
decreased candidacidal activity (Ferrari et al., 1980).
In vivo gentamicin and amikacin given to normal healthy adults
resulted in a transient decrease in chemotaxis but an increase in
75.
random migration of their neutrophils (Khan et al., 1979)• The
observed inhibition occurred one hour after the injection but not at
21+ hours and did not correlate with the antibiotic concentration in
the serum.
9.2 Macrophages
In contrast to the neutrophil, the effect of antibiotics on the
macrophage, despite its importance in the immune response has received
only limited attention. In vivo rifampicin has been shown to inhibit
the phagocytic activity of mouse peritoneal macrophages when given
intraperitoneally (Bassi et al., 1973)• I*1 this case the main target
of the antibiotic was shown to be the phagocytosing cell. Ampicillin
and tetrocycline were shown to enhance the phagocytosis of Listeria
monocytogenes by human monocytes (Adam, 1982). Similarly, penicillin,
gentamicin, tobramycin and tetracycline were shown to enhance the
phagocytosis of L.monocytogenes by cultured human monocytes, although
ampicillin had an inhibitory effect in this study (Cifarelli et_ al.,
1982). Gephalothin and gentamicin were reported to have no effect
on phagocytosis but to increase the intracellular killing of bacteria
by guinea-pig alveolar macrophages (Brunner and Undeutsch, 1982).
Therefore the effect observed with some antibiotics, for example,
gentamicin, may depend on the type of mononuclear phagocyte studied.
When human peripheral blood monocytes were incubated for one
hour with ceftazidine, a depressed chemiluminescent response was
observed (Gulden et al., 1983)- AC,1370 as well as augmenting
neutrophil function, was shown to increase the phagocytosis of
bacteria by mouse peritoneal macrophages in vitro and in vivo
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(Ohnishi _et al. , 1983)* This antibiotic appears to potentiate
phagocytic function as well as having a bactericidal effect.
The effects of azlocillin, ticarcillin and tobramycin on rat
alveolar macrophages and human monocytes are investigated in this
thesis.
9-3 Lymphocytes
The effect of antibiotics on the humoral and cell-mediated
responses has been reviewed (Hauser and Remington, 1982a) and will be
briefly discussed below.
An early study showed that tetracycline, erythromycin and peni¬
cillin had no effect on human lymphocyte proliferation in response
to PHA (Bam et al., 1975)- Munster et_ al., (1977) measured BNA
synthesis of PHA stimulated lymphocytes and found that tetracyclines
suppressed BNA synthesis in a dose-dependent fashion, while 3.lactams
had no effect and gentamicin slightly stimulated BNA synthesis.
However, another study showed that two B.lactams, moxaiactam and
cefuroxine depressed the PHA response of lymphocytes when incubated
with the cells and PHA (Manzella and Clarke, 1983)- Pre-incubation
of the lymphocytes with the antibiotics had no effect and the depressive
effect was less marked when Con A was the mitogen. Tetracycline and
fusidic acid have been shown to inhibit the mitogenic response of T
and B lymphocytes,in vitro antibody production and protein synthesis
in unstimulated lymphocytes (Banck and Forsgren, 1979; Thong and
Ferrante, 1979)- These antibiotics have also been shown to reduce
the delayed type hypersensitivity reaction to sheep erythrocytes
(Thong and Ferrante, 1980). Chloramphenicol was shown to suppress
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antigen-induced lymphocyte blastogenesis, but not lymphokine pro¬
duction by stimulated lymphocytes (Lamert and Sohnle, 1979).
Generally studies have failed to demonstrate any effect on
cell mediated immunity by aminoglycosides or penicillins (Banck
and Forsgren, 1979; Hauser and Remington,1982b). However,
cephalosporins have been shown to produce a dose-dependent reduct¬
ion in the human lymphocyte response to PHA, PM and Con A (Chaperon
and Sanders, 1978; Banck and Forsgren, 1979)» although ceftazidine
has no effect on these functions (Gnarpe et al., 198I+). Another
study showed that antibiotics including peneicillin and gentamicin
reduced in vivo antibody production in rabbits (Lochmann et_ al.,
1979). In vitro gentamicin was shown to have no effect or antibody
synthesis (Forsgren et al., 1980).
9.1). Transport into cells
The effect of an antibiotic may be related to its ability to
penetrate into the phagocytic cells of the host. Penicillins and
cephalosporins are taken up poorly by rabbit and human alveolar
macrophages and neutrophils as intracellular levels were shown to
be low (Johnson et al., 1980a; Prokesch and Hand, 1982). Similarly
aminoglycosides do not attain high intracellular levels although they
are taken up to a greater extent than the B.lactams (Prokesch and
Hand, 1982; Hand et al. , 198)4).
Lipid soluble antibiotics such as rifampicin, chloramphenicol
and the tetracyclines are taken up by alveolar macrophages and
concentrated within the cell (Hand et al., 1983)0 Erythromycin
and clindamycin are actively taken up into cells via the nucleoside
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transport system and are concentrated fifteen to fifty times within
alveolar macrophages in minutes (Johnson et al., 1980a; Hand and
King-Thompson, 1982).
The ability of an antibiotic to enter the alveolar macrophage
has been shown to correlate well with the efficacy of the drug in the
treatment of certain intracellular pulmonary infections (Hand et al.,
I98I4.). This ability may also effect the host cell and the obser¬
vation that tetracyclines have greater and more consistant effects
on neutrophils than the B.lactams, may be a result of the former's
greater uptake into the phagocytes.
Although clear conclusions and generalisations are difficult
to make from the studies discussed, it would seem that many anti¬




AIMS OP THE PRESENT STUDY
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Pulmonary infection with mucoid, alginate producing P.aeruginosa
is a major problem in CP. Studies discussed in the introduction have
indicated that CP patients do not have a general immune defect, but
that secondary immune defects may arise as a result of the infection.
The advantages that the mucoid forms have over the non-mucoid forms
were also discussed. The first aim of this thesis was to investigate
the hypothesis that the production of alginate, gives mucoid P.aeruginosa
a selective immunological advantage over non-mucoid forms.
The binding of bacteria to macrophages by specific receptors is
the first step in the recognition process that leads to phagocytosis
and the subsequent elimination of the bacteria. Therefore the effects
of alginate isolated from a mucoid P.aeruginosa strain on rat alveolar
macrophage function and receptor expression were investigated by study¬
ing:
1) The binding and phagocytosis of non-mucoid P.aeruginosa and
Staph.albus.
2) The binding of antibody sensitised sheep erythrocytes to Pc
receptors and the phagocytosis of latex.
The effect of alginate on the opsonisation of non-mucoid
P.aeruginosa was also examined.
Mucoid P.aeruginosa are rarely eradicated from the CP lung even
after intensive antibiotic therapy. Therefore, any adverse or advant¬
ageous effect an antibiotic may have on the alveolar macrophage, which
as discussed previously, is so important in pulmonary defense, may
argue against or in favour of its long term use. The second aim of
this thesis was to investigate the effect of low levels of antibiotics
(similar to those attained in the CP lung) on alveolar macrophage
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function and receptor expression. Three antibiotics namely azlocillin,
ticarcillin and tobramycin were studied at concentrations above and below
the MIC for P.aeruginosa h92a Rev1. Monolayers of rat alveolar
macrophages were prepared and assays were carried out to determine
the effect of the antibiotics on:
1) Lectin-like receptors - by studying the binding of unopsonised
bacteria.
2) Phagocytosis of opsonised P.aeruginosa.
3) Pc receptors by the rosette technique using antibody sensitised
sheep erythrocytes.
The antibiotics were either pre-incubated with the macrophages
or added to the monolayers with the indicator cells. For each
assay the effect of the antibiotics on the indicator cells (opsonised
bacteria or sensitised erythrocytes) was also examined.
The mechanism of action of tobramycin on Pc receptors was further
investigated by studying the effect of supernatants taken from tobra¬
mycin-treated macrophages on:
1) The binding of EA^ to Pc receptors after treatment of the erythro¬
cytes with supernatant.
2) The binding of EA^ to supernatant-treated alveolar macrophage
monolayers.
3) The agglutination of EA^.
Polyacrylamide gel electrophoresis was also carried out to determine
the protein content of the supernatants.
Experiments on the effect of the three antibiotics on human
monocyte Pc receptor expression were performed to determine the





1.0 BUFFERS AND STAINS
All chemicals were analytical grade, obtained from 3.D.H.
Chemicals Ltd., Poole, Dorset or Fisons Scientific apparatus,
Loughborough, Leicestershire, unless otherwise stated.
1.1 Dulbecco's phosphate buffered saline (D.FBS)
This was prepared from tablets (Oxoid, Basingstoke). One
tablet was dissolved in 100 ml of distilled water.
1.2 D.PBS with calcium and magnesium (P.FBS.'B')
This was prepared by dissolving 2g CaCl and 2g MgCl in 100 ml
of distilled water. 0.5 ml was then added to 100 ml D.PBS.
1.3 Eagle's, Minimum Essential Medium (MEM)
Eagle's MEM was prepared by mixing 10 ml of 10 times concentrated
Eagle's MEM (Wellcome Research Laboratories, Beckenham, Kent), 1 ml,
1M Hepes, 5 nil, l±% sodium bicarbonate, 1 ml, 0.2M glutamine and
making the volume up to 100 ml with distilled water.
1.3.1 Eagle's MEM with antibiotics
This was prepared as above except that 0.1 ml of penicillin
and streptomycin (200,000 U ml ^) were added.
1.h EDTA (20mM)




0.5 ml of formaldehyde was added to 100 ml of 0.9% saline.
1.6 Glycine buffer
16.3g of aminoacetic acid (glycine) and 12.65g of NaCl were
dissolved in distilled water. The pH was adjusted to 8.2 with
NaOH (10% solution) and the mixture made up to 1 litre with dis¬
tilled water.
1.7 Glycine, Bovine serum albumin (G.BSA)
One g of bovine serum albumin (Sigma) was added to one litre
of glycine buffer.
1.8 Hanks balanced salt solution (HBSS)
Hanks stock solution(Oxoid, Basingstoke) pack A and pack B
were dissolved in one litre of distilled water. Equal volumes (50ml)
of each stock solution were added together and made up to one litre
with distilled water.
1.9 Ecrmol-HBSS (1%)
One ml of formaldehyde was added to 99ml HBSS.
1.10 Gelatin-EBSS (1%)




This was prepared by dissolving 23«83g Hepes buffer (Plow
Laboratories, Irvine, Scotland) in distilled water. The pH was
adjusted to 7.6 with 5N.NaOH and the final solution made up to
100 ml with distilled water.
1.12 Iso-sensitest broth
23-kg of iso-sensitest broth (Oxoia, Basingstoke) were dis¬
solved and made up to one litre with distilled water.
1.13 Lysis buffer
This was prepared by dissolving 8.2g NH^Cl, 1g KHCO^ and
0.037g Na^EBTA and making up to one litre with distilled water.
1.11+ Sodium bicarbonate buffer (b%)
Pive g of sodium bicarbonate were dissolved and made up to
100 ml with distilled water.
1.15 Sodium chloride ( 2. 5>M)
This was prepared by dissolving 1l+.6g of NaCl and making up
to 100 ml with distilled water.
1.16 Tris HC1 buffer (5mM)
This was prepared by dissolving 2.l+2g of Tris buffer (Tris
hydroxymethyl methylamine) and making up to one litre with distilled
water. The pH was adjusted to 7-b with 1N HC1 and the volume made
up to four litres with distilled water.
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1.17 May Grunwald/Giemsa stain
May Grunwald stain was diluted 1:6 with buffered water,
pH 6.8 (tablets from Gurr, Searle Laboratories).
Giemsa stain was diluted 1:30 with buffered water. Cell
monolayers were stained for three minutes in each stain in the
above order, and washed with water.
1.18 Trypan blue
1% aqueous trypan blue was added to the cell suspension in
a 1:1 ratio.
1.19 White cell diluting: fluid
A stock solution was prepared by adding 0.1g gen.tian violet
to 100ml of 1% acetic acid. For use, the stock was diluted 1:10
with 1% acetic acid and one part cell suspension was added to nine
parts stain.
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2.0 PURIFICATION OF CELLS
2.1 Animals
Male Sprague-Dawley, specific pathogen free (SPF) rats were
obtained from the centre for laboratory animals, Edinburgh University.
2.2 Rat alveolar macrophages
Rats were killed with sodium pentobarbitone, ( 5>0mg/animal I.P.),
exsanguinated and the trachea and lungs removed. Alveolar macrophages
were obtained by lavage, via a tracheal cannula, with pre-warmed
3). PBS and heparin (10U ml ). Fifty ml of lavage fluid was collected
and centrifuged at 200g for 10 minutes. The macrophages were sus¬
pended in Eagles MEM to give a final viable cell count of 2 x 10^
ml ^.
2.3 Human monocytes
Monocytes were separated according to the method of Boyum (1968).
Blood from healthy donors was drawn into siliconised universals,
containing 10 units of heparin ml and diluted with an equal volume
of physiological saline. The diluted blood was layered onto Ficoll-
Hypaaue cushions, specific gravity 1.078 (Pharmacia, Uppsala, Sweden)
in a 3:1 ratio and centrifuged for I4O minutes at l+00g. The cells
at the interface containing monocytes and lymphocytes were collected,
washed twice in D.PBS and resuspended in Eagle's MEM to give a final
6 —1
viable cell count of 10 ml
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2-2+ Preparation of monolayers
One ml of the prepared cell suspension was layered onto
13mm diameter glass coverslips in l6m.ni well diameter tissue culture
plates (Nunc, Copenhagen) and incubated for 30 minutes at 37°0.
Non-adherent cells were removed by washing with warm Eagle's MEM.
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3-0 PREPARATION OF THE INDICATOR CELLS
3.1 P.aeruginosa
P.aeruginosa strains were obtained from Dr J.R.W. Govan,
Bacteriology Department, University of Edinburgh. Strain l+92a
is a mucoid, alginate-producing strain isolated from the sputum
of a cystic fibrosis patient and U92a Rev1 is an isogenic non-
mucoid revertant of this strain.
The bacteria were grown for 2l+ hours at 37°C on nutrient
agar (Columbia agar base, Oxoid) and harvested by scraping from
the plate with a glass slide. Killed suspensions were prepared
(from viable suspensions) by 2k hour exposure to 0.3% formalin at
U°C, followed by washing with saline three times.
3.1.1 Optical density calibration of P.aeruginosa
To permit the rapid and consistant quantification of the
number of bacteria in a suspension, a calibration curve based on
optical density was constructed. Bacterial suspensions of
P.aeruginosa l+92a and i|.92a Rev1 were diluted and abscrbancy
measured on a spectrophotometer (UV30 Pye Unicam) set at a wave
length of 3U0nm. Colony counts were then performed on the
suspensions, so that a curve could be constructed (Figure 1).
This curve was used to estimate the whole cell concentration of




Optical density calibration curve of mucoid P.aeruginosa U92a
and its nonmucoid revertant U92a Rev1.
(• •) i+92a (mucoid)
(• •) U92a Rev1 (non -mucoid)
The y axis shows the absorbancy of the bacterial suspension
at a wavelength of 5U0nM.
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3.2 Staphylococcus albus
A strain of staph albus was obtained from the Departmental
teaching collection. The organisms were grown in horse digest
broth and harvested in log phase. Killed suspensions were pre¬
pared from viable suspensions by 2b hour exposure to 0.5% formalin
at i)°C. Bacterial concentration was estimated spectrophoto-
metrically at a wavelength of 5U0nm. An absorbancy of O.ij.2 was
7 -1
equivalent to 2 x 10 organisms ml
3.3. Preparation of immune serum
A suspension of heat-killed P.aeruginosa l+92a Rev1 was washed
10 -1
and resuspended in saline at a concentration of 10 ml . The
bacteria were mixed with an equal volume of a 2% suspension of
alhydrogel (Miles Laboratories, Slough) at 37°C for one hour. The
mixture was then centrifuged at 2,000g for 15 minutes and the bacterial
10 -1
pellet resuspended in saline at a final concentration of 10 ml
One ml was injected I.P. into each rat four times at weekly intervals.
One week after the last injection the animals were killed and exsan¬
guinated. Blood was collected from the posterior vena cava, allowed
to clot and centrifuged at 1,000g for 30 minutes. The serum was
heat-inactivated (56°C for 30 minutes) and stored at -20°C.
3-b Detection of agglutinating antibody
10 —1
A suspension of P. aeruginosa 1+9 2a Rev1 (10 ml ) was prepared
in G.BSA. Latex suspension (Difco) was adjusted spetrophotometrically
to read 192 at 51+0nm and a 0.5% solution prepared in G.BSA. The
92.
bacteria and latex solutions were mixed in equal volumes and left at
room temperature for five minutes. Doubling dilutions of immune
serum were made in a V-bottomed micro titre plate (Sterilin) so that
each well contained 2^ul of serum and 25>ul of the bacteria and latex
mixture was added to each well. The plate was incubated for two
hours at 37°C and left overnight at 1+°C. Streaming of the latex part¬




9 -1Bacteria at a concentration of 10 ml were added to immune
serum diluted with G.HBSS in a 1:10 ratio. The suspension was
mixed for 20 minutes at 37°C and centrifuged at 2,000g for 15 minutes.
The bacterial pellet was resuspended in BBSS to give a final concen¬
tration of 10^ bacteria ml-^.
3.5.2 Staph albus
3 _1
Bacteria at a concentration of 5 1 10 ml were added to h eat
inactivated normal rat serum diluted in G.HBSS in a 1:10 ratio. The
procedure was continued as above and the bacteria resuspended in
7-1
HBSS to give a final concentration of 5 x 10 ml
3-6 Preparation of IgG2b sensitised sheep red blood cells (EA^)
Sheep cells in alsevers were obtained from tissue culture services
(Slough, Berkshire). The red cells were washed three times with
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9 -1HBSS and suspended at a final concentration of 10 ml . This
concentration was determined by making a 1:30 dilution of red cells
with distilled water and allowing the cells to lyse. At a red
9 -1cell concentration of 10 ml , this solution will read 0.35 at
5!|.1nm on a spectrophotometer (Pye Unicam, UY30).
An equal volume of antibody, in this case a mouse monoclonal
IgG2b against sheep red cells (Clone Sp2HL, Sera Laboratories,
Q A
Crawley Down) was mixed with sheep red blood cells (lO^ml- ) and
incubated at 37°C for 30 minutes. The red cells were then washed
three times in HBSS and resuspended tc a final cell concentration
of 2.5 x 107 ml-1.
3-7 Form-plisation of red blood cells
Sheep red blood cells were washed three times with D.PBS
resuspended in 100 ml of D.PBS for every 20 ml of packed cells and
placed in a conical flask. 20 ml of formalin was added to visking
tubing submerged in the red cell suspension and gently stirred at
I4. C for 3 hours. The swollen dialysi3 sac was then punctured,
allowing the formalin to slowly escape, and removed. Gentle mixing
was then continued for 18 hours (overnight). The formalised cells
were then washed five times with D.PBS and stored at L|°C. Prior
to use they were washed twice in HBSS. The erythrocytes were sensitised
with antibody as described above.
3.8 Preparation of complement coated sheep red blood cells(EA^)
9 —1
An equal volume of sheep red blood cells (10 ml ) were mixed
with a mouse monoclonal IgM (Clone Sp1 HL, Sera-Lab, Crawley Down)
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at the maximum sub-agglutinating dose, in this case a 1:5 dilution.
The mixture was incubated at 37°C for 30 minutes, washed twice in
HBSS and resuspended in HBSS at a final cell concentration of
8 1
10 ml , to give EAjyj,
A preparation of yeast cell walls in azide 0.2ml (obtained from
Dr J Stewart, Department of Bacteriology) was washed twice and sus¬
pended in 1ml HBSS. One ml of AB serum (previously absorbed against
sheep red blood cells) was added and the mixture incubated at 37°C
for 30 minutes and centrifuged at 1,000g for 10 minutes. The super-
nate (R^) was collected and serially diluted. Equal volumes of R^
8 —1 o
and EA^ (10 ml ) were incubated at 37 0 for l+O minutes. The mixture
was washed twice and resuspended to a final cell concentration of
2.5 x 107 ml"1.
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U. ASSAYS
At the end of each assay described in this section, the coverslips
were air-dried, fixed in methanol and stained with May Grunwald/Giemsa.
Triplicate coverslips were used and 200 macrophages counted on each
coverslip.
b>1 Bacterial binding
Macrophage monolayers were overlaid with one ml of Staph.albu3
*7 -j 8 1(5 x 10' ml- ) or P.aeruginosa (5 x 10 ml- ) in D.PBS.'B' and
incubated for two hours at i+°G. The monolayers were then washed
ten times with D.PBS'B'. The results were expressed as the percentage
of cells binding bacteria at two or more discrete points.
U-2 Phagocytosis
One ml of opsonised bacteria were overlaid onto macrophage mono¬
layers and incubated for 30 minutes at 37°C. Extracellular bacteria
were removed by vigorous washing with HBSS (ten times). The results
were expressed as the percentage of macrophages that contained five
or more bacteria..
U.3 Fc receptor assay
7 —1
Two ml of EAq (2.5 x 10' ml ) were added to the macrophage or
monocyte monolayer centrifuged for four minutes at 30g and incubated
for 30 minutes at 22°C (room temperature). Non-adherent red cells
were removed by gentle washing with HBSS and the coverslips were
finally dipped into 1% formol HBSS to prevent red cell lysis.
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The results were expressed as the percentage of macrophages
binding two or more erythrocytes.
k.h Phagocytosis of EA^,
7 —1
Two ml of EA^ (2.5 x 10 ml ) were added to the macrophage
monolayer, centrifuged for four minutes at 30g and incubated for
30 minutes at 37°0. Extracellular erythrocytes were removed by
washing five times with BBSS.
The results were expressed as the percentage of macrophages
that had phagocytosed two or more erythrocytes.
U.9 Phagocytosis of latex
The macrophage monolayers were overlaid with one ml of HBS3
and 20ul of latex suspension (Difco Laboratories, Surrey) adjusted
spectrophotometrically to read 192 at a wavelength of 9U0nm. The
monolayers were then incubated for one hour at 37°C. Non-phagocytosed
particles were removed by repeated washing with HBSS.
The results were expressed as the percentage of cells that
had taken up five or more latex particles.
k.6 C3 receptor assay
7 —1
Two ml of E4.c (2.9 x 10 ml" ) were added to the macrophage mono¬
layer and the procedure carried out as previously described for the
detection of Pc receptors.
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5-0 ALGINATE STUDIES
5.1 Production and, extraction of Pseudomonas alginate
The method used was a modification of that reported by Evans and
Linker (1973) and- Govan and Fyfe (1978). Colonies of P.aeruginosa
ll92a were taken from 21+ hour culture grown on Pseudomonas Isolation
agar (PIA, Difco) at 37°C and used to inoculate 30 ml volumes of
broth containing 1% Bacto-peptone (Difco) and 2% sodium gluconate.
The cultures were grown for 1+8 hours in an orbital incubator 100 rev
min at 37 C to achieve maximum alginate production. The culture
broth was mixed with 2.5M NaGl in a ratio of 25:1 and centrifuged
at 20,000g for one hour. The bacterial pellet was discarded and
the supernatant spun for one hour at 20,000g. Three volumes of
95% ethanol were slowly added to the supernate and gently stirred.
The resultant gelatinous precipitate was removed by means of a glass
rod, washed twice in 95% ethanol, once with absolute ethanol,freeze-
dried and stored at i|°C. The alginate was checked for contamination
with protein and nucleic acid by measuring spectrophotometric extinction
values at 280 and 260nm.
5.2 Treatment of macrophages with alginate
Alginate was reconstituted in BBSS at concentrations ranging
-1 -1
from 0.25 mg ml to 2mg ml . One ml of alginate was added to
macrophage monolayers and incubated at 37°C for 30 minutes. The
macrophages were subsequently washed and the assays performed as
described above. In some experiments vigorous washing was carried
out and this involved washing the monolayers five times with HBSS
98.
after the 30 minute incubation period.
5.3 Addition of alginate with the indicator cells
The alginate was reconstituted in HBSS (for red cells) or
D.PBS'B' (for bacterial binding) and one ml was added to the mono¬
layers with the EA_ or bacteria.
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6.0 ANTIBIOTIC STUDIES
The three antibiotics used in this study were:
Tobramycin - Eli Lilly, Basingstoke, England
Azlocillin - Bayer, Germany
Ticarcillin - Beecham, Brentford, England
6.1 Determination of the minimum inhibitory concentration (MIC)
The stock antibiotic was diluted in sterile distilled water
to ten times the highest test concentration, then finally diluted
in isosensitest broth. Doubling dilutions were made in sterile
glass tubes. For each set of dilutions, there was a growth control
(no antibiotic) and a media control (no inoculum). Each tube (except
the media control) was inoculated with 100ul of P.aeruginosa i+92a Rev1
6—1 o
at 10 ml in isosensitest broth and incubated for 2k hours at 37 C.
The growth of bacteria was monitored by the turbidity of the sus¬
pension. The MIC was taken as the lowest concentration of antibiotic
at which there was no turbidity in the overnight culture. Solutions
were checked by plating out 0.1 ml on nutrient agar and measuring
growth after 18 hours. Calcium was added to the isosensitest broth
to give a final concentration of 1.6mM, to allow for the calcium con¬
centration of the media used in the assays.
6.2 Antibiotic treatment of macrophages
a) The antibiotics were diluted in Eagles MEM and one ml was
added to the monolayers. The macrophages were then incubated
at 37°C and washed once prior to performing the assays
100.
described above.
b) The antibiotics were diluted in HBSS and added to the macro¬
phage monolayer with the indicator cells.
6.3 Treatment of indicator cells with antibiotics
8 —1 8 1
One ml of EA^ (10 ml ) or opsonised bacteria (5 x 10 ml )
were incubated with an equal volume of antibiotic dilutions in
HBSS for 30 minutes at 37°C. The mixture was then centrifuge! at
200g and the erythrocyte or bacterial pellet washed twice with
HBSS. The cells were resuspended in HBSS and an Fc receptor or
phagocytic assay performed as described above.
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7.0 STUDIES ON THE SUHERNATANTS
7.1 Preparation of dialysis tubing
g
Dialysis tubing, /32, (Scientific Instrument Centre, London)
was boiled in 2% NaECO^ for one hour, washed and boiled in 20mM
EDTA for one hour. The tubing was rinsed thoroughly in distilled
water and stored at 1)°C in 20mM EDTA. Prior to use the tubing
was washed with distilled water.
7.2 Preparation of supernatant3
fiat alveolar macrophage monolayers were incubated with tobra¬
mycin diluted in Eagles MEM at 37°C. After gentle shaking, the
supernatants were removed and frozen at -20°C. The frozen material
was then freeze-driea, reconstituted in a small amount of distilled
water and dialysed against 5>mM Tris HC1 for ij.8 hours at i;0C. When
dialysis was complete, the dialysate appeared clear and was removed
from the tubing. The solutions were freeze dried and stored at
-20°C.
7.3 Supernatant inhibition studies
7.3.1 EAg
The freeze dried supernatants were reconstituted to their
original volume with HBSS and incubated with an equal volume of
EA^ (lO^ml ^) for 30 minutes at 37°C. The erythrocytes were then
7—1 _ _
washed twice in HBSS and resuspended at 2.5 x 10 ml . The Fc
receptor assay was then performed as previously described.
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7.3-2 Macrophages
The freeze dried supernatants were reconstituted to the original
volume in HBSS and incubated with macrophage monolayers at 22°G for
one hour. The monolayers were then washed twice and the Be receptor
assay performed as previously described.
7-b Polyacrylamide gel electrophoresis (PAGE)
PAGE was performed in the presence of sodium dodecyl sulphate
(SDS) on 1C^ (w/v) polyacrylamide slab gels with a 10mM k% (w/v)
stacking gel as described by Poxton and Brown (1979)- The dis¬
continuous buffer system (gels at different pH) of Laemelli (1970)
was used. Breeze dried supernatants were reconstituted in lOOui
of single strength sample buffer and treated for three minutes in
a boiling water bath. 60 ul of each sample was loaded onto the
gel. Electrophoresis was performed at constant voltage, initially
at 60 V, until the sample had reached the separating gel, then at
1^0 V until the bromophenol blue tracking dye was approximately 5 cm
from the bottom of the gel. The gel was carefully removed from
the glass plates and stained overnight with Coomassie Brilliant
Blue G or S (Sigma) and destained with the solutions described by
Poxton and Sutherland (1976) to identify the protein bands.
The molecular weight marker used in these studies was in the
range 12,300 - 78,000 daltons.
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7.5 Agglutination of erythrocytes
8 1
EAq were prepared as previously described (2 x 10 ml- ),super-
natants were serially diluted in a V bottomed 96 well plate (Sterilin)
so that each well contained 50ul. EA^ were added (50ul) mixed and
incubated for one hour at room temperature, to allow agglutination
to occur.
7-6 Inhibition of agglutination
Supernatants were incubated with formalised EA_, for two hours
U'
at i4°C. The mixture was centrifuged at i+OOg for 10 minutes, the
supernatants collected and tested for EA^ agglutination as above.
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8.0 CALCULATIONS
The percentage inhibition or enhancement was calculated as
the difference between control and test divided by the control times
100.
Inhibition = ^ ~ ^ x 100
C
T — C
Enhancement = x 100
C
8.1 Statistics
Analysis was performed by the student *t* test. As differences
between experiments were similar to differences within an experiment,










The establishment of mucoid, alginate producing strains of
P.aeruginosa in the lungs of CP patients is associated with a
poor prognosis (Henry ejt al., 1982) and contributes to the persistence
of the infection (Doring and Hjzfiby, 1983)« This suggests that the
bacterial alginate may be a contributing factor in the pathogenesis
of Pseudomonas infection in CP patients.
The immune status of the CP patient was discussed in the
Introduction. Failure to eradicate mucoid P.aeruginosa from the CP
lung is not thought to be due to a general immune defect (di Sant'Agnese
and Davis, 1976). However it is possible that immune function in
the CP lung may be impaired and the infection exacerbated a3 a
result of alginate production by P.aeruginosa.
The purpose of these studies was to investigate if alginate had
any effects on alveolar macrophages in the hope of furthering the
understanding of the pathogenic properties of alginate. Alginate
separated from a mucoid strain of P.aeruginosa was used to determine
the effect on phagocytosis and binding of particles to rat alveolar
macrophages. Preliminary experiments were necessary to determine
the optimal conditions for demonstrating the presence of receptors
and the phagocytosis of opsonised bacteria. These experiments are
described at the beginning of the relevant section.
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SECTION I
TEE EFFECT OF ALGINATE ON "LECTIN-LIKE" RECEPTORS
109.
1.0 DETERMINATION OF OPTIMAL CONDITIONS FOR THE BINDING OF
P.AERUGINOSA AND STAPH.ALBUS TO RAT ALVEOLAR MACROPHAGES
Optimal conditions for "bacterial binding to C^H mouse peritoneal
macrophages has been determined by H.Ogmundsdottir (PhD thesis, 1979)•
She showed that binding of bacteria to macrophage monolayers took
place at 4 C and required two hours incubation for maximal binding.
These conditions were shown to apply to a number of bacterial species
including Staphylococcus, Streptococcus, Escherichia and Pseudomonas
(Freimer et al. , 1978) and other cell types, including mouse alveolar
macrophages (Glass et al., 1981).
Dose response curves for the binding of P.aeruginosa to rat
alveolar macrophages were carried out under these conditions as
shown in Figure 2. The percentage of macrophages binding bacteria was
directly related to the bacterial concentration used. At concentrations
10 —1
of P. aeruginosa 1+92a Rev1 above 10 ml , the number of background
bacteria made the preparation difficult to count. At concentrations
9 -1of Staph.albus above 10 ml no further increase in binding was
observed. Formalin-killed P.aeruginosa U92a Rev1 were more readily
bound than live bacteria, although less readily bound than Staph.albus.
Unwashed preparations of mucoid P.aeruginosa U92a did not
11
bind to rat alveolar macrophages, even at concentrations of 10
_-]
organisms ml where in contrast to P.aeruginosa l+92a Rev1 the back¬
ground was low. A similar effect had previously been observed for
mouse peritoneal and pulmonary macrophages (Oliver and Weir, 1983)-
Binding of Staph.albus subsequently led to phagocytosis if the
monolayers were incubated at 37°0, but this was not the case for
P.aeruginosa that remained attached without being phagocytosed.
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PLATE I
Binding of P.aeruginosa k92a Rev1 to rat alveolar macrophage
monolayer (May Grunwald/Giemsa, x 1 ,250 magnification. )
111.
PLATE II
Binding of Staph.albus to rat alveolar macrophage monolayers
(May Grunwald/Giemsa, x 1,250 magnification)
112.
6 7 8 9 10
LOG BACTERIAL CONCENTRATION
Figure 2
The effect of increasing concentrations of Staph,albus (£s—&),
formalin-killed P.aeruginosa U92 Rev1 (0 0) and live lj.92a Rev1 (• •)
on the binding by rat alveolar macrophages. Each point represents the
mean of 2 experiments.
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2.0 INHIBITION OF P.AERUGINOSA BINDING 3Y D-GLUCOSE AND D-GALACTOSE
TO RAT ALVEOLAR MACROPHAGES.
Inhibition studies were carried out to determine whether
P.aeruginosa bound to alveolar macrophages by the lectin-like receptor
that had previously been identified on mouse alveolar macrophages for
Staph.albus (Glass et al., 1981).
A suspension of live, washed P.aeruginosa was used at a concen-
9 —1
tration that gave 20-30% binding (2 x 10 ml ). Macrophage mono¬
layers were pre-exposed to a range of concentrations of D-glucose
and D-galactose (5-20 mM) prior to overlaying the P.aeruginosa as
described in the Materials and Methods section. D-glucose and
D-galactose reduced the binding of P.aeruginosa at 5» 10 and 20 mm
concentrations (F<0.05). Inhibition of binding reached a maximum
at 10mm and the inhibition observed with glucose was slightly though











The effect of D-glucose (# •) and D-galactose (0 0) on the binding
of P.aeruginosa U92a Rev1 to rat alveolar macrophages. Each point
represents the mean - 1 SEM of three experiments.
115.
3.0 TEB EFFECT OF ALGINATE ON BACTERIAL BIRRING TO RAT
ALVEOLAR MACROPHAGES
The effect of increasing concentrations of pseudomonas alginate,
extracted as described in the Materials and Methods section on the
binding of a non-alginate producing P.aeruginosa and Staph.albus
is shown in Figure J4. Concentrations of alginate above 2 mg ml
were not used, as at this viscosity of the material, it was difficult
to ensure an even suspension over the monolayers.
The alginate obtained from strain l+92a inhibited the binding of
its non-mucoid variant l+92a Rev1 to alveolar macrophages in a dose-
dependent manner (P<0.05). Similar results were obtained when the
bacterial binding was studied using Staph.albus. When the macrophages
were pre-incubated with alginate for 30 minutes, inhibition of the
binding of Staph.albus was greater than that observed with P.aeruginosa
reaching 70% at an alginate concentration of 2 mg ml . Addition of
the alginate to the monolayers at the same time as P.aeruginosa
U92a Rev1, resulted in inhibition of binding that was greater (P< 0.05)
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The effect of alginate on the binding of P.aeruginosa and Staph.albus
to rat alveolar macrophages. Monolayers were pre-incubated with alginate
for 30 minutes and P.aeruginosa (9 •) or Stanh.albus (0 0) added.
Alternatively alginate was added with P.aeruginosa to the monolayer
(• •). Each point represents the mean - 1 SEM of four experiments.
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U. 0 SUMMARY
Staph.albus and a non-mucoid strain of P.aeruginosa bound in
a dose-dependent fashion to rat alveolar macrophages. Binding was
inhibited by D-glucose and D-galactose, indicating the involvement of
the "lectin-like" receptor on these macrophages. Mucoid P.aeruginosa
did not bind to the macrophages even at high concentrations of bacteria.
Alginate extracted from a mucoid strain of P.aeruginosa inhibited
the binding of Staph.albus and P.aeruginosa to the macrophages in a
dose-dependent fashion. This inhibition occurred if the cells were
incubated with alginate prior to addition of the bacteria and in the
case of P.aeruginosa the inhibition of binding was significantly




TEE EFFECT OF ALGINATE ON PHAGOCYTOSIS
119.
1.0 INTRODUCTION
As alginate inhibited the binding of P.aeruginosa it was con¬
sidered important to determine its effect on the phagocytosis of
opsonised bacteria, as unopsonised bacteria, as previously noted,
were not taken up by these particular macrophages. It has been
shown that pseudomonas alginate inhibits the phagocytosis of non-
mucoid forms of the organism by rabbit neutrophils (Schwartzman and
Boring, 1971)• The purpose of these experiments was to extend these
observations to a population of alveolar macrophages and investigate
the effect of pre-incubation of these cells with alginate.
120.
2.0 DETERMINATION OF THE OPTIMAL CONDITIONS FOR PHAGOCYTOSIS OF
?.AERUGINOSA BY RAT ALVEOLAR MACROPHAGES
The strain of P.aeruginosa used, in these studies was a non-
nrucoid revertant of the mucoid strain l±92a, as described in Materials
and Methods. Studies were not carried out with the mucoid bacterial
strain for two reasons. Pirst, opsonisation of these bacteria would
necessitate a washing procedure, that would render the bacteria no
longer mucoid, second, unopsonised bacteria were not phagocytosed and
8 —1
were toxic to the macrophages at concentrations above 10 ml
For phagocytosis of P.aeruginosa U92a Rev1 by rat alveolar macro¬
phages to occur, the bacteria were opsonised with specific immune
serum. Opsonisation of the bacteria with fresh autologous serum, mouse
serum,serum from rats intra-tracheally infected with P.aeruginosa, foetal
calf serum or human serum did not result in phagocytosis of the bacteria
by these cells. An immune serum was prepared as described in Materials
and Methods. The serum was non-agglutinating as measured by the
method described in Chapter III.
Dose response curves for the dilution of serum and bacterial
concentration required for opsonisation and subsequent phagocytosis
were constructed. The percentage of macrophages that had taken up
bacteria was directly related to the dilution of antibody, although
it reached a maximum at a dilution of 1/20 (Figure 5)- Phagocytosis
by the macrophages was also related to the concentration of bacteria
in the opsonisation mixture and increased with increasing bacterial
9 -1






opsonised P. aeruginosa l+92a Rev1 hy rat
(May Grunwald/Giemsa, x 1,25Q magnification.)
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Figure 5
The effect of increasing the concentration of immune serum for opsonisation
of P.aeruginosa on the phagocytosis of this organism by rat alveolar




The effect on phagocytosis of increasing the concentration of P.aerugjnosa
in the opsonisation mixture, when a serum dilution of 1/20 was used.
Each point represents the mean - 1 SEM of three experiments.
124.
Staph.albus was opsonised with heat-inactivated normal rat
serum (presumably because of the presence of anti-staphlococcal anti¬
body) .
125.
3.0 THE EFFECT OF ALGINATE OH THE PHAGOCYTOSIS OF P.AERUGINOSA
8 —1
Bacteria were used at a final concentration of 5 x 10 ml
with a 1/80 dilution of immune serum in the opsonisation mixture to
give 30 - i+0% phagocytosis.
Pseudomonas alginate inhibited the phagocytosis (P <0.05) of
non-mucoid P.aeruginosa when pre-incuhated with the macrophage mono¬
layers for 30 minutes. This effect was dependent on the concentration
of alginate and was reduced by 5>0% if the macrophages were vigorously
washed five times after alginate treatment (Figure ?)• The phagocytic
capacity of the macrophages returned to normal when these macrophages
were re-incubated in Eagles MEM alone for 30 rninute3 after alginate
treatment.
Inhibition of phagocytosis reached a maximum of 90% when the
alginate was added to the macrophage monolayers together with the
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Figure 7
The effect of increasing concentrations of alginate on the phagocytosis
of the non-niucoid. P.aeruginosa U92a Rev1.
(• • ) Pre-treatment of macrophage with alginate.
(® Addition of alginate with bacteria to the monolayers.
Each point represents the mean - 1 SEM of four experiments.
(O C) Alginate was vigorously washed from the macrophages prior to
the addition of the bacteria. Each point represents the mean of two
experiments.
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i+.O THE EFFECT OF ALGINATE ON THE PHAGOCYTOSIS OF STAPH.ALBTTS
The effect of alginate on the phagocytosis of Staph.albus
was studied to investiage the specificity of the inhibiting action
of the alginate. Staph.alhus was opsonised at a concentration of
8 —1
10 bacteria ml with a 1/1+0 dilution of heat-inactivated pooled
normal rat serum to give 30-i+0$> phagocytosis. Pseudomonas alginate
inhibited the phagocytosis (p<0.03) of Staph.albus when pre-incubated
with the macrophage monolayer for 30 minutes (Figure 8). The degree
of inhibition was related to the concentration of alginate and reached
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Figure 8
The effect of increasing concentrations of pseudomonas alginate on .
the phagocytosis of opsonised Staph.albus "by rat alveolar macrophages.
Each point represents the mean - 1 SEM of four experiments.
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5.0 THE EFFECT OF NON-PSEPTOMONAS ALGINATE ON TEE! PHAGOCYTOSIS
OF P.AERUGINOSA
Alginic acid can be extracted from Macrocystis uyrifera (kelp)
and shows structural similarities to pseudomonas alginate. The
effect of this algal alginate on the phagocytosis of non-mucoid
P. aeruginosa lj.92a Rev1 was investigated to determine if non-alginate
products from P.aeruginosa l+92a were the cause of the observed results
with pseudomonas alginate.
Alginic acid inhibited the phagocytosis of the non-mucoid
revertant in a dose dependent fashion when pre-incubated with the
macrophage monolayer for 30 minutes (Figure 9). The observed
inhibitory effect was reduced by extensive washing, in a manner similar
to that observed for pseudomonas alginate (Figure 9)- Concentrations
of alginic acid above 2mgml were used due to its low viscosity
and inhibition reached 100% at 20mgml . Inhibition of phagocytosis
also reached a maximum of 100% when the alginic acid was added to
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Figure 9
The effect of increasing concentrations of alginic acid on the phagocytosis
of P.aeruginosa k92a Rev1. The macrophages were pre-incubatea for
30 minutes with alginic acid and washed gently (§■ 1) or vigorously
(• §). Each point represents the mean - 1 SEM of three experiments
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Figure 10
The effect of increasing concentrations of alginic acid on the
phagocytosis of opsonised P.aeruginosa l+92a Rev1, when added with the
bacteria to the macrophage monolayers. Each point represents the
mean - 1 SEM of three experiments.
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6.0 THE EFFECT OF ALGINATE ON CELL VIABILITY
The inhibitory effects of the alginate maybe a result of
the toxicity of the substance to alveolar macrophages. Although
this seemed unlikely as alginic acid had similar inhibitory effects
on the phagocytosis of non-mucoid P.aeruginosa, the effect of
pseudomonas alginate on cell viability was investigated.
-1 -1
At concentrations of 1mgml and 2mgml there was a slight,
though not significant increase in cell death (Table 1) that may be
a result of cell suffocation by the viscous alginate or cytolytic
toxin contaminating the extract. However the percentage of cell
death was not sufficient to account for the observed inhibitory
effects on alveolar macrophage function.
133.
Concentration
alginate mg ml ^
% Dead Cells
0 15 - U
0.25 15 - 3 2
0.5 16-5
1.0 20-6
2.0 21 i 5 2
TABLE I
The effect of alginate on cell viability. Alveolar
macrophages were incubated, for 30 minutes with alginate.
washed and the viability estimated with trypan blue.




Non-mucoid P. aeruginosa i+92a Rev1 required specific immune
serum for opsonisation and subsequent phagocytosis by rat alveolar
macrophages. Alginate extracted from a mucoid strain of P.aeruginosa
inhibited the phagocytosis of the non-mucoid revertant and Stauh.
albus by the macrophages. Inhibition was observed when the cells
were incubated with the alginate prior to addition of the bacteria
and reduced if the alginate was removed from the ceils by washing.
Alginic acid, an algal compound structurally similar to
pseudomonas alginate inhibited phagocytosis in a similar manner,
so that the observed inhibition is not likely to be a result of
bacterial impurities in the pseudomonas alginate.
135.
SECTION III
THE EFFECT OF ALGINATE ON BACTERIAL OPSONISATION
136.
1.0 INTRODUCTION
As pseudomonas alginate was shown to inhibit phagocytosis
it was considered possible that opsonisation might also be affected
by binding of the alginate to the bacteria. Alginate has been
shown to block the receptor for opsonic antibody on non-mucoid
P.aeruginosa (Baltimore and Mitchell, 1980). However these
workers found that the alginate had no effect on the opsonisation
of non-mucoid strains when added to the bacteria and serum mixture.
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2.0 THE EFFECT OF ALGINATE ON OPSONISATION
Alginate was added to the "bacteria and serum mixture which
was incubated for 20 minutes, washed and added to the macropnage
monolayers. As unopsonised P.aeruginosa are not phagocytosed,
any decrease in phagocytosis in this system would indicate an impair¬
ment of opsonisation.
Opsonisation of the non-rmiccid revertant by immune serum was
— 1 —1
inhibited (P< 0.05) at 0.12 mgml and 0.25 mgml and almost totally
inhibited (P< 0.001) at concentrations above 0.5 mgml ^ (Figure 11).
The inhibitory effect was not due to inadequate pelleting of the
bacteria in the alginate and serum mixture during the washing pro¬
cedure as colony counts showed that there was no difference in the
control and experimental bacterial concentrations of the pellet.
Opsonisation of Staph.albus was inhibited by pseudomonas alginate
but to a lesser extent than that observed with P.aeruginosa. This
may be due to the fact that unopsonised Staph.albus are phagocytosed
by alveolar macrophages. Therefore total inhibition of opsonisation
will not result in a similar degree of inhibition of phagocytosis.
138.
Figure 11
The effect of increasing concentrations of pseudomonas alginate on
the opsonisation of non-mucoid P.aeruginosa (• 8) and Staph.alhus .
(• •). Each point represents the mean - 1 SEM of five experiments
(P.aeruginosa) or three experiments (Staph.alhus).
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3.0 THE EFFECT OF CALCIUM CONCENTRATION ON INHIBITION OF OPSONISATION
Calcium ions cause pseudomonas alginate to gel and become
more viscous in nature (Govan, 1983). Therefore the effect of
| |
calcium concentration on the alginate-induced inhibition of
opsonisation was investigated.
HBSS containing 2.5>mm calcium4-1" (to correspond to the concen¬
tration present in the CP lung (Rabin, 1980)), 1.26mm calcium4-1"
(normal HBSS concentration) and D.PBS containing no calcium4"4" was
used during the opsonisation procedure.
There was no significant difference in the inhibition of
opsonisation, measured by bacterial uptake into macrophages, at
-1 —1
alginate concentrations of O.^mgml and 1 mgml , between the
three media concentrations of calcium4-1" (Figure 12).
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Figure 1 2
The effect of calcium on the inhibition of cpsonisation caused by 0.5
_i
or 1 mg ml pseudomonas alginate. The y axis represents the percentage




Pseudomonas alginate inhibited the opsonisation of non-macoid
P.aeruginosa and Staph.alhus in a dose-dependent fashion. Inhibition
was not dependent on calcium concentration, as inhibition was still
| |




TEE EPPECT OF ALGINATE ON THE BINDING OF ANTIBODY
COATED SHEEP RED BLOOD CELLS TO Ec RECEPTORS AND
THE PHAGOCYTOSIS OP LATEX PAETICLES
143.
1.0 INTRODUCTION
In the previous sections, pseudomonas alginate was shown to
inhibit the binding and phagocytosis of bacteria by rat alveolar
macrophages and bacterial opsonisation. It was therefore postul¬
ated that the alginate was acting as a barrier, surrounding the
macrophage and preventing the attachment of bacteria to the cell
membrane. Investigation of this hypothesis was carried out by
studying the effect of alginate on binding of antibody coated
sheep red blood cells (EA^) to Fc receptors and the nonspecific
uptake of latex particles by alveolar macrophages.
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2.0 DETEKMBTATION OF THE OPTIMAL CONDITIONS FOR TEE DETECTION
OF Fc RECEPTORS
Antibody-coated sheep red blood cells(EA^) were used to detect
the presence of Fc receptors. Macrophages were incubated with
serum-free Eagles MEM. This was essential as the presence of
foetal calf serum (1C%) in the medium enhanced (P<0.05) the expression
of Fc receptors on rat alveolar macrophages (Figure 13)- The anti¬
body used in this experiment was an IgG against sheep red blood
cells, raised in rabbits (donated by G.Dougherty, Bacteriology
Department). The observed increase in Fc receptors may be a
result of the rounding up of the macrophages caused by the foetal
calf serum. The Fc receptors would then be closer together and
more likely to bind sensitised erythrocytes. Foetal calf serum
had no effect on Fc receptor expression of human peripheral blood
monocytes (results not shown), which are smaller and more rounded
than alTeolar macrophages.
The antibody used in all other experiments was a monoclonal
IgG2b raised in mice against sheep erythrocytes (sera-lab). Binding
of sensitised erythrocytes was directly related to the concentration
of antibody used and reached a maximum of 62.5% at a 1/1+0 dilution
(Figure 11+). Human peripheral blood monocytes had lower avidity
Fc receptors than rat alveolar macrophages, although a maximum of
57-5% binding was reached at an antibody dilution of 1/1+0.
145.
PLATE IV
Rat alveolar macrophage rosette formation with EA_ (prepared
with mouse IgG2h monoclonal as the sensitising antibody). (May




The effect of increasing concentrations of IgG antibody on rosette
formation "by alveolar macrophages incubated in Eagles 3YEEM without
serum (® • ) or containing 10% foetal calf serum (0 0),. Each
point represents the mean - 1 SEM of three experiments.
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DILUTION OF ANTIBODY x103
Figure 1U
The effect of increasing the amount of sensitising antibody (lgG2b)
on the binding of EA^ by rat alveolar macrophages (• •) and human
peripheral blood monocytes (0 0). Each point represents the mean
of two experiments.
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3-0 TEE EFFECT OF ALGINATE ON Fc RECEPTORS
The effect of pseudomonas alginate on Fc receptors was studied
with an antibody dilution that gave 30-1+0% binding of 3A^ to the
alveolar macrophages.
Alginate reduced (P<0.05) the binding of EA^ to the macrophages
(Figure 15). This inhibition was greater when the alginate was
incubated together with the sheep erythrocytes than when the macro¬




The effect of increasing concentrations of pseudomonas alginate on
rosette formation by EA^ to alveolar macrophages.
(♦ « ) Pretreatment of macrophages with alginate.
(# t ) Addition of alginate with EA^ to the monolayers. Each
point represents the mean - 1 SEM of four experiments.
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U.O THE EFFECT OF ALGINATE ON THE PHAGOCYTOSIS OF LATEX PARTICLES
Pseudomonas alginate inhibited the phagocytosis of latex
particles by rat alveolar macrophages in a dose-dependent fashion
(Figure 16). When the macrophages were pre-incubated for 30 minutes,
— 1 —1
phagocytosis was inhibited (P<0.05) at 1mgml~ and 2mgml~ .
Inhibition was increased at all concentrations used when the alginate
was added with the latex to the macrophages, (P<0.05) at 0.25mgml
—1 —1 —1
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.Figure 16
The effect of increasing concentrations of alginate on the
phagocytosis of latex particles by pseudomonas alginate.
(® •) Pre-treatment of macrophages with alginate.
( • •) Addition of alginate with latex particles to the monolayers
Each point represents the mean - 1 SEM of three experiments.
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5.0 SUMMARY
Pseudomonas alginate inhibited the "binding of sensitised
sheep erythrocytes to alveolar macrophage Pc receptors and the
phagocytosis of latex particles by these cells. These results
support the hypothesis that the alginate binds nonspecifically to
the macrophage and prevents particle attachment. Greater inhibition
was observed when the alginate was added along with the indicator
cells. The test particles may be trapped by the viscous mucoid
material and prevented from coming into contact with the macrophages.
153.
PART B
THE EFFECT OF ANTIBIOTICS ON RAT ALVEOLAR




In Part A it was shown that alginate extracted from a mucoid
strain of P.aeruginosa had an inhibitory effect on the phagocytosis
and opsonisation of bacteria. If these effects occur in vivo,
they may partly explain the predominance of mucoid P.aeruginosa in
CP patients. However the results do not take into account the
effect of antibiotic therapy on the bacteria or the host. Although
antibiotic treatment may improve the clinical condition of the CP
patient, the bacteria are rarely eradicated from the lung and re¬
infection occurs (Kulezycki jet al. , 1973). One of the reasons
for this may be that antibiotics penetrate poorly through the
thick bronchial secretions that occur in CP patients, so that
levels above the MIC are rarely achieved in the CF lung. Levels
of antibiotics obtained in CP sputum are low compared to those
found in serum and often below the MIC (Malmborg et al., 1981).
Conventional antimicrobial sensitivity testing only considers
the interaction between drug and micro-organisms, generally ignoring
possible effects that the antibiotic may have on the host immune
defense mechanisms. Tobramycin, azlociilin and ticarcillin are
three antibiotics that have been widely used during CP therapy for
chronic P.aeruginosa lung infection. The purpose of this study
was to investigate the possibility that the low levels of these
antibiotics achieved in the CP lung may affect alveolar macrophage
function. As shown in Part A, macrophage function may already be




TEE EFFECT OF TOBRAMYCIN, AZLOCILLIN AND TICARCILLIN




The MIC of each antibiotic was determined as described
in Materials and Methods, the values being given in Table II.
Concentrations of the three antibiotics above and below the MIC
were studied in the range 1/8 MIC - 8 x MIC value. These concen¬
trations are well within the therapeutic range and similar to the
concentration of antibiotics obtained in the lungs of CF patients
(Malmborg et al., 1981; Hoogkamp-Korstanje and van der Laag, 1983)•
The antibiotics were either pre-incubated with the alveolar macro¬
phages or added to the monolayers with the opsonised bacteria.
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Minimum inhibitory concentrations (MIC) of the antibiotics
used in this study. The concentration is that which
inhibited growth of an overnight culture of P.aeruginosa
1+92 a Rev 1. Each antibiotic was tested three times and
at regular intervals.
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2.0 TEE EFFECT OF THE ANTIBIOTICS ON PHAGOCYTOSIS-DOSE RESPONSES
The optimal conditions for phagocytosis of P.aeruginosa have
already "been described in Part A. Azlocillin and tobramycin in¬
hibited the phagocytosis of P.aeruginosa U92a Bev1 when they were
added to the alveolar macrophage monolayers at the same time as
the opsonised bacteria. This inhibition was significant (P<0.05)
at I/I4MIC to 8 x MIC values for azlocillin (Figure 17) and at 1/8MIC
to 1/2MIC values for tobramycin (Figure 18).
To determine whether the antibiotics were having a direct effect
on the phagocytes, macrophage monolayers were incubated with tobra¬
mycin, azlocillin and ticarcillin for 30 minutes prior to the addition
of bacteria. Azlocillin enhanced phagocytosis at I/I4MIC (F<0.0$)
and MIC (P<0.01) values but at other concentrations studied had no
effect (Table III).
Figure 19 shows that the phagocytosis of opsonised P.aeruginosa
was inhibited by tobramycin. This effect was significant at 1/8MIC
and MIC values (P<0.05) and at I/I4MIC, 1/2MIC and 2 x MIC values
(P <0.01). Inhibition of phagocytosis was still observed after
extensive washing of the monolayers to ensure the removal of any
extracellular antibiotic. However, the values returned to control
levels when the macrophages were re-incubated in normal Eagles MEM
without antibiotics (Table IY).
Ticarcillin had no effect on the phagocytosis of P.aeruginosa
with either treatment at the concentrations studied (Table 7).
The observed effects were not a result of any toxicity as
neither tobramycin or azlocillin affected cell viability as measured




















The effect of increasing concentrations of azlocillin on the
phagocytosis of P.aeruginosa by rat alveolar macrophages, when the
antibiotic was added, with the bacteria to the monolayers. Each
-L












The effect of increasing concentrations of tobramycin on the phagocytosis
of P.aeruginosa by rat alveolar macrophages when added with the bacteria
to the monolayers,
experiments.
Each point represents the mean - 1 SEM of three
161 .
Concentration Phagocytosis Binding EA_
— 1






























The effect of azlocillin on alveolar macrophages. Macrophage
monolayers incubated with azlocillin for 30 minutes prior to
assays. Each figure represents the mean of three experiments


























The effect of increasing concentrations of tobramycin on phagocytosis
by rat alveolar macrophages. The macrophages were incubated with
antibiotic for 30 minutes, and washed before addition of P.aeruginosa.




Wash well 27. h + 6.2













Effect of washing and re-incubation on tobramycin treatment
of macrophages. Monolayers were treated for 30 minutes with
0.13 pgm ml tobramycin. Some monolayers were vigorously
washed (five times) and bacteria added. Other monolayers were
washed twice and incubated in fresh Eagles MEM for various times
prior to addition of bacteria. Each figure represents the mean
J-
of three experiments - 1 SEM.
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Concentration Added with bacteria Pre-treatment







11.1 12.8 + 10.0
10 7.6
+
10.2 26.8 + 11.9
20 10.6 + 10.5 6.1 + 10.2
bo 10.0 + 13.3 2.6
+
7.3








The effect of ticarcillin on the phagocytosis of opsonised
P.aeruginosa by rat alveolar macrophages. Each figure shows
the % inhibition and represents the mean - 1 SEM of three
experiments.
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3.0 TBE EFFECT OP TOBRAMYCIN ON "EBCTIN-LIKB" RECEPTORS
When tobramycin was incubated for 30 minutes with rat alveolar
macrophages, prior to the addition of unopsonised P.aeruginosa, the
binding of the bacteria was inhibited (P<0.05) (Figure 20). This
inhibition was maximal at 2 x MIC, at which value, the level of
inhibition reached 65% (P<0.01). Therefore tobramycin has an
effect on the binding of unopsonised bacteria similar to that
observed for the phagocytosis of opsonised bacteria. However
the effect of tobramycin on the "lectin-like" receptor was not
pursued as phagocytosis of P.aeruginosa does not occur via this
receptor on rat alveolar macrophages.
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Figure 20
The effect of increasing concentrations of tobramycin on binding
of unopsonised P.aeruginosa to rat alveolar macrophages. The
macrophages were incubated for 30 minutes with antibiotic prior to
addition of the bacteria. Each point represents the mean - 1 SEM
of three experiments.
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k.O TIMS COURSE OF THE INHIBITION OF THE PHAGOCYTOSIS AMD
BACTERIAL BINDING BY TOBRAMYCIN.
The effect of 1/2MIC value (0.15 Jigm ml ^) of tobramycin on
alveolar macrophages was studied when the antibiotic was incubated
with the cells at various times. Phagocytosis was inhibited when
the macrophages were incubated for 15 minutes to 120 minutes.
However this inhibition was only significant (P<0.06) up to 60
minutes. By 120 minutes inhibition was reduced and the level of
phagocytosis had almost returned to the original value (Figure 21).
Inhibition of the binding of uncpsonised P.aeruginosa occurred at
the four time intervals (P<0.05) with the maximal response occurring














The time course of the percentage inhibition of phagocytosis of
opsonised bacteria (§ §) and binding of unopsonised bacteria (0 0)
by alveolar macrophages, after pre-treatment with 1/2MIC value of
tobramycin. Each point represents the mean - 1 SEM of three experiments.
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5.0 SUMMARY
Tobramycin inhibited the phagocytosis of opsonised P.aeruginosa
and the binding of unopsonised P.aeruginosa when pre-incubated with
macrophage monolayers for 30 minutes. These effects were dose and
time-dependent. Azlocillin and ticarcillin had no effect on the
phagocytosis of P.aeruginosa when the antibiotics were pre-incubated
with the macrophage monolayers.
Inhibition of phagocytosis of P.aeruginosa was observed when
tobramycin or azlocillin was co-incubated with the macrophage mono¬
layers and opsonised bacteria while ticarcillin had no effect.
170.
SECTION II
THE EFFECT OE TOBRAMYCIN, AZLOCILLIN AND TICARCILLIN ON THE




As tobramycin and azlocillin had an effect on the phagocytic
function of macrophages, which in this case was mediated by the Pc
receptor, the effect of the antibiotics on the receptor was invest¬
igated. To ensure specificity the sheep erythrocytes were sensitised
with a mouse monoclonal IgG2b. Optimal conditions for the binding
of EA^ to macrophages were described in Part A. The antibiotics
were either pre-incubated with the macrophage monolayers or added
to the monolayers at the same time as the erythrocytes.
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2.0 THE EFFECT OF ANTIBIOTICS ON FcBECSPTORS - DOSE RESPONSE
Azlocillin and tobramycin both inhibited the binding of EA(j
to macrophage monolayers when added with the sheep erythrocytes.
With azlocillin the effect was significant (P<0.05) until a
maximal inhibition occurred at I/I4MIC, thereafter declining until
at I4 x MIC value, the effect was not significant (Figure 22).
For tobramycin the effect was dose-dependent reaching a
maximum at the MIC value. Inhibition was significant (P<0.01)
at 1/liMIC, to 2 x MIC values (Figure 23).
Pre-treatment of the macrophages for 30 minutes with tobra¬
mycin resulted in enhanced binding of EAq> which was significant
(P< 0.03) at 1/8MIC to 2 x MIC (Figure 2k)- Azlocillin had no
effect on the binding of EA^ to the macrophages when it was pre-
incubated with the cells for 30 minutes (Table III).
As with phagocytosis, ticarcillin had no effect on the binding














The effect of increasing concentrations of azlocillin on the binding
of EA_ to rat alveolar macrophages, when the antibiotic was added with(j
the erythrocytes. Each point represents the mean - 1 SEM of four
experiments.
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Figure 23
The effect of increasing concentrations of tobramycin on the binding
of EA_ to rat alveolar macrophages when the antibiotic was added with





The effect of increasing concentrations of tobramycin on Fc receptor
expression of alveolar macrophages. The macrophage monolayers were
incubated for 30 minutes with antibiotic and washed prior to the addition
of EA_.
(A a) incubated at 37°C assay 22°C
(• •) incubated at Lt°C assay 1+°G
(o o) incubated at 22°C assay 22°C
Each point represents the meanT 1 SEM of three experiments.
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Concentration Added with bacteria Pre-treatment
jigm ml ^ to macrophages of macrophages
% Inhibition % Enhancement
2.5 33-1 - 6.1+ 3-1 - 10.2
5 8.5 - 10.l+ 10.1+ -- 9.3
10 11+.1+ ± 10.3 19.2 - 10.0
20 11.2 - 11.2 17.1 - 5-3
1+0 7.3 - 8.5 12.3 - 6.5
80 22.7 - 1+.0 7.3 - 6.2
160 1+2.6 - 13.7 17.3 - 6.6
TABLE 71
The effect of ticarcillin on the binding of EA^ to rat alveolar
macrophages. Each figure represents the mean - 1 SEM of three
experiments.
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3.0 THE EFFECT OF TEMPEBA.TTJKE ON TOBRAMYCIN-Iin)TTCEI) ROSETTE
ENHANCEMENT
Macrophage monolayers were incubated with tobramycin at k°C
and room temperature and the Fc rosette assay performed at the
corresponding temperature. For the experiment performed at L|°C
the erythrocytes were sensitized with a higher concentration of
antibody to compensate for the decreased formation of rosettes at
this temperature. The macrophages were incubated with tobramycin
at 37°C as previously noted, but in this case the Fc receptor assay
was performed at room temperature as phagocytosis occurs at 37°C.
At i|°C binding of EA„ was enhanced (P<0.05) at concentrations
above 1/UMIC and (P<0.01) at 2 x MIC and 8 x MIC values (Figure 2b) •
This effect was dose-dependent and reached a maximum of 6b-5% at
8 x MIC. This maximum was similar to that obtained when the cells
were incubated with tobramycin at 37°C and the assay performed at
22°C. However in this case a lower concentration of tobramycin
was required to attain a similar result. The observed fall-off
of enhancement in the 37°C experiment did not occur when the procedure
was carried out at l4°C. However as higher concentrations were
not studied, the possibility that enchancement may eventually drop
at L|°C cannot be excluded.
When the experiment was carried out at room temperature enhance¬
ment was lower than that at ij.0C (P<0.05) and was only significant
at 1/2MIC, 2 x MIC and 8 x MIC values. However the observed effect
was dose-dependent and showed a similar pattern to that observed
at L|°C.
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Tobramycin slightly enhanced binding of EA_ to Fc receptors
(P <0.05 at MIC and 8 x MIC) when incubated with the macrophages


























The effect of tobramycin on the "binding of EA^ to alveolar
macrophages. The macrophages were incubated with tobra¬
mycin at i|°C for 30 minutes prior to the assay which was
performed at room temperature (22°C). Each figure repre¬
sents the mean of three experiments - 1 SEM.
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1+.0 TIMS COURSE OF TOBRAMYCIN IEDUCED ENHANCEMENT OF Fc RECEPTORS
Binding of EA^ to Fc receptors on rat alveolar macrophages
was increased (P<0.05) when 1/2MIC value (0.15 ugm ml- ) of
tobramycin was incubated with macrophages for 10,20 and 30 minutes
(Figure 25). However at 60 minutes, the level of binding had
returned to control values and at 120 minutes, binding was decreased
although not significantly.
Table "VTII shows the effect of all concentrations of tobramycin
when incubated with the macrophages for one and two hours prior to
addition of the EAq* Inhibition of binding was only significant
(P<0.05) when macrophages were incubated for 2 hours with 8 x MIC of
tobramycin. At one hour the enhancement was slight and the effect
became inhibitory at 2 x MIC.
The inhibition of EA^ binding observed at two hours did not
increase with longer times of pre-incubation (Table IX). However
inhibition was significant (P<0.05) when 1/2MIC tobramycin was
incubated with the macrophages for three hours.
181 .
Figure 25
Time course of the effect of tobramycin on binding of EA^ to rat
alveolar macrophages, after pre-incubation of the macrophages for
30 minutes with 1/2MIC value of tobramycin. Each point represents
the mean - 1SEM of three experiments.
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Concentration One Hour Two Hours



























The effect of tobramycin on the binding of EA„ to rat alveolar
Lr
macrophages. The macrophages were incubated with antibiotic for
one or two hours prior to the assay. Each figure represents the
mean - 1 SEM of three experiments.










Time course of the effect of tobramycin on the binding of
EA-, to rat alveolar macrophages. The macrophages were
\jr
-1
incubated with 0.15 pgm ml tobramycin at various times
prior to the Ec receptor assay. Each figure represents
the mean - 1 SEM of three experiments.
*(p < o.o5)
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5.0 THE EFFECT OF TOBRAMYCIN ON THE PHAGOCYTOSIS OF EA„
Lr
Tobramycin caused a decrease in phagocytosis of bacteria
yet an apparent increase in Fc receptor expression. This paradox
was studied by investigating the effect of the antibiotic on the
phagocytosis of EA . The macrophages were incubated for 30 minutes
VJ
at 37°C with tobramycin and washed, then EA^ were added and incubated
for a further 30 minutes at 37°C. The phagocytosis of EA^ was
inhibited in a dose-dependent fashion and was significant (P<0.05)
at values of I/I4MIC and above (Figure 26). Therefore these results
are similar to those observed for the phagocytosis of P.aeruginosa
and tobramycin appears to have a different effect on phagocytosis




Phagocytosis of EA^ (prepared with mouse IgG2h monoclonal
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Figure 26
The effect of increasing concentrations of tobramycin on the phago¬
cytosis of EAn by rat alveolar macrophages. The macrophages \<rere
incubated with antibiotic for 30 minutes prior to the addition of




Tobramycin enhanced the binding of EA^ to rat alveolar
macrophages when the phagocytes were pre-incubated with tobramycin
for 30 minutes. This effect was dose, time and temperature
dependent. Conversely pre-incubation of macrophages with tobra¬
mycin resulted in a decrease in the phagocytosis of sensitised
erythrocytes. Azlocillin had no effect on Fc receptors when
pre-incubated with the macrophages.
Binding of EA^ to Ec receptors on the macrophages was inhibited
in a dose-dependent fashion when either tobramycin or azlocillin
was co-incubated with the macrophage monolayers and erythrocytes.
Ticarcillin had no effect on EA^ binding with either procedure.
187.
SECTION III




It was shown in the previous section that tobramycin and
azlocillin had an inhibitory effect on phagocytosis and Fc
receptor expression when added with the opsonised bacteria or
EA,, (indicator cells) to the macrophage monolayers. Therefore
these effects may be a result of the action of the antibiotic
on the indicator cells as opposed to a direct effect on the
macrophages. To examine this possibility, these two antibiotics
were incubated with opsonised bacteria or sensitised sheep erythro¬
cytes for 30 minutes and the cells washed prior to their addition
to the macrophage monolayers. The effect of tobramycin on the
opsonisation procedure was also evaluated.
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2.0 THE EFFECT OF TOBRAMYCIN ON THE INDICATOR CELLS AND
OPSOHISATION
Tobramycin did not alter the phagocytosis of opsonised
P.aeruginosa or the binding of EA^ when incubated with these
cells (Table X). However the phagocytosis of EA^ was enhanced
after tobramycin treatment of the sheep erythrocytes (Figure 27).
This effect was significant (P<0.05) at 1/8MIC, 2 x MIC and
1+ x MIC values, and (P<0.01) at k x MIC value. Tobramycin was
also added to the antibody and bacterial mixture during opsonisation,
the cells washed and added to the macrophages. After this treat¬
ment there was no difference in the subsequent phagocytosis of the
bacteria as compared to untreated bacteria (Table Xl). Therefore
tobramycin has no effect on the opsonisation procedure as measured
by subsequent phagocytosis.
190.
Concentration Phagocytosis of Binding of EJL,
U"
,-1 bacteria n/ ,
}igm ml % Inhibition
% Inhibition
0.037 8.5 - 9.1 11.1+ - !+• 2 (-)
0.075 3-3 ± 11+.8 18.1+ ± 5.6 (-)
0.15 2.1+ ± 5-7 5-2 - 2.1+
0.3
+
iorA 12.3 28.1 - 10.2
0.6 1+. 2 ± 6.1 1.1+ - 1+.2
1.2 10.2 - 1+.1 6.6 - 3.6
2.1+ 1+.8 ± 2.2
TABLE X
The effect of tobramycin on the indicator cells. The opsonised
bacteria or EA^ were incubated for 30 minutes at 37°C with
tobramycin and washed before addition to the alveolar macrophages.
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Figure 27
The effect of increasing concentrations of tobramycin on the
phagocytosis of EA^. The sensitised sheep erythrocytes were
incubated with the antibiotic for 30 minutes, and washed prior to
addition to the macrophage monolayer. Each point represents the
mean - 1 SEM of three experiments.
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Concentration Phagocytosis
jigm ml % Inhibition
0.037 6.1+ ± 11.1
0.07 0.5 - 9.9 (-)
0.15 8.8 i 8.7
0.3 12.5 - 10.2
0.6 1+.9 ± 6.1+
1.2 15.1+ ± 7.0
2.1+ 13.1 ± 9.7
TABLE XI
The effect of tobramycin on opsonisation. Tobramycin was
added to the bacteria and serum mixture during opsonisation.
Each figure represents the mean - 1 SEM of four experiments.
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3.0 THE EFFECT OF AZLOCILLnr ON THE INDICATOR CELLS
Azlocillin had no direct effect on the indicator cells as
the phagocytosis of P.aeruginosa or the binding of EA^ was
unaltered after incubation with the antibiotic (Table XII).
Therefore, although the continual presence of this antibiotic
appears to be required for inhibition of phagocytosis and Pc
receptor expression to occur, the observed effects are not a
result of any direct action of azlocillin on the bacteria or
erythrocytes.
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Concentration Phagocytosis of Binding of EA^
-1-1 Bacteria n/ T
p.gm ml % Inhibition
% Inhibition





2.5 2.5 + 7.5 16.1 + 10.2
5.0 3.5


















The effect of azlocillin on the indicator cells. The opsonised
bacteria or EA^ were incubated for 30 minutes at 37°C with
azlocillin and washed before addition to the alveolar macrophages.
Each figure represents the mean - 1 SEM of three experiments.
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U.O SUMMARY
Tobramycin and azlocillin had no direct effect on either
opsonised P.aeruginosa or sensitised sheep erythrocytes as
measured by their subsequent phagocytosis or binding. However
sensitised sheep erythrocytes became more susceptible to phago¬
cytosis after treatment with tobramycin for 30 minutes. Tobra¬
mycin had no effect on the opsonisation of P.aeruginosa by immune
serum as measured by the subsequent phagocytosis of the bacteria
by the alveolar macrophages.
196.
SECTION 17




Tobramycin was shown to enhance Fc receptor expression,
when pre-incubated with the macrophages for 30 minutes, but
enhancement no longer occurred if macrophages were incubated
for 60 minutes or longer with the antibiotic. It therefore
seemed possible that Fc receptors were being shed from the
macrophage membrane as a result of the tobramycin treatment.
This possibility was investigated by taking the supernatants
from tobramycin treated macrophage monolayers and examining
their effect on EA^ and freshly prepared macrophage monolayers.
Electrophoretic separation of the supernatants on polyacryl-
amide gel was also performed.
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2.0 THE EFFECT OF SUPERNATMTS ON EA„
Lr
Supernatants were taken from macrophages that had been treated
with tobramycin for one hour and prepared as discribed in Materials
and Methods. The supematants were made up to the original volume
and mixed in a 1:1 or 2:1 ratio with the EA„ for 30 minutes at
U"
37°C. The erythrocytes were then washed and added to fresh
macrophage monolayers and ah Fc receptor assay performed. The
binding of the treated EA-, was decreased in a dose-dependentU-
fashion (Figure 28). The effect was greater (P< 0.0£) at the
higher supernatant: EA^ ratio of 2:1, where inhibition reached
a maximum of $Q% at ij. x MIC value of tobramycin and was signifi¬
cant (P<0.01) at MIC - 8 x MIC values.
When the supernatants were taken from macrophage monolayers
that had been incubated for two hours, binding of the EA_, was
decreased to a lesser extent than supernatants obtained at one
hour. However this decrease was significant (P<0.05) at 1/8MIC,
k x MIC and 8 x MIC and (P<0.01) at MIC and 2 x MIC values, reaching
a maximum of 37*5% inhibition at the highest concentration used
(Figure 29).
Supernatants taken from macrophages that had been incubated
for 30 minutes with tobramycin had no effect on the binding of
EAq (Table XIII).
Dialysis cf the supernatants removed any tobramycin that might have
been present as at the highest concentration used, there was
no inhibition of growth of P.aeruginosa when cultured with the
prepared supernatants. Therefore the results are not attributable
to the possible presence of tobramycin in the supernatant.
199.
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Fig-are 26
The effect of supernatants taken from macrophages incubated with tobra¬
mycin for one hour, on the binding of EA^ to alveolar macrophages.
Supernatants were incubated with EA„ for 30 minutes at a 1:1 ratio
(0 0) or 2:1 ratio (• 9) prior to the Fc receptor assay. Each
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Figure 29
The effect of supernatants taken from macrophages incubated with
tobramycin for two hours, on the binding of EAn to rat alveolar macro-
\JT
phages. Procedure as described for Figure 28 and the ratio of super¬
natant to red cells was 1:1. Each point represents the mean - 1 5EM
of four experiments.
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Concentration Binding of treated EA_Lr
A
jigm ml % Enhancement




0.15 2.0 ± U.o
0.3 6.9 - 12.2
0.6 19.8 ± 7.1
1.2 19.3 - 8.0
2.b 16.6 — 6.2
TABLE XIII
The effect of supernatants from macrophages treated with
tobramycin for 30 minutes, on the binding of EA^ to
alveolar macrophages. Supernatants were incubated with
EA^ for 30 minutes at a 3;1 ratio. Each figure represents
the mean - 1 SEM of four experiments.
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3.0 THE EFFECT OF SHTEB1IATANTS ON ALVEOLAR MACROPHAGES
Supernatants, prepared as previously described were incubated
with fresh alveolar macrophage monolayers for one hour at room
temperature and the cells washed, prior to performing an Fc
receptor assay. The binding of EA^ to the macrophages was
increased, (P<0.05) at 1/8MIC, (P<0.01) at MIC, 8 x MIC, 16 x MIC,
after incubation with supernatant reconstituted to original volume
(Figure 30).When the supernatant was diluted 1:5> binding was
increased, but to a lesser extent (P-<0.05)» showing a concen¬
tration effect. At this dilution enhancement of rosette formation
was significant (P < 0.05) at 8 x MIC and(P<0.01) at the ICG and
16 x MIC values. With undiluted supernatant the maximum response
(77%) was reached at 8 x MIC value.
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Figure 30
The effect of supernatant taken from macrophages incubated, with tobramycin
for one hour on alveolar macrophages. The macrophages were incubated with
supernatant for one hour and washed prior to the addition of the EAq-
(• i)dialysate reconstituted in original volume
(0 0) 1/5 dilution
Each point represents the mean - 1 SEM of three experiments.
204.
k.O THE EFFECT OF STJPEHNATAHTS ON THE BINDING OF STAPH ALBUS
To check the specificity of the effects that the supernatants
had on EA^ and macrophages.Staph.albus were incubated with super¬
natants for 30 minutes at 37°C, washed and added to macrophage
monolayers. There was no observed effect on the binding of
bacteria that had been treated (Table XIY) indicating the presence




tobramycin ]igm ml ^
0.03 7.h - h.2
0.15 1.7 - 3.6
0.3 2.7 - 2.5
1.2 2.9 - 3-0
2.k 3-05 - 1+.1
TABLE XIV
The effect of supernatants on the binding of Staph.albus
to rat alveolar macrophages. The bacteria were incubated
with supernatants at 37°C for 30 minutes, washed and added
to the monolayers. Each figure represents the mean - 1 SEM
of three experiments.
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5.0 THE EFFECT OF SUPEMATAHTS ON THE AGGLUTINATION OF SENSITISED
ERYTHROCYTES
Concentrated supernatants from tobramycin treated macrophages
(10ml supernatant reconstituted in one ml EBSS after freeze-drying)
caused the agglutination of EA_, in Y bottomed microtitre plates.'
Kjt
Agglutination occurred until a dilution of 1/8 was reached. Control
supernatants did not show this effect at the concentrations studied.
Supernatants that had been absorbed with formalised EA^, were
no longer capable of agglutinating fresh EA_.
207.
6.0 POLYACRYLAMTDE GEL ELECTROPHORESIS (PAGE)
The supernatants from tobramycin treated macrophages inhibited
the binding of EA-, on incubation with the red cells and enhanced
EAj, binding on incubation with the macrophages, but had no effect
on bacterial binding. Therefore it seemed likely that the super-
natants contained a blocking factor that bound to red cells or
sensitising antibody and inhibited the attachment of the cells to
the macrophage Ec receptor. Conversely the factor would bind to
the macrophage membrane and cause enhanced binding of EAq- PAGE
was performed on supematants from treated and untreated macrophages
to examine the possibility that a blocking factor was present in
the treated supernatants.
Plate VT shows a PAGE gel of the supematants that had been
prepared as described in Materials and Methods, 100jil of each
sample was loaded onto the gel. The supernatant from macrophages
treated with 2.1+p.gmml tobramycin contained more material, especially
at two bands approximating to 66,000 and 1+5,000 M.Vt. The control
which contained medium alone and medium with tobramycin showed very
faint bands, so that the observed effect was not due to the tobra¬
mycin present in the supernatant, but protein released from the
macrophage monolayers.
Plate VII shows a repeat of this experiment and again the super-
-1
natant from 2.1+Pgml tobramycin treated macrophages contains more
protein than the control supernatant, especially at two bands.
This indicates that the first result was not a "loading"effect .
The molecular weight marker was over-diluted in this experiment so
208.
that the hands are too faint to he seen.
Sensitised erythrocytes were also treated with supernatants,
washed and the resulting supernatant studied on PAGE. This
experiment was performed to determine whether the EA^ hound a
factor contained in the supernatant. If this occurred the
hands containing more material with supernatant alone, would he
removed in incubation with EA^. However from Plate "VTI it would
appear that the red cells were lysed during the procedure so that
conclusions cannot he drawn. Tobramycin supernatants do,though
appear to cause more damage to the red cells than control supernatants.
In this experiment the supernatants were not dialysed prior to
incubation with the EA-,, so that it is possible that the antibiotic
VJ
may have a direct effect on the red cells. It was previously shown
that tobramycin treatment of EA^ caused an increase in the phagocytosis




Polyacrylamide gel eletrophoresis of supernatants taken from untreated
(control) and tobramycin treated macrophages monolayers after one hour
incubation at 37^0.
a = molecular wt marker:- 12,300, 17,200, 23,700, 14.3,000, 66,200,
76-78,000.
b = Eagles MEM alone
—1
c = Eagles MEM containing 2.1; pgm ml tobramycin
d = Control supernatant
e = Supernatant from macrophages treated with 0.3 P-gm ml tobramycin
f = Supernatant from macrophages treated with 2.l+ pgm ml tobramycin
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Plate VII
Polyacrylamide gel electrophoresis of supernatants taken from EA^ incubated
with macrophage supernatant for 30 minutes at 37°C and of supernatants from
macrophages described in Plate VI.
a = EAn incubated with control supernatant(j-
b = EA^ incubated with 0.3 pgm nil tobramycin supernatant,
c = EA^ incubated with 2.1+ pgm ml tobramycin supernatant
d - control supernatant
e =0.3 pgm ml supernatant
f =2.1; pgm ml supernatant
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7.0 SUMMARY
Supematants taken from tobramycin treated macrophages inhibited
the binding of EA^ to Fc receptors, when pre-incubated with the
EA.£ and enhanced the binding of EA.^ to Ec receptors when pre-incubated
with the macrophages. The supernatants had no effect on the binding
of Staph.albus to macrophages when incubated with the bacteria.
These results indicated the presence of a factor in the supernatants
that possibly bound to the antibody on the red cells to inhibit
attachment to the macrophage Pc receptor. Furthermore, the tobramycin
supernatants caused the agglutination of EA^. This activity was
lost after incuba.tion with formalised EAq* Polyacrylamide gel
electrophoresis revealed that more protein is released from tobramycin
treated macrophages, especially at two bands that may correspond to
the Pc receptor.
Supernatants containing tobramycin caused more damage to sensitised
erythrocytes than control supernatants.
212.
SECTION V
TEE EFFECT OE TOBRAMYCIN, AZLOCILIIN AND TICARCILIIN ON Fc
RECEPTORS ON HUMAN PERIPHERAL BLOOD MONOCYTES
213.
1.0 INTRODUCTION
In the previous sections, tobramycin and azlocillin were shown
to have an effect on the Fc receptor expression of rat alveolar
macrophages. These results indicated the necessity for studies
on human cells, for only then could any clinical relevance of
these effects be determined. Alveolar macrophages from healthy
volunteers and patients are difficult to obtain, especially in a
non-clinical setting. Peripheral blood monocytes are the precursor
cells of alveolar macrophages (Thomas et_ al., 1976), and are readily
and easily obtained. Therefore some studies were carried out on
the effect of the three antibiotics,although mainly tobramycin,
on the binding of IgG2b sensitised sheep erythrocytes to human
peripheral blood monocytes.
214.
2.0 THE 3FFECT OF TOBRAMYCIN ON Fc RECEPTORS
Tobramycin inhibited the binding of EA„ to human peripheral
blood monocytes when the antibiotic was added with the erythrocytes
to the monolayers. Inhibition occurred when results from six
different individuals were pooled , (P<0.05) at I/I4MIC, 1/2MIC
and MIC values (Figure 31) and the curve obtained was similar to
that observed when rat alveolar macrophages were studied. Inhibition
of binding was also observed (P<0.05) at I/J4MIC to 2 x MIC values
when monocytes taken from the same individual on different days
were studied (Figure 31)•
When the monocytes were pre-incubated with tobramycin for
30 minutes prior to the addition of EA_,, there was no effect on
VJ
Fc receptors when results from different individuals were pooled
(Table XV"). This may be a result of individual variation, for
when cells were taken from a single individual and studied on
different days, tobramycin treatment caused a decrease (P<0.05)
(Figure 32) or an increase (Figure 33) in the binding of EA^ to
the monocytes. In this case a longitudinal study may reveal

















1-20-037 0-075 0-15 0*3 0-6




The effect of increasing concentrations of tobramycin on binding of EA_
to human monocytes, when the antibiotic was added with the erythrocytes.
(• •)results pooled from six different individuals
(0 0)results from monocytes taken at different days from the same individual
Each point represents the mean - 1 SEM of six experiments (•—•) or four
experiments ( 0 0).
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Concentration Binding EA^
















2.k b.Q + 12.3
TABLE XV
The effect of tobramycin on human monocytes. Monocyte
monolayers were incubated with antibiotic for 30 minutes.
Each figure represents the mean of five experiments (each















The effect of increasing concentrations of tobramycin on the binding of
SiL, to human monocytes taken from one individual. The monocytes were
pre-incubated with antibiotic for 30 minutes and washed prior to the
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Fiacre 33
The effect of increasing concentrations of tobramycin on the binding of
EA^ to human monocytes. The monocytes were incubated for 30 minutes
with antibiotic prior to the addition of the erythrocytes. Results from
two individuals shown. Each point represents the mean of two experiments.
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3.0 THE EFFECT OF AZLOCILLIN JfflD TICARCILLIN ON Fc RECEPTORS
When azlocillin was added to monocyte monolayers with the
EA^, binding was enhanced when monocytes were taken from the
same individual (Figure 31+). However this experiment was only
repeated twice, so that any significant difference could not be
estimated. Ticarcillin had no effect on the binding of EA^ to














The effect of increasing concentrations of aalocillin on the binding
of EA^ to human monocytes, taken from the same individual. The antibiotic
was added with the erythrocytes to the monocyte monolayers. Each point
represents the mean of two experiments.
221 .
Concentration Binding EA,,
}igm ml ^ % Enhancement
2.5 19.5 - 10.2 (-)
5 6.1+ i h.2 (-)
10 17.2 - 8.1
20 13.5 - 9.2 (-)
i+0 7.5 - 6.1
80 9.U - U.2
160 5.6 ± 2.b
TABLE XVI
The effect of ticarcillin on the binding of EA^ to human
peripheral monocytes. The ticarcillin was added with the
EA^ to the monocyte monolayers. Each figure represents the
mean - 1 SEM of three experiments. The cells were taken from
the same donor on different days.
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1+.0 SUMMARY
These studies were only preliminary, so that few firm conclusions
can be drawn from them. However, they do indicate the necessity
for further work on the effect of antibiotics on human monocyte
receptor expression.
Tobramycin inhibited the binding of EA^ when added with the
erythrocytes to the macrophages. This effect was observed whether
results from different individuals were pooled or when monocytes
were taken from the same individual on different days. However
pre-incubaticn of the monocytes with tobramycin had no effect on
Fc receptors, when results from different volunteers were pooled.
This was due to individual variation as in one individual tobramycin
treatment resulted in a decrease in EA^ binding, while in two individuals
an increase was observed.
Azlocillin enhanced binding of EA_ when added with the
Lr
erythrocytes to the monolayers, although only one individual was
studied. Ticarcillin had no effect on Pc receptor expression,






1.0 ALVEOLAR MACROPHAGE, PHAGOCYTOSIS M) RECEPTOR EXPRESSION
1.1. Animals
The obvious choice for studying the effects of alginate and anti¬
biotics on alveolar macrophages in relation to CP would be a human
model. However human alveolar macrophages from normal, healthy
individuals are extremely difficult to obtain especially in a non¬
clinical setting. The ethics of unnecessary bronchopulmonary lavage
on humans is also questionable. Animal studies were therefore
instigated to evaluate the future potential of human studies. The
rat was chosen as the animal model because alveolar macrophages
are readily obtained from these animals and they are cheap and easily
maintained. A few studies on human peripheral blood monocytes, the
precursors of alveolar macrophages (Thomas et_ al., 1976) were carried
out in the antibiotic study to indicate any antibiotic effects on the
human system.
1.2 Techniques
Lung lavage is a standard procedure for obtaining alveolar
macrophages from animals and has been described in detail (Holt, 1979c).
Although many workers lavage the lung, while intact in the animal, in
this study removal of the lung prior to lavage ensured a two-fold
increase in cell retrieval. Pre-warming the medium to 37°C before
lavage was also required to obtain optimal numbers of macrophages.
Lignocaine has been reported to be an effective aid in obtaining high
numbers of alveolar macrophages by lavage, although a period of
recovery is required for the cells which appear highly vacuolated
after treatment (Holt, 1979c; Miller and Poster, 1981). As high
numbers of cells were obtained without the use of lignocaine, this
method was not employed as alveolar macrophage function may alter
after long periods in culture. Lignocaine is effective in detaching
macrophages from the adhesive forces holding them to the alveolar
surface, so that cell populations may differ according to the lavage
medium employed. When 50ml of lavage fluid was collected,
7 710 -2 x 10 viable alveolar macrophages were obtained from one rat
lung. It was interesting to note that the second 25ml fraction
contained twice the number of macrophages than the first 25ml fraction.
Therefore the procedure of collecting 50ml was strictly adhered to, so
that differences between experiments, as a result of the selection of
particular macrophage populations/ were minimised. Considerable hetero¬
geneity has been observed within macrophage populations from the lungs
of normal rats with respect to cell size, surface morphology and cyto¬
chemistry (Holt et al. , 1982; O'Neill et al., 1981;). Holt et al.,
(1982) found that macrophages obtained from early washes contained a
predominance of large cells rich in Pc receptors (82%) while preparations
from later washes contained mainly small macrophages with low Pc
receptor avidity. Therefore when the amount of lavage fluid collected
is not regulated, Pc receptor expression may differ between experiments.
Macrophages obtained by lavage may not fully represent the
resident alveolar macrophage population, so that results must be
treated with caution. The main advantage of this technique is that
an almost pure population (96-99%) °f functionally active alveolar
macrophages may be obtained from a healthy animal.
Macrophages were studied asmonoiayers; in this system the oxygen
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tension resembles that found in the lung more closely than when cells
are in suspension (Hearst et al., 1980). In studies that involve
bacteria, macrophage monolayers have another advantage over cells
in suspension, in the former case macrophages do not round up and
bacteria can be easily observed within tie cell or bound to the membrane.
Washing bacteria from cells in suspension is also extremely difficult
and a high level of background bacteria usually ensues.
Cells were cultured in serum free medium as the presence of
serum increased Fc receptor avidity (Figure 13) and bacterial binding
(j. Stewart, personal communication). The absence of serum may
also correlate more closely with the environment in the lung alveoli,
where the macrophages lie in contact with the surfactant lining of
the alveoli (Hocking and Golde, 1979)- Alveolar macrophages readily
adhered to the glass coverslips and as only a low percentage were
still in suspension after one hour, selection of a highly-adherent
population did not appear to occur.
1.3 "lectin-like" receptors
10 —1
Even at high concentrations (10 ml ) of P.aeruginosa, 100%
of alveolar macrophages did not exhibit bacterial attachment (Figure 2).
This may be a reflection of the assay system as there was a limit to
the number of bacteria that could be overlaid onto the monolayers, or
it may be that a subpopulation of these macrophages do not express
"lectin-like" receptors. Similar results were found for the binding
of Staph.albus to guinea-pig alveolar macrophages (E.J. Glass, PhD
thesis, 1981) and mouse alveolar macrophages (Glass et al., 1981).
A plateau of bacterial binding was not reached for P.aeruginosa as
227.
10 -1
concentrations higher than 10 organisms ml resulted in a bacterial
background that made counting extremely difficult. However, counts
10
over 10 are unlikely to be reached clinically, so observations at
higher concentrations would appear to be irrelevant.
Formalin-killed P.aeruginosa bound to the macrophages more
readily than live organisms (Figure 2). This may be a result of
membrane alteration by the formalin rendering the bacteria more suscep¬
tible to binding. Live P.aeruginosa were therefore used in all
future experiments to resemble the in vivo situation.
Staph.albus bound to a greater extent than formalin-killed or
live P.aeruginosa. This difference may be a result of the coccal
structure and gram positive nature of Staph.albus compared to the
gram negative bacillus nature of P.aeruginosa.
Mucoid P.aeruginosa did not bind to alveolar macrophages and
bacteria were absent from the background, even at concentrations of
11 -1
10 organisms ml . The alginate produced by these bacteria may
prevent the organisms from contacting the macrophages as washed
bacteria did exhibit binding (results not shown). The alginate
may also prevent the bacteria from "sticking" to the glass ccverslips,
so that the bacterial background is low. . Centrifugation of the plates
after addition of mucoid P.aeruginosa to aid macrophage bacterial
contact, did not result in binding.
D-glucose and D-galactose inhibited the binding of non-mucoid
P.aeruginosa to rat alveolar macrophages indicating that binding at
least in part was due to the "lectin-like" receptor. Binding of
Staph.albus via this receptor has been demonstrated for a number of
cell types (Glass et_ al., 1981). At the highest sugar concentrations
(20mm) studied, 100% inhibition was not observed and a maximum
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bacterial binding inhibition of 1+9% was reached at 10mm D-glucose.
Binding of bacteria may take place by other sugar components, when
one of them is blocked, although experiments in which more than one
sugar was added at the same time to the macrophage monolayers were
inconclusive (J. Stewart, personal communication) . The bacteria
may also be binding to the phagocyte surface by mechanisms that
are independent of the recognition of these sugars. Non-specific
binding involving hydrophobic charge effects and other membrane
biomechanical forces may contribute to the observed adherence
(Wilkinson, 1976). P.aeruginosa contain lectins in the cell wall
(Glick and Garber, 1983) that may bind to specific sugars on the
macrophage membrane in a similar way to that observed for C.uarvum
(Bagg et_ al., 1981) and E.coli which binds to a mannose-specific
lectin (Ofek et al., 1977). However, when bacteria are incubated
with sugars prior to binding, inhibition does not occur (j. Stewart,
personal communication).
Bacterial attachment via lectin-like receptors does not necessarily
bring about phagocytosis. The receptor may act in a similar way to
the complement receptor which binds bacteria to the surface so that
other receptors may initiate phagocytosis (PeaTon, 1981+)- P.aeruginosa
were phagocytosed by mouse peritoneal macrophages when warmed to
37°C after binding at 1+°G (Oliver and Weir, 1983)- However, unopson-
ised P.aeruginosa were not phagocytosed by rat alveolar macrophages after
binding at l+°G, although Staph.albus were taken up by these cells.
This may be due to an insufficient number of bacteria binding to the
macrophage, for the initiation of ligand-receptor interactions and
subsequent phagocytosis. Alternatively the bacteria may have toxic
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effects on the macrophage, so that phagocytosis is inhibited, as P.aeruginoss
produce leucocidins. However as these macrophages phagocytose
opsonised bacteria and mouse peritoneal macrophages phagocytose
unopsonised bacteria this seems unlikely. "Lectin-like" receptors
may be important in antigen presentation, because of the possible
association with IA (Stewart et al., 1982). Therefore if P.aeruginosa
are able to escape initial phagocytosis and antigen presentation, this
may enhance their pathogenicity and confer P,aeruginosa with advantages
over other bacterial species such as Staph.albus that are phagocytosed
unopsonised. However failure to phagocytose unopsonised P.aeruginosa
may be a characteristic of the rat alveolar macrophage as remarkable
differences in alveolar macrophage receptor expression and function
have been observed between animal species (Nguyen et al., 1982).
1.k Phagocytosis
For P.aeruginosa to be phagocytosed by rat alveolar macrophages,
it was necessary to opsonise the bacteria with specific immune serum.
Bacteria opsonised with fresh rat serum were not phagocytosed by
these cells. P.aeruginosa strains do vary in their requirements for
opsonisation (Peterson, 1982). However these bacteria have been
found to require opsonisation with specific immune antibodies, before
phagocytosis will take place (Reynolds et al., 1975b). Some forms of
P.aeruginosa are not opsonised by IgG alone and require an intact
complement pathway for opsonisation (Baltimore and Shedd, 1983)•
The opsonin requirement of a particular bacterial strain may influence
its pathogenicity as bacteria that are readily taken up by macrophages
will be cleared more effectively than bacteria that are only phagocytosed
once an immune response has been initiated. The requirements for
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opsonisation may also depend on cell type as mouse peritoneal macrophages
phagocytosed P.aeruginosa opsonised with normal mouse serum, while
rat alveolar macrophages did not (personal observation).
Agglutination tests on the immune sera raised against P.aeruginosa
l+92a Rev1 revealed low titres of agglutinating antibody indicating
that the bacteria did not bind sufficient antigen for agglutination
to occur above dilutions of one in four.
Mucoid bacteria were not studied in the phagocytosis assay as
the washing procedure involved in opsonisation renders the bacteria
no longer mucoid. It has been shown that alginate blocks the anti¬
genic receptor of the bacteria so that opsonisation of mucoid bacteria
does not occur (Baltimore and Mitchell, 1980). Although the alginate
has been shown to be antigenic (Bryant est al. , 1983? Pier e£ al. , 1983)
serum against these bacteria was not raised. However the washing of
bacteria opsonised with such serum would still remove the alginate
coated with antibody.
A microscopic assay was employed to detect phagocytosis and
unphagocytosed bacteria were effectively washed away. Bound bacteria
did not remain after the washing procedure as monolayers left at
room temperature bound opsonised bacteria but phagocytosis did not
occur. When these plates were vigorously washed the bound bacteria
no longer remained. Thus the microscopic technique was adequate for
the purpose of these studies and phagocytosed bacteria within cell
vacuoles were easily distinguished. Trypsin treatment of the macro¬
phages to remove bound bacteria from the cells was not necessary in
this system and was disadvantageous as the enzyme appeared to be
slightly toxic to the alveolar macrophages.
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The optimum conditions for phagocytosis largely depended on
the dilution of antibody and concentration of bacteria in the opson-
isation mixture. Bacteria that were opsonised and subsequently
diluted before addition to the macrophages were not adequately phago-
cytosed. At high concentrations of bacteria in the opsonisation
mixture, phagocytosis was decreased, possibly as a result of ineff¬
ective coating of the excess number of bacteria by antibody.
1.5 Fc receptor expression
Receptors for IgG on the macrophage membrane were detected
and studied using the rosette technique. This method is well
established and involves the sensitisation of erythrocytes with
specific antibody that will subsequently bind to the Fc receptors
on the macrophage membrane. The antibody used in this study was a
monoclonal IgG2b raised in mice against sheep erythrocytes. This
particular monoclonal was readily available and gave consistent
results. At the time of this study a rat antibody against sheep
erythrocytes was not available. Although the mouse monoclonal may
not bind specifically to the rat IgG2b receptor, it does bind to
IgG Fc receptors on rat macrophages (Boltz-Nitulescu et al., 1981).
In the human system, IgG3 binds to a greater extent to Fc receptors
than other subclasses of IgG (Naegel et al. , 198l|.). However the
mouse monoclonal IgG2b bound to human monocyte Fc receptors and was
used to detect these receptors in this study. The drawback of this
heterologous system is that although the sensitised sheep erythrocytes
form rosettes with alveolar macrophages and monocytes, the specificity
of the binding receptor is unknown.
The Fc receptor assay was performed at room temperature (22°C)
to minimise phagocytosis of the EA^ "by the macrophages. At 37°C
the erythrocytes were readily taken up "by the cells (Plate V).
At the highest concentration of antibody (1:2 dilution) 100%
positive Fc rosetting cells were not observed (Figure 1U). The
formation of macrophage-EA^ rosettes occurs only when there are
ligand-receptor interactions between many macrophage Fc receptors
and the erythrocyte antibody. This union is dependent on the
density of bound antibody on the red cells and also on the ease with
which the macrophage Fc receptors can move in the plane of the membrane.
This failure to attain 100% resetting cells is not a result of the
restriction in the amount of antibody that can be bound to the sheep
erythrocytes as even at a dilution of one in two the antibody is
subagglutinating. Ox erythrocytes are able to bind more molecules
of antibody per cell than sheep erythrocytes (Hallberg et al.,1973)•
However 100% rosetting cells did not occur, when ox erythrocytes and
rabbit antiox antisera were used unless the macrophages were cultured
in foetal calf serum (Figure 13)- Therefore the low number of
rosetting cells may be a result of the size of the alveolar macrophage
and the spatial arrangement of the Fc receptors on the ruffled plasma
membrane. When the cells are incubated with foetal calf serum their
appearance becomes more rounded, i.e. they are less spread out, and
Fc receptor avidity increases (Figure 13)- The observation that the
Fc receptor avidity and size of the smaller more rounded human mono¬
cyte do not alter when the cells are incubated with foetal calf serum,
supports this theory. Moreover the mouse monoclonal antibody may have
a low affinity for rat Fc receptors.
Alternatively there may be a subpopulation of alveolar macrophages
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present in the monolayer with low Fc receptor avidity, these may
include redundant macrophages or newly recruited monocytes. As
previously noted, different lavage fractions contain macrophages with
low or high Pc receptor avidity (Holt et al., 1982) and it is well
established that subpopulations of macrophages express differences
in Pc receptor avidity (Moore and McBride, 1980). In this study
heterogeneity in terms of alveolar macrophage cell size was observed
and the presence of low avidity Pc receptor bearing cells may partly
account for the low number of rosetting cells.
The dilution of sensitising antibody plotted against the percent¬
age of rosette forming cells produces a sigmoidal curve (Pigore 1J+),
similar to those reported by Rhodes (1975) for guinea-pig alveolar
macrophages, indicating a normal distribution of cellular avidities
for IgG amongst these populations.
1.6 Complement receptors
Experiments using the rosette technique with complement coated
sheep erythrocytes (described in Materials and Methods) failed to
demonstrate the presence of complement (03) receptors on rat alveolar
macrophages. Sheep erythrocytes were sensitised with a monoclonal
IgM before the addition of complement components and zymosan depleted
serum. The zymosan removes the terminal complement components and
therefore allows more C3 to be deposited on the erythrocytes. These
results agree with those of Coonrad and Rehm (1982) who failed to
detect receptors for CR1 , CR2 or CR3 on rat Sprague-Dawley alveolar
macrophages. Alveolar complement receptors were detected on peritoneal
and alveolar macrophages from Lewis-Wistar rats. Long-Evans and
234.
Wistar rats also lacked. C3 receptors on their alveolar macrophages
indicating that this phenomena is strain specific. The reason for
the lack is -unknown "but may he related to lipids in the alveolar
lining material (Coonrad and Yoneda, 19^3)• Lavage fluid added to
peritoneal macrophages caused the loss of C and Fc receptors by the
macrophages.
As the alveolar macrophages in this study lacked C3 receptors,
the effect of alginate and antibiotics on their expression was not
studied.
2.0 THE EFFECT OF ALGINATE ON ALVEOLAR MACROPHAGES
2.1 "Lectin-like" receptors
Rat alveolar macrophages were shown to possess "lectin-like"
receptors (Eigure 3)> although they hound fewer bacteria than mouse
peritoneal macrophages (Oliver and Weir, 1983)• Rat alveolar macro¬
phages have a low percentage of la bearing cells, approximately 10%
(personal observation) and as there appears to be an association
between la and lectin-like receptors (Stewart et_ al., 1982) this
may account for the low level of bacterial binding to these cells.
The alginate used in these studies was produced by a mucoid strain
of P.aeruginosa that was originally isolated from a patient with CP.
Bacteria were grown under optimum conditions for alginate production
and the procedure for extraction was adapted from the method described
by Govan (1975). The alginate was free from any contaminating protein
as measured on a spectrophotometer and was considered pure enough for
the inhibition assays. The non-mucoid revertant of the original
mucoid P.aeruginosa was studied as this bacteria is genetically
similar, but does not produce alginate or mutate back to the mucoid
form (j.W. Govan, personal communication). These two strains thus
formed a good system for studying the effect of alginate on bacterial
binding.
The alginate inhibited the binding of unopsonised non-mucoid
P.aeruginosa to rat alveolar macrophages in a dose-dependent fashion
(Eigure l+). This inhibition occurred when the macrophages were pre-
incubated with alginate and when alginate was added with the bacteria
to the monolayers. In the latter procedure, the bacteria were, in
effect, made mucoid by addition of the alginate and inhibition was
236.
greater in this case. This is probably due to the alginate acting
as an inhibitory matrix on the bacteria and macrophage as opposed to
only the macrophage. However, from the results it is uncertain
whether the inhibition observed after pre-incubation of the macrophages
with alginate is due to a specific lectin-ligand interaction or to
the alginate simply forming a mechanical barrier on the macrophage
surface. The exopolysaccharide alginate may however be binding to
lectin-like receptors in a similar way to other sugars (Weir and
Ogmundsdottir, 1980) and inhibit the binding of organisms other than
P.aeruginosa. In this study the binding of Staph.albus to macrophage
monolayers was blocked after alginate treatment of the macrophages.
In fact Staph.albus binding was inhibited to a greater degree than
that of P.aeruginosa (Pigure l+). This observation could be due to
differences between the bacterial strains and their binding capabilities.
Staph.albus binds more readily, but inhibition of binding is greater
than with the gram negative P.aeruginosa bacillus. It is also
possible that P.aeruginosa may bind to the alginate on the macro¬
phages as it was observed that bacteria sometimes bound to the alginate,
which at high concentrations was stuck to the coverslips. These
findings do not exclude the possibility that the alginate may coat
the macrophage by physiochemical mechanisms, for example hydrophobic
interaction rather than binding via a specific receptor. Alginate
gels in the presence of bronchial electrolytes so that in vivo it
tends to be a viscid fluid rather than free-flowing (Govan, 1983;
Govan _et al., 1983)* Therefore in vivo it is even more likely to




The process of phagocytosis has two phases, attachment of the
particle to the cell membrane followed by ingestion, after which
intracellular killing usually takes place. In this study phagocytosis
was measured by estimating the number of macrophages that had ingested
bacteria.
These studies show that phagocytosis of non-mucoid P.aeruginosa
is inhibited when monolayers of alveolar macrophages are incubated
for 30 minutes with alginate, prior to the addition of the bacteria
(Figure ?)• Inhibition was increased when the alginate was added
with the bacteria and decreased when the cells were vigorously washed
to remove the excess alginate. Inhibition was not specific for
P.aeruginosa as the phagocytosis of Staph.albus was also inhibited
in a dose-dependent fashion, when the macrophages were pre-incubated
with alginate (Figure 8). These results confirm and extend obser¬
vations by other workers. Schwartzman and Boring (1971) showed that
alginate inhibited the phagocytosis of bacteria by rabbit neutrophils
when the alginate was added to the bacteria and cell mixture. In
this study phagocytosis of P.aeruginosa was inhibited to a greater
extent than that of E.coli or S.aureus. However phagocytosis was
measured by determining the viable bacterial count in the mixture
after cell lysis, so that intracellular killing as opposed to phago¬
cytosis was measured. Other results indicating that alginate
inhibits phagocytosis have been reported for guinea-pig and rat
alveolar macrophages (Ruhen et al., 1980). A recent study has
demonstrated significantly reduced phagocytic uptake of mucoid
organisms by human neutrophils when compared to non-mucoid strains
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(Meshulam et al., I98I4). When mucoid strains were grown to produce
less alginate their uptake was increased. However these workers
washed the bacteria and used normal human serum as the opsonin
source, so that the results may be a reflection of strain differences
in opsonin requirements as opposed to an effect of alginate, per se.
The results in this thesis suggest that the alginate acts as an inhib¬
itory matrix or barrier to prevent attachment and phagocytosis as
vigorous washing which removed the alginate from the cells, resulted
in phagocytosis returning to control values.
It is possible that the inhibitory effects were caused by a
toxic bacterial product contaminating the alginate. To investigate
this possibility alginic acid, a chemically similar compound isolated
from Macrocystis Pyrifera (Kelp) was studied for its effect on phago¬
cytosis. This compound inhibited the phagocytosis of P.aeruginosa
l+92a Rev1 when pre-incubated with the macrophages and when added to
the monolayers with the bacteria (Figures 9»10)« Inhibition was
reduced by approximately when the macrophages were vigorously
washed after treatment, which agrees with the alginate results. The
lower viscosity of this compound enabled the preparation of high
concentrations with the result that 10C^ inhibition was achieved.
The observation that low concentrations of commercial alginic acid
__-j
(0.03mg ml ) caused inhibition of phagocytosis suggests that the
effect is not due to viscosity. The pseudomonal alginate is extremely
viscous and solutions above 2mg ml were difficult to make whereas
alginic acid was not viscous to the eye at 20mg ml . Viscosity was
not measured due to the lack of equipment. Accurate measurements
were not thought necessary in these experiments, as concentrations
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were worked out by weight. Therefore in vivo where higher concen¬
trations of alginate may occur within the lung, inhibition of phago¬
cytosis may reach higher levels than those observed in vitro.
Alginate did not significantly affect cell viability after
incubation with the macrophages for 30 minutes, so that the observed
inhibitory effects were not a result of alginate toxicity. Viability
was slightly decreased at concentrations of 2mg ml alginate which
may be due to the viscous nature of the compound. The high viscosity
may lead to "suffocation" of a small percentage of the macrophages.
The percentage of cell death at this concentration was not high enough
to be responsible for the antiphagocytic effects of the alginate.
2.3 Opsonisation of bacteria
Opsonisation involves the combination of bacteria or other particles
with certain serum proteins, so that the bacteria are more susceptible
to phagocytosis (Winkelstein, 1973)- Thus any impairment of this
process would be advantageous to the infecting bacteria. The alginate
from mucoid P.aeruginosa was shown to inhibit the opsonisation by
specific antibody of the non-mucoid revertant. At high concentrations
of alginate, opsonisation was almost totally blocked, as measured by
the subsequent inhibition of phagocytosis (Pigure 11). This inhibition
indicates that the alginate is acting on the bacteria to prevent the
attachment of the antibody to the bacterial cell wall. This result
does however conflict with the work of Baltimore and Mitchell (1980)
who reported that the opsonisation of two non-mucoid strains, which
required antibody for opsonisation, was not inhibited by the addition
of mucoid material to the opsonophagocytic mixture. However, in this
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study, the antiserum, bacteria and neutrophils were incubated together
and viable bacterial counts performed to estimate phagocytosis. There¬
fore the opsoniation procedure was not separated from the phagocytic
process in this case. These workers also used a different technique
for alginate separation and the material was a very crude extract
which may also explain the difference in results. These workers
also reported that the immunodeterminant for opsonic antibody in
non-mucoid strains is blocked in the mucoid strain as higher concen¬
trations of antiserum were required to achieve the same reduction in
mucoid strains (that is intracellular killing) as compared with non-
mucoid transformant3 of the same strain.
In the study reported here, the alginate also appears to be
blocking the binding of antibody to a specific immunodeterminant on
the non-mucoid bacterial cell wall. The alginate may simply surround
the bacteria to prevent antibody attachment. Even if the alginate
is washed away from the bacteria during the washing procedure, opson-
isation will not have taken place, so that subsequent phagocytosis will
not occur. However in vivo, the alginate itself would be the outer
coat of the bacteria and antibodies against antigenic determinants
of the alginate may be produced. Although the evidence suggests that
anti-alginate antibody is an ineffective opsonin (Bryant et al., 1983)
and that such antibody may even be harmful if it forms immune complexes
in CE sera (Berdischewsky et al., 1980; Moss and Hsu, 1982). Anti-
alginate serum was not raised in this study because of the problems
involved in setting up the assay. For example even if anti-mucoid
antibody was produced, opsonisation of the mucoid bacteria would
involve a washing procedure that would render the bacteria no longer
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mucoid. Schwarzmann and Boring (1971) reported that mucoid P.aeruginosa
were phagocytosed "by rabbit neutrophils in the presence of serum but
the bacteria had been washed prior to the phagocytic assay. Although
in vivo, mucoid bacteria may be opsonised, the results shown here on
the effect of alginate on phagocytosis indicate that the bacteria may
still resist phagocytosis. Also as alginate can inhibit opsonization
of non-mucoid isogenic strains in vitro, in vivo inhibition of the
opsonisation of non-mucoid strains may occur, which may result in the
maintenance of a non-mucoid population to act as a resevoir from which
further mucoid variants could arise. Rough ana mucoid strains isolated
from CP patients are both coated with antibodies of IgA, IgG and IgM
classes (Haun and Holschaw, 1976), so that opsonisation dees occur
in vivo. The opsonisation of Staph.albus was also inhibited, although
to a lesser extent than P.aeruginosa, by the presence of alginate in
the serum and bacteria mixture. This low level of inhibition may be
a result of unopsonised Staph.albus being taken up by the alveolar
macrophages (as previously noted) so that phagocytosis is observed even
when opsonisation is totally blocked.
2.1; Pc receptors and the phagocytosis of latex.
Further evidence for the barrier effect of the alginate came from
the studies on the binding of antibody sensitized sheep erythrocytes
to Pc receptors and the phagocytosis of latex particles. To date,
there are no reports in the literature on the effect of alginate on
these processes. Both binding of EA^ and the phagocytosis of latex
were inhibited when the macrophages were incubated with alginate
for 30 minutes prior to the addition of the erythrocytes or latex
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particles. The phagocytosis of latex by macrophages is a non¬
specific process which does not involve specific receptor-ligand
interactions (Ryter and DeChastellier, 1982). These results
support the hypothesis that the alginate acts as an inhibitory
matrix and barrier to prevent the attachment of bacteria and other
particles by specific receptors and non-specifically to the macrophage.
Inhibition was greater when the alginate was added to the macrophage
monolayers with the EA^ or latex particles. This may be a result
of the test particles being inhibited from coming into contact with
the macrophages by the alginate matrix. During the Pc receptor
assay, the erythrocytes were centrifuged gently onto the macrophage
monolayers, so that in this case the alginate may prevent adequate
settling of the erythrocytes onto the macrophage monolayers.
A study with sheep alveolar macrophages has shown that protein
synthesis and latex particle endocytosis is inhibited in the presence
of diluted airway mucus (Woodside et al., 1983)- The hypersecretion
of mucus that is observed in the CP lung may therefore exacerbate any
of the inhibitory effects of the alginate.
2.5> Mechanism of action
The alginate from mucoid P.aeruginosa thus appears to have a
mechanism of action that is likely to protect the bacteria from the
host's immune response by preventing phagocytosis and the initiation
of the immune response. This is achieved by the alginate acting as
a barrier to prevent the attachment and phagocytosis of bacteria and
other particles to the alveolar macrophage membrane, and the opson-
isation of non-mucoid P.aeruginosa or other bacteria, by specific
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antisera. Other protective mechanisms have also been described
for this material, as the presence of alginate has been shown to increase
the resistance of P.aeruginosa to surfactants (Govan, 1975) or
carbenicillin (Govan and Fyfe, 1978).
It is not unusual for bacteria to secrete material that affords
them protection against the hosts immune response. The streptococcal
hyalaronic acid capsule has been found to prevent the attachment of
two groups of Group A streptococci to mouse peritoneal macrophages
(Whitrack et_ al. , 1981). The cell wall material from Cr:/T>tococcus
neoformans has also been shown to inhibit the attachment and phago¬
cytosis of nonencapsulated yeast cells by macrophages (Kozel and
Mastroianni, 1976). This effect is a result of the capsule presenting
a surface that is not recognised by the phagocyte. The inhibition
can be corrected by opsonising antibody that is specific for any
surface determinant on the capsule, that will than bind to the Pc
receptor on the macrophage. However unlike alginate which is not
a capsule, the Cryotococcus neoformans capsule will only inhibit
phagocytosis when it is bound to the yeast and has no direct effect
on the macrophage (Kozel and Gotschlich, 15'82).
The capsule of S.aureus has been shown to hinder opsonisation
by masking cell wall peptidoglycan and therefore interferring with
natural immunity (Wilkinson et al., 1979). The M protein of Group A
streptococci may act in a similar way. Encapsulated E.coli are more
pathogenic than unencapsulated forms as the capsule blocks complement
fixation and opsonisation (Horwitz and Silverstein, 1980). Therefore
capsular antigens may mask common outer membrane components. Although
alginate is non-capsular it may act in an analagous way. In fact as
it is not tightly bound to the bacteria it is free to form as an
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inhibitory matrix and barrier on other particles and cells, which may
in fact account for the enhanced pathogenicity of the mucoid organism.
If the in vitro inhibitory effects of alginate on phagocytosis
and opsonisation reported in this thesis, occur in vivo, they may
partly explain the predominance of mucoid P.aeruginosa in CP. These
effects are also likely to maintain and exacerbate chronic infection
with P.aeruginosa by protecting the bacteria from the hosts immune
response.
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3.0 THE EFFECT OF ANTIBIOTICS ON RAT ALVEOLAR MACROPHAGES
Three antibiotics used in the treatment of pulmonary infection
due to P.aeruginosa, in OF patients were used in this study. These
were tobramycin, an aminoglycoside which is highly active against
P.aeruginosa and the B.lactams, azlocillin and ticarcillin. The MIC for each
antibiotic against P.aeruginosa i4_92a Rev1 was estimated to give an indi¬
cation of the doses required for the study. The MIC of any antibiotic
will vary considerably, depending on the bacterial strain and the con¬
ditions of the assay. However as P.aeruginosa b92a Rev1 was used in
the phagocytic assays, this organism was used to determine the MIC
of each antibiotic. Doses below and above the MIC were studied to
give a gcod range. Antibiotic concentrations below the MIC occur
in the bronchial secretions of CP patients (Malmborg et al., 1981).
The MIC of an aminoglycoside is known to increase in the presence of
calcium ions (D'Amato et al., 1975). For azlocillin and ticarcillin
calcium ions do not generally influence MIC values, but may for
certain isolates i.e. the effect is strain dependent. Therefore
2.18 x 10 ^ M Ca+' as Ca C1p. 2Hp0 was added to the isosensitest
broth to allow for the possible increase in the MIC of the three
antibiotics, in the presence of elevated calcium levels that occur
in CF patients (Rabin et al., 1980). Alginate has been shown not
to bind antibiotics in the presence of physiological saline levels
(Tannenbaum et al. , 198i|.) so that it should not affect the MIC.
3-1 Phagocytosis
The results from these studies indicate that at low concentrations
certain antibiotics affect alveolar macrophage function in vitro.
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Tobramycin and azlocillin inhibit the phagocytosis of opsonised
bacteria in a dose-dependent fashion when added to the macrophage
monolayers with the bacteria. Only tobramycin had any effect on
phagocytosis when the antibiotic was pre-incubated with the macro¬
phage monolayer.
3.1.1 Azlocillin
The inhibitory effects of azlocillin on macrophages appeared to
depend on the continual presence of the antibiotic on the macrophage
monolayers, as the antbiotic had no effect on phagocytosis except at
two concentrations when pre-incubated with the macrophages. Similar
requirements have been observed for other antibiotics. For example
ampicillin and tetracycline were shown to enhance the phagocytosis
of Listeria monocytogenes by human monocytes but only when the opson¬
ised bacteria and antibiotics (at MIC levels) were added together
(Adam, 1982). Pre-treatment of the macrophages resulted in the
same phagocytic activity as the control. Carbenicillin at 1/16 of the
MIC value was similarly shown to increase the phagocytosis of
P.aeruginosa by rabbit neutrophils, but only when added to the
cells with the bacteria (Nishida et al. , 1976). The results reported
here also agree with those of Hawkey et al., (1983) who showed that
azlocillin and carbenicillin had no effect on the phagocytosis of
Candida by human neutrophils when the cells were incubated with
antibiotic prior to the assay.
The continual presence of the antibiotic in the phagocytosis
mixture does not affect the bacteria in the assay system even at
high concentrations. Incubation of the opsonised P.aeruginosa
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with azlocillin prior to their addition to the macrophage monolayer
did not affect the phagocytosis of the bacteria (Table XII). It
is therefore unlikely that the bacterial cell wall is rendered more
susceptible to phagocytosis by azlocillin in the short time of the
phagocytic assay. Azlocillin may bind divalent cations, that are
necessary for phagocytic function (Gnarpeand Leslie, ^Ib) • The
major effect of tetracyclines on in vitro function of neutrophils
has been shown to be mediated by their divalent cation chelating
effect (Glette et al., 1981+). The results of these studied depended
on the concentration of divalent cations in the reaction mixture and
differences between antibiotics were shown to be due to their lipid
solubility and different cation chelating ability (Glette et al.,
198U).
Alternatively azlocillin may bind to the macrophage plasma
membrane and alter the receptor avidity for the opsonised particles.
Although the observation that azlocillin had no effect or an enhancing
effect when pre-incubated with the phagocytes may preclude this
possibility. However the azlocillin may only bind loosely to the
membrane, so that it is washed away during the washing procedure after
pre-incubation. Moreover if azlocillin exerts its inhibitory effects
by being loosely bound to the macrophage membrane, its continual
presence may be necessary so that high concentrations remain in the
medium surrounding the cell. Therefore continual binding of the
antibiotic can take place, resulting in a decrease in phagocytosis.
Penicillin has been shown to interact with HLA — A and B antigens
in such a way that they can no longer be recognised by their specific
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antisera (Claas et al., 1983)* When lymphocytes from healthy donors
were incubated with penicillin and washed before HLA typing, the
cytotoxic reactivity of some typing sera with their corresponding
antigen was blocked. Penicillin is also capable of binding to
polymorphic structures on cell membranes, so that it is feasible
that azlocillin may also be capable of binding to specific receptors
on the macrophage membrane. Most penicillins are not actively taken
up into macrophages (Hand et_ al., 1983) s0 that it seems unlikely
that during pre-incubation, azlocillin is taken up by the macrophages
and rendered inactive.
3.1.2 Ticarciilin
Ticarcillin, although structurally similar to azlocillin (Prince
and Neu, 1983) had no effect on phagocytosis with either pre-incubation
or addition with the bacteria. Ticarcillin lacks the ureido group that
gives azlocillin its potent antimicrobial activity, so that it could
be this group that gives azlocillin its anti-phagocytic activity.
However ticarcillin can interact with polymorphic non-HLA structures
on platelets and neutrophils (Claas et al. , 1983)5 so that it would
appear to be capable of binding to cells. Azlocillin also contains
less sodium than ticarcillin (McLaughlin e_t al. , 1983) although this
would seem to be an unlikely reason for the observed differences
between the two 3-lactams. Although azlocillin is approximately
four times more active than ticarcillin in vitro against P.aeruginosa
there is no evidence to suggest that azlocillin is more effective in
vivo (Eodson, 1980). If the anti-phagocytic effect of azlocillin
occurred in vivo, this may provide an explanation for the incompatability
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of in vitro and in vivo antimicrobial activity.
3.1.3 Tobramycin
Tobramycin, an aminoglycoside, inhibited the phagocytosis of
opsonised P.aeruginosa, when pre-incubated with the macrophages and
when added with the bacteria to the monolayers. Thus this antibiotic
may bind to the macrophage membrane, to alter receptor expression,
avidity or spatial arrangement so that binding and subsequently
phagocytosis is decreased. Binding of an antibiotic to the cell
membrane may occur in four ways:
1) insertion into the membrane lipid
2) physical modification of the receptor structure
3) stimulation of the cell to modify receptor function
I4.) formation of an antibiotic-receptor complex. (Gray et al. , 1983)
As tobramycin is antagonised by phosphate, it is possible that the
antibiotic bindsto phospholipids via phosphate in the macrophage
membrane to exert its action. Hifampicin has been shown to compete
with radiolabelled FMLP chemoattractant for binding sites on neutrophils
and to displace already bound FMLP, while having no effect on C$a.
(Gray et al., 1983)•
As the bacteria were opsonised with IgG, binding occurred via
Fc receptors, so that phagocytosis would take place by the "zipper"
mechanism of Griffin et al., (1975). Tobramycin may decrease the
number of ligand receptor interactions or cause them to be discontinuous,
so that phagocytosis is decreased. As tobramycin decreases phagocytosis
after pre-incubation with the macrophages it would appear to be tightly
bound to the membrane so that it is not washed away, as may occur with
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azlocillin. The observation that phagocytosis is still inhibited after
vigorous washing of the treated macrophages, argues in favour of this
hypothesis. In contrast a study on human neutrophils showed that
when tobramycin-treated neutrophils were washed prior to measuring
their chemotactic response inhibition was no longer observed, indicating
that in this case the antibiotic was loosely bound and no longer
capable of affecting chemotaxis (Seklecki et al., 1978). Tobramycin
did not affect the chemotactic factor and was shown to be acting
directly on the neutrophil membrane. Tobramycin may therefore bind
more tightly to alveolar macrophages than neutrophils or more anti¬
biotic may be required to be continually bound for an effect on
chemotaxis to be observed.
Tobramycin is taken up slowly by macrophages (Johnson et al., 1980a)
so that the inhibitory effect may be due to stimulation of the macro¬
phage by the antibiotic to result in modified receptor expression and
phagocytosis. Antibiotics that have an inhibitory effect on cells
often have inhibitory effects on the transcription or protein synthesis
of the bacteria (Porsgren and Schmelling, 1977). Tobramycin's rapid
bacterial activity is a result of its ability to block bacterial
protein synthesis, via the 30S ribosomal subunit. Therefore protein
production necessary for the phagocytic response of the macrophage to
occur, eould be blocked at the transcription stage or later, so that
phagocytosis is inhibited. However whether these effects would be
exerted during the short incubation times involved in the assays is
debatable.
Tobramycin was shown not to have an effect on the phagocytosis of
P.aeruginosa after the bacteria had been incubated for 30 minutes with
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the antibiotic, so that it would appear to be having a direct effect
on the macrophage. The observed decrease in phagocytosis does not
agree with the findings of Cifarelli et al., (1982) who shewed that
tobramycin increased the phagocytic capacity of human macrophages.
This discrepancy may be due to the fact that these workers studied
cultured human monocytes, which were incubated with the antibiotic
— 1
for three or 2b hours at only one concentration (2.7pg2i ml ) of
tobramycin. Also phagocytosis was measured by the uptake of
zynosan.
A time course for the effect of tobramycin was performed (Figure 21)
and showed that the inhibition of phagocytosis was highest when the
macrophages were incubated with the antibiotic for 15 minutes. 3y
120 minutes inhibition was no longer significant and had returned to
control levels. The loss of effect at two hours may be a result of
the antibiotic losing its activity and its uptake and degradation by
the macrophages, so that the amount of active tobramycin present is
too low to affect phagocytosis. This result would argue in favour
of the antibiotic exerting its action on the membrane. The half-
life of tobramycin is one and a half to three hours, so that at two
hours (two and a half by the end of the assay) some activity may be
lost. The question of how tobramycin exerts its effects on the
macrophage membrane is dicussed further in the section on Fc receptors.
3.2 "Lectin-like" receptors
Tobramycin inhibited the binding of unopsonised P.aeruginosa
to rat alveolar macrophages when the cells were pre-incubated with
the antibiotic for 30 minutes. Thus the effect on binding is similar
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to that observed for phagocytosis with this antibiotic. The
maximal response however occurred after 60 minutes incubation as
opposed to 15 minutes for phagocytosis although the inhibition was
diminished at 120 minutes. These time differences between binding
and phagocytosis may be a result of the temperature at which the
assays were carried out. Binding was performed at U C, so that
the antibiotic would not be taken up during the assay period, whereas
the phagocytic process occurs at 37°C so that in this case the
antibiotic may be taken up and inactivated by the macrophages.
The effect of temperature on phagocytosis was not studied as this
process only occurs at 37°C. Phagocytosis is not observed at
l4°C, when only binding will occur.
3.3 Fc receptors
3.3-1 Azlocillin
Azlocillin had an inhibitory effect on Fc receptor expression,
as measured by the rosette technique, similar to that observed for
phagocytosis. Thus inhibition occurred when the antibiotic was
added to the monolayer with the erythrocytes, but not when the macro¬
phages were pre-incubated with azlocillin. As phagocytosis of the
bacteria opsonised with IgG is initiated by the Fc receptor, this
study shows that azlocillin affects the Fc receptor resulting in a
decrease in phagocytosis. Azlocillin had no direct effect on the
sensitised erythrocytes (Table XII). These results therefore suggest
that azlocillin exerts a direct effect on the macrophage membrane to
alter Fc receptor expression resulting in a concomitant decrease in
phagocytosis. Thus it seems unlikely that the antibiotic has a
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direct effect on the process of phagocytosis itself. Although the
continual presence of azlocillin is required for an inhibitory effect,
this may reflect the in vivo situation. In vivo it is likely that
the alveolar macrophages will continually be in the presence of the
antibiotic and bacteria, although the concentration of the former may
fluctuate.
3.3*2 Ticarcillin
Similar to the results obtained for phagocytosis, this anti¬
biotic had no effect on Fc receptor expression. The reasons for the
observed lack of effect compared with azlocillin have already been
discussed.
3.3.3 Tobramycin
When tobramycin was added with EA_ to the macrophage monolayers,
\jr
Pc receptor expression was inhibited, but when the macrophages were
pre-treated for 30 minutes with the antibiotic, there was an apparent
increase in Pc receptor expression (Figures 23,21).). This latter
result seemed paradoxical as the phagocytosis of opsonised bacteria
was decreased after 30 minutes pre-incubation. Further investigation
revealed that the phagocytosis of EA^ was inhibited in a similar way
to that of opsonised P.aeruginosa, when the macrophages had been pre-
incubated with tobramycin for 30 minutes. It therefore appeared
that the antibiotic exerted a different effect on the macrophage
receptor than on phagocytic function, but only after pre-incubation.
Tobramycin treated macrophages did not bind unsensitised erythrocytes
(results not shown) so that the effect was not due to non-specific
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binding of erythrocytes. A time course study revealed that the
observed Fc receptor enhancement was only transient (Figure 25>).
Significant enhancement did not occur when the macrophages were
treated for 60 minutes and at 120 minutes, inhibition of EA_, binding
VJ
was observed. Therefore tobramycin caused an initial increase in
Fc receptor expression, followed by a decrease. The effect at
120 minutes being similar to that observed for phagocytosis at 30
minutes. Increased macrophage Fc receptor expression, manifest as
increased avidity for lightly sensitised erythrocytes is a well
documented index of macrophage activation (Rhodes et al. , 1981).
Increased Fc receptor expression as measured by rosetting techniques
has been reported in adjuvant activated as compared to resident
alveolar macrophages (Arend and Mannik, 1973)• However it is
unlikely that activation of the macrophages would occur in 30 minutes
as methods for in vitro macrophage activation usually require 21+ hour
exposure of the ceils to the activating agent. Activation would
also not account for the subsequent decrease in receptor expression.
A new semisynthetic cephalasporin, AC 1370 has been shown to exert
its action by binding to mouse peritoneal macrophages to cause their
activation (Ohnishi et al., 1981+). Soluble factors are then released
from the macrophages which in tarn activate neutrophils, so that
phagocytic activity is increased. However these workers incubated
the macrophages for 20 hours with the antibiotic so that activation
could occur. The effect of tobramycin over such a long period of
time was not investiaged in this thesis as a high percentage of
alveolar macrophages do not remain viable after overnight culture
in serum free medium. The results of Ohnishi et al. , (198I4.) do
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show that antibiotics can affect macrophage function, and to this
extent agree with the results reported here.
From Figure 2k it can be seen that the effect of tobramycin on
Fc receptors varies considerate according to the temperature at which
antibiotic treatment and the Fc receptor assay are carried out.
When the macrophages are incubated at 37°C and the assay performed
at room temperature, the observed rosette enhancement drops at four
times the iFC value. Therefore high tobramycin concentations
incubated with macrophages for 30 minutes appear to have a similar
effect to that observed with low concentrations (1/2 MIC) incubated
with macrophages for 60 minutes.
When the macrophages were incubated at U°C and the assay performed
at i+°C, enhancement was dose-dependent, reaching a maximum at the
highest concentration of tobramycin. At L|°C, the antibiotic will
remain on the outside of the cell, as phagocytosis or active uptake
of molecules will not occur at this temperature (Silverstein et al.,
• 1977). Therefore at i|.0C, higher concentrations of antibiotic may
be required for a similar effect to that observed at 37°C, when
antibiotic uptake will occur. There was also no decline in the
response at l4°C indicating that this effect is temperature dependent.
When the incubation and assay were carried out at room temperature
enhancement was significantly lower than that observed at Jf0C. Similar
results were also obtained when the macrophages were treated at Lj°C
and the assay carried out at room temperature. The possibility that
enhancement would increase with higher concentrations of tobramycin at
this temperature,was not investigated in this study. It is possible
that at room temperature, the antibiotic is more loosely bound to the
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membrane, so that enhancement is not as marked as that observed at
b°c.
From these results it would appear that tobramycin may exert its
effects in two ways. As enhancement occurs at Ii°C, tobramycin does
not necessarily depend on active metabolism of the cell. In this
case the antibiotic appears to bind to the macrophage membrane,
probably forming an antibiotic receptor complex that results in
alteration of the receptor and increased binding of EA^to the cell.
A preliminary experiment on the effect of time on this response
revealed that enhancement still occurred when the cells were incubated
with tobramycin at l4°C for one hour and two hours, although enhancement
reached a maximum at one hour. Tobramycin may also exert its action
by altering the cell once it has been taken up. This effect may
result in decreased phagocytosis or receptor expression. Thus at
30 minutes more antibiotic is bound to the membrane than present
inside the cell and receptor expression is enhanced, whereas at 120 min¬
utes, the concentration of antibiotic may be higher within the macro¬
phage and inhibition is observed. Therefore at l4°C when the antibiotic
is not taken up r inhibition of EA^ binding is not observed even
after two hours.
At room temperature, there may be a slow rate of uptake of the
antibiotic, which may only be loosely bound to the membrane and the
metabolic rate of the macrophage is decreased, with the overall effect
that only slight Fc receptor enhancement is observed at this temperature
compared to that at U°C.
It is also possible that tobramycin may act in a different way
at 37°C than at l+°C. At Lj°C tobramycin will be acting directly on
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the membrane but at 37°C, it may exert its effects from within the
macrophage and. alter the turnover of the Pc receptor, so that an initial
increase is followed by a decrease as intracellular pools are reduced.
If tobramycin does have two mechanisms of action, one outside the
cell, and one inside the cell, the overall result would be determined
by temperature and time, as the results suggest.
After two hours pre-incubation, inhibition occurs at all concen¬
trations studied, while at one hour the response is variable. Maximum
inhibition occurs at three hours after which the response levels off.
As the half-life of tobramycin is one and a half to three hours, the
decline in effect after three hours may be a result of the antibiotic
going "off" as well as its degradation and inactivation by the macro¬
phages. The observation that Pc receptor expression is inhibited
when tobramycin is added with the erythrocytes indicates that the
mechanism of action is different again in this system. It is possible
that the red cells bind the antibiotic so that less is available for
binding to the membrane. On the other hand the presence of the red
cells may alter the binding of the tobramycin, and the {arrangement of
the receptor so that inhibition rather than enhancement is observed.
It is interesting to note that the observed inhibition reaches a
maximum at MIC, thereafter declining to insignificant levels.
Although the sensitised sheep erythrocytes become more susceptible
to phagocytosis after tobramycin treatment, they do not bind more
readily to the macrophage. This effect seems paradoxical but may be
a result of the antibiotic altering the erythrocyte membrane in such
a way that bound cells are more readily phagocytosed. Therefore a
higher proportion of bound untreated erythrocytes remain unphagocytosed.
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At the present time there are no reports in the literature to
confirm or disagree with these findings that tobramycin has a direct
effect on a specific receptor.
3.1+ Studies on supernatants from tobramycin treated macrophages
As tobramycin treatment of alveolar macrophages resulted in an
increase in Fc receptor expression, followed by a decrease, it was
postulated that Pc receptors could be released into the supernatant
during incubation with the antibiotic. This hypothesis was invest¬
igated by analysing the supernatants from tobramcyin treated macro¬
phages.
The binding of EA^, to macrophages was found to be inhibited
after the erythrocytes had been pre-incubated with supernatnants from
tobramycin treated macrophages. On incubation with the macrophages,
the supernatants enhanced the binding of EAq. Therefore it seemed
likely that Pc receptor (Fc-R) material was present in the supernatants
and was binding to the antibody on the EA^ to inhibit their binding to
macrophage Pc receptors and attaching to the macrophage membrane to
enhance the binding of EA-,. Other receptors, including the lectin-
VJ"
like receptor, present in cell lysates can be inserted into the
macrophage membrane (j. Stewart, unpublished results). Pc-R like
material has been isolated from supernatants of peripheral human mono¬
nuclear cells, in consequence of a i4.°C-37°C temperature shift (Sandor
et al., 1978). Incubation of this material with sensitised erythrocytes,
resulted in inhibition of their binding to monocytes. Other workers
have tested supematants from normal or activated lymphocytes for the
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presence of Fc-R-like material (Caraux and Serrou, 1979). They found
a soluble factor that combined with Fc fragment antigen complexed
IgG to inhibit the binding of immune complexes to Fc receptors on cell
surfaces. This soluble factor also caused the haemagglutination of
erythrocytes sensitised with a subagglutinating dose of IgG.
Supernatants from untreated macrophages also contained some Fc-R
like material, so it would appear that tobramycin increases the "normal"
release of the Fc receptor from the membrane. This phenomena would
explain the decrease in enhancement observed at the 60 minute and
120 minute incubation times of the macrophages with the antibiotic.
However it does not explain the initial enhancement observed after the
15 minute and 30 minute tobramycin incubation times. The initial
action of tobramycin may be to increase the number of Fc receptors or
their spatial arrangement in ways that were previously discussed, with
a resulting increase in the number of Fc receptors that can be shed
into the medium. There may be two populations of Fc receptors present
on the macrophage membrane, one that is shed and one that remains firmly
bound (Sandor, et al., 1979)•
The number of shed receptors was dose-dependent but did not
significantly increase after two hour treatment of the macrophages
(Figures 28,29). This may indicate that lost receptors are not replen¬
ished, so that shedding effectively decreases the number on the mem¬
brane or forms an equilibrium. Sandor et al., (1979) reported that
in their system a continuous secretion of the Fc-R material did not
occur. Lost receptors that are not replenished, would explain the
inhibition observed at two to five hours of tobramycin treatment of
macrophages. Supernatants taken from macrophages treated for 30
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minutes appeared to contain little Fc-R material as inhibition of
binding of treated EA„ did not occur. Thus initial Fc receptor
enhancement would appear to be followed by an increase in the shedding
of the receptors from the membrane.
Further evidence for the presence of Fc receptors in the super¬
natant came from haemagglutination studies. Supernatants were incub¬
ated for one hour with formalised erythrocytes sensitised with the
monoclonal IgG2b antibody (F.EA-) to avoid lysis. The erythrocytes
were washed and the resulting supernatant concentrated by freeze-
drying. This supernatant, unlike unabsorbed supernatants did not
cause the agglutination of EA_. Therefore the material responsible
for agglutination had been removed by the F.EA^ further indicating
its Fc-R nature.
3-ii-. 2 Polyacrvamide gel electrophoresis
Page gel analysis revealed that more material was present in
two bands at approximately i|.7,000 and 60,000 daltons in supernatants
from tobramycin-treated macrophages than control supernatants. Some
cellular material is also present in the supernatants of untreated
control cells, but there seems to be a general increase in the release
of material from tobramycin treated macrophages. This observation
was not thought to be a loading effect as 100p.l of each sample was
precisely measured into each chamber and the experiment was repeated
(Plate VII). The quantity of material in the band corresponding to
U7,000 daltons was almost double in the supernatant from treated
macrophages to that of supernatant from untreated cells. The exact
molecular weight of the rat alveolar macrophage Fc receptor is
unknown but the molecular weights of other Fc receptors range from
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35,000 to 100,000 daltons. Two polypeptide chains with molecular
weights of approximately 60,000 and J+7,000 daltons have "been isolated
from the Fc receptor of a mouse macrophage cell line (Melman and
Unkeless, 1980). It is possible that these two bands represent
the Fc receptor that from the studies described earlier appears to
be shed from the macrophage membrane.
Supernatants that have not been dialysed and still contain
tobramycin appear to affect the erythrocyte membrane to a greater
extent than control supernatants (Plate VTl). All the bands are
increased in supernatants from tobramycin treated cells indicating
that greater lysis has occurred. Tobramycin would appear to be
responsible for this effect as dialysed supernatants did not cause
increased lysis or band formation ( results not shown). This effect
would explain the increased phagocytosis of EA^ after tobramycin
treatment as it indicates alteration or rupture of the membrane that
may facilitate phagocytosis but not binding of the EAq-
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k.O EFFECT OF ANTIBIOTICS ON HUMAN MONOCYTES
Initial studies on human peripheral blood monocytes indicated
that tobramycin and azlocillin had an effect on the Fc receptor
expression of these cells, while ticarcillin had no effect. This
follows the pattern observed for rat alveolar macrophages.
Tobramycin inhibited the binding of EA^ when the antibiotic
was added to the monolayers with the erythrocytes. Inhibition was
significant when results from different individuals were pooled and
when one individual was studied at different times (Figure 31)•
However when the monocytes were pre-incubated with tobramycin, indiv¬
idual variation affected the results. When results from different
individuals were pooled, the antibiotic appeared to have no effect.
On closer investigation, however it was observed that tobramycin
inhibited or enhanced Fc receptor expression depending on the
individual under study. Overall these opposite effects would cancel
out and tobramycin would appear to have no effect on Fc receptors.
Individual variation is not uncommon for human macrophage function.
For example alveolar macrophages from different individuals were
shown to vary in their antigen presenting capacity (Toews et al. , 19814.).
This longitudinal study demonstrated that macrophages from some
individuals present antigen, some suppress lymphocyte proliferation
while others exhibit responses that fall between the two. Therefore
longitidunal studies may give different results from studies that
involve pooling results from different individuals and their use is
indicated in this study.
Similar to the study on rat alveolar macrophages, tobramycin
appears to have different mechanisms of action depending on the
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assay procedure employed. Individual variation may "be a result of
differences in Pc receptor avidity and affinity. Differences observed
between pre-incubation of macrophages with tobramycin and addition
of the antibiotic with the erythrocytes to the macrophage monolayer
would have to be investigated further at an individual level.
Azlocillin caused enhancement of EA_ binding to monocyte Fc
u-
receptors, but the continual presence of the antibiotic was required.
In this case the results do not agree with those observed with rat
alveolar macrophages. This may be a result of the different nature
of the two cell types and would have to be examined more fully.
Although only a few studies on human monocytes were carried
out, they yield enough information to indicate that antibiotic- effects
may occur in the human system and that further work is necessary.
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5.0 GENERAL DISCUSSION
Alginate has been shown to inhibit the binding and phagocytosis
of P.aeruginosa to alveolar macrophages which may partly explain the
chronicity of infection with the mucoid organism. Tobramycin and
azlocillin have also been shown to inhibit the phagocytosis of P.
aeruginosa, while ticarcillin has no effect. Therefore these two
antibiotics would appear to exacerbate the effects of the alginate
on macrophage function. P.aeruginosa once established in the CP
lung are seldom if ever eradicated despite treatment with these
antibiotics alone or in combination. However therapy with these
antibiotics has been associated with clinical improvement (Marks et al.,
1976) snd azlociilin and tobramycin in combination are effective at
temporary eradication of the mucoid organism (Miller and H0iby, 1981).
The clinical improvement of antibiotic treated patients indicates that
the advantageous antimicrobial activity of the antibiotic outweighs
any disadvantageous effect it might have against the host cells.
However this may not always be the case, for there is a fall in
efficacy when antipseudomonal treatment is repeated (Mbller and
H0iby, 1981). At the beginning of a bacterial infection, eradication
may be achieved by antibiotics regardless of their effect on the host
cells. However once the infection is established and mucoid strains
have emerged, the effect on the host cell may become more important.
Luring chronic infection, that occurs in CE patients, the immune
system may become hyperfunctional and actually cause tissue damage.
In this case suppression of the immune response by an antibiotic
may be advantageous to the host. Thus the benefit to be derived from
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an antibiotic may depend on the time and stage of the infection
at which it is given. The antimicrobial effect of an antibiotic
in vitro may not always be reflected in vivo even when standard doses
give serum or tissue levels exceeding minimal inhibitory concentrations.
On the other hand an antibiotic may succeed clinically contrary to
expectations (Ernst and Sande, 1981). These discrepancies may be
attributable to host factors and the effects of an antibiotic on the
patients own immune defence system, which are not taken into account
during in vitro testing.
The results discussed in this thesis however were all obtained
from in vitro stuides, done mainly on rat-macrophages so that extra¬
polation to the human situation in vivo is difficult. In vivo
many factors have to be taken into consideration, for example the
immune status of the patients, the extent and time of the infection
and previous antimicrobial therapy. However it is arguable that
antibiotic effects on the hosts immune response, as indicated in
these studies may be relevant to the antibiotic management of CE
patients.
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6.0 CONCLUSIONS MP SUGGESTIONS FOR FURTHER STUDIES
6.1 Alginate studies
Alginate, a mannuronic and guluronic acid polymer produced by
mucoid P.aeruginosa acts as a barrier or inhibitory matrix to prevent
the attachment and phagocytosis of bacteria and other particles by rat
alveolar macrophages. Similarly alginate acts to inhibit the opson-
isation of non-mucoid P.aeruginosa by specific antibody. This action
of the alginate may confer a selective advantage on the mucoid form
of P.aeruginosa and partly explain the pathogenicity of this organism.
It has recently been established that in the presence of bronchial
electrolytes, mucoid bacteria can be washed without the loss of cellular
alginate (J.G. Govan, personal communication). This should now
enable studies on the mucoid form of P.aeruginosa to be carried out.
The ability of anti-alginate antibody to act as an effective opsonin
could be determined. The ability of alveolar macrophages to bind
and phagocytose the opsonised mucoid organism could also be evaluated.
Thus the experiments described in this thesis could be extended, and
the role of alginate investigated further.
The alginate may surround or coat the macrophage to exert its
inhibitory effects. This possibility could be investigated by
immunofluorescence. Fluorescein labelled anti-alginate antibody
could be prepared and added to macrophages that had been incubated
with alginate. Using microscopy, macrophages showing fluorescence would
indicate the presence of alginate on the cell membrane. The same
technique could be applied to investigate coating of non-mucoid
bacteria with the alginate during the opsonisation procedure.
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A method for intra-tracheally infecting rats with P.aeruginosa
enclosed in agarose heads has been described (Cash et al., 1979)•
In vivo studies could be carried out using this rat model to indicate
the importance of the immune system during the infection and the
effector cells that are most important in the eventual eradication of
the infection. This work would involve the use of immunosuppressive
and activating drugs to determine their effect on the time for erad¬
ication of the bacteria. Also differences in infection between mucoid
and non-mucoid P.aeruginosa could be established. Alveolar macrophages
could be obtained from infected animals and tested for any functional
differences from cells of healthy animals. Subpopulations could
be separated using an elutriator and differences determined between
control and infected alveolar populations, for example their ability
to present antigen, phagocytosis and Pc receptor avidity.
Conclusions drawn from animal studies cannot be extrapolated
to the human situation. Therefore the need for human studies may
arise. Sxperiments on the effect of alginate on human alveolar
macrophages could be carried out, or as these cells are difficult
to obtain, human peripheral blood monocytes.
6.2 Antibiotic studies
These studies have shown that low concentrations of antibiotics
may affect alveolar macrophage function and receptor expression.
Although ticarcillin had no effect on phagocytosis or Pc receptor
expression, azlocillin had an inhibitory effect that was dependent
on the continual presence of the antibiotic. On the other hand
tobramycin inhibited phagocytosis but enhanced Pc receptor expression
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on alveolar macrophages that had been incubated with the antibiotic
for 30 minutes. This response was found to be dose, time and
temperature dependent. Further work on the mechanism of action
of tobramycin indicated that this antibiotic caused an initial
increase in Fc receptor expression followed by an increased shedding
of the receptor from the membrane into the surrounding medium.
Initial studies on human peripheral blood monocytes also indicated
that azlocillin and tobramycin affected Fc receptor expression of
these cells. These results suggest an enormous scope for future
work and indicate the necessity of many more experiments to extend
and clarify these observations. Future studies that could continue
from this work are outlined below:
1) The determination of the quantitative effect of tobramycin on
Fc receptors by using a more sensitive assay for their detection.
For example radio-labelled antibody aggregates will bind to Fc
receptors. Using this technique scatchard plots could be drawn
so that the number of receptors/cell and affinity of the receptor
could be calculated.
2) Further studies on supernatants from antibiotic-treated macro¬
phages could be carried out. Polyacrylamide gel electrophoresis
of EA_ absorbed supernatants could show whether the material absorbed
\JT
by the sensitised erythrocytes, corresponded to the Fc receptor.
The presence of Fc receptors in the supernatant will inhibit the C1
or complement dependent haemolysis of IgG but not IgM sensitised
erythrocytes (Fridman et al., 1981). Quantitation of Fc receptor
material can be estimated by this test system. One unit of Fc
receptor has been defined as the quantity required to inhibit 50%
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of hemolysis of EAlgG in excess of complement. The number of units
in various supernatants thus represents the reciprocal of the dilution
of a supernatant that inhibits 50% hemolysis. Thus the effect of
tobramycin on the shedding of Fc receptors could be estimated quant-
itively. Other assays that could be carried out to confirm the
presence of the Fc receptor include the inhibition of binding of
radiolabelled C1q, antibody dependent cell cytotoxicity, enhanced
precipitation of antigen antibody complexes and the arming of Fc
receptor negative cells.
3) Further studies on human monocytes could be performed to extend
the reported observations. The effect of pre-treatment of tobra¬
mycin on Fc receptor expression in different individuals could be
more thoroughly examined. A larger number of individuals could
be studied, so that the predominating effect could be determined.
Also clarification of the apparent reverse effect of azlocillin on
human monocytes as compared to rat alveolar macrophages could be
investigated by performing more experiments, and by studying the
effect of time, temperature and dose"on the results.
I4) Other cell populations could be studied. The cells in this
thesis do not possess complement receptors, so these receptors were
not investigated. However many other populations of cells do
possess these receptors and the effect of antibiotics on this
receptor could be investigated in a similar way to that described in
this thesis for the Fc receptor.
5) The effect of antibiotics on other macrophage functions could
be investigated. These would include antigen presentation, intra¬
cellular killing and the production of lymphokines and other mediators.
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During a hyperimmune response tissue damage may occur as a result of
the over-production of various enzymes such as elastase by macrophages
and neutrophils. Therefore the effect of an antibiotic on enzyme
release may be important in the long term treatment of hyperimmune
patients.
6) In vivo studies on animals treated with antibiotics would
ascertain whether macrophage function and receptor expression is
modified after such treatment. This could be further extended to
work on normal healthy volunteers as some studies have already described
(Grant et al., 1983; Cullen et al., 1983)-
7) This study has concentrated on the mechanism of action of
tobramycin on the Fc receptor, however other antibiotics may have
similar or apposite effects. - A range of other antibiotics that
are used for long term therapy could be examined for their effect
on macrophage receptors. Comparative studies of different antibiotics
could be clinically important and indicate the choice of antibiotic for
a particular patient.
The cystic fibrosis patient is only one of many compromised
individuals in whom even a :uarginal influence on host immune response
may have a significant effect on the eventual outcome of antibioitc
treatment. Ultimately, studies on patients undergoing long term
antibiotic therapy could be carried out to evaluate the effect of the
drug on the hosts immune system.
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SUMMARY
Alginate obtained from a mucoid strain of Pseudomonas aeruginosa was shown to inhibit
the phagocytosis of an isogenic non-mucoid revertant by rat alveolar macrophages.
Phagocytosis of Staphylococcus albus, binding of sensitized sheep erythrocytes to Fc
receptors and uptake of latex particles were also inhibited. These results suggest that the
alginate acts as a barrier, surrounding the macrophage preventing the attachment of
bacteria or other particles to the plasma membrane. This conclusion was supported by
showing that alginic acid, a polysaccharide from seaweed structurally similar to alginate
also inhibited the phagocytosis of non-mucoid Ps. aeruginosa. The alginate also inhibited
opsonisation of the non-mucoid revertant by a non-agglutinating hyperimmune serum. It
is proposed that alginate confers a selective advantage on mucoid producing forms of Ps.
aeruginosa by impairing the host immune response by its action on alveolar macrophages
and opsonization of bacteria.
Keywords alveolar macrophages cystic fibrosis Pseudomonas alginate phagocyto¬
sis opsonization
INTRODUCTION
Strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis (CF) have been found
in culture to produce alginate,-a D-mannuronic and D-guluronic acid polymer linked by O-acetyl
groups (Doggett et al., 1966). The presence of these mucoid strains in the lungs of CF patients is
associated with a poor prognosis (Hoiby. Andersen & Bendixen, 1975) and contributes to the
persistence of the infection (Doring & Hoiby, 1983). This suggests that the alginate produced by the
bacteria may be a contributory factor in the pathogenesis of pseudomonas infection in CF.
Failure to eradicate mucoid Ps. aeruginosa strains is a major problem in the treatment of CF and
is not thought to be due to a general immune defect (di Sant'Agnese & Davis. 1976). However, it is
possible that immune function in the lung may be impaired and exacerbated as a result of alginate
production by Ps. aeruginosa.
Previous work in this laboratory has shown that the alginate obtained from a mucoid producing
strain of Ps. aeruginosa inhibited the binding of a non-mucoid revertant to mouse peritoneal and
pulmonary macrophages (Oliver & Weir, 1983). Schwartzmann & Boring (1971) have reported that
alginate can inhibit the phagocytosis of non-mucoid strains by rabbit neutrophils and preliminary
studies have been reported on guinea-pig alveolar macrophages (Ruhen, Holt & Papadimitriou,
1980).
Correspondence: Professor D. M. Weir, Immunology Laboratory, University of Edinburgh Medical
School, Teviot Place, Edinburgh EH8 9AG, UK.
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The purpose of this study was to extend these observations and to investigate these effects in
more detail as the pathogenic properties of alginate are not understood.
We used alginate separated from a mucoid strain of Ps. aeruginosa to determine its effect on the
opsonization of a non-mucoid revertant strain and the phagocytosis of opsonized bacteria and
other particles by rat alveolar macrophages.
MATERIALS AND METHODS
Animals. Male Sprague-Dawley rats (250 g) were obtained from the Centre for Laboratory
Animals, University of Edinburgh.
Bacteria. Ps. aeruginosa strains were obtained from Dr J. R. W. Govan, Bacteriology
Department, University of Edinburgh. Strain 492a is a mucoid, alginate producing strain isolated
from the sputum of a CF patient and 492a Rev 1 is an isogenic non-mucoid revertant of this strain.
The bacteria were grown for 24 h at 37°C on nutrient agar (Columbia agar base, Oxoid) and
harvested by scraping from the plate with a glass slide. Bacterial concentrations were calibrated
with a spectrophotometer (SP30; Pye Unicam) at 540 nm. A reading of 0-3 was equivalent to 5 x 108
bacteria/ml.
Staphylococcus albus. A strain of 5. albus was obtained from the departmental teaching
collection. The organisms were grown in horse digest broth, harvested in log phase and killed by 24
h exposure to 0-5% formalin at 4°C. Concentrations were calibrated spectrophotometrically as
above (0-42 = 2 x 107 bacteria/ml).
Extraction of alginate. The alginate was extracted from Ps. aeruginosa 492a, as previously
described (Oliver & Weir, 1983).
Preparation ofsensitized sheep erythrocytes (EA G). EAG were prepared as described elsewhere
(Glass, Stewart & Weir, 1982). The anti-sheep erythrocyte antibody used was a murine monoclonal
(IgG2b-MAS 013c, clone Sp2; Sera-Lab. Ltd., Crawley Down, Sussex, UK).
Preparation ofhyperimmune serum. Heat killed Ps. aeruginosa 492a Rev 1 were washed in saline
adjusted to a final concentration of 5 x 109 bacteria/ml and mixed with an equal volume of
Alhydrogel (2% solution) (Miles Laboratories). The mixture was incubated at 37°C for 1 h, washed
and resuspended in saline to give a final concentration of 5x 109 bacteria/ml. Five rats, each
received four weekly i.p. injections of 1 ml of bacteria. They were killed and exsanguinated 1 week
after the last injection. The serum was collected, pooled and heat inactivated at 56°C for 30 min and
stored at — 20°C.
Opsonization of bacteria. Hyperimmune serum was diluted 1:80 with Hanks' balanced salt
solution (HBSS) containing 0-1% gelatin (GHBSS) and 9 ml was added to 1 ml of a suspension of
5 x 109 bacteria/ml. The mixture was incubated for 20 min in a shaking water bath at 37°C, washed
and finally resuspended in HBSS to give a final concentration of 5 x 108 bacteria/ml.
Inhibition ofopsonization. Serum was diluted 1:40 with GHBSS and mixed with an equal volume
of alginate at different concentrations. Opsonization was then carried out as described above.
Macrophages. Animals were killed with sodium pentobarbitone (50 mg/animal) and exsan¬
guinated. The trachea and lungs were removed and lavaged using a tracheal cannula with
Dulbecco's phosphate-buffered saline (DPBS), containing heparin (10 units/ml), pre-warmed to
37°C. Fifty millilitres of lavage fluid was collected and centrifuged at 200# for 10 min. The
sedimented cells were resuspended in Eagles MEM without serum (buffered with sodium
bicarbonate and supplemented with glutamine, final concentration 2 mM) to give a final viable cell
count of 2 x 105 macrophages/ml.
Preparation ofmonolayers. Monolayers were prepared as previously described (Oliver & Weir,
1983). Non-adherent cells were removed by washing with warm Eagles MEM.
Phagocytosis. Macrophage monolayers were overlaid with 1 ml ofbacterial suspension in HBSS
and incubated for 30 min at 37°C. Unphagocytosed organisms were removed by vigorous washing
with HBSS. Coverslips were air dried, fixed in methanol and stained with May-Grunwald-Giemsa.
Triplicate coverslips were used and 200 macrophages counted on each coverslip. The results were
expressed as the percentage of macrophages that had phagocytosed five or more bacteria.
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Fc receptor assay. Two millilitres of EAG (2-5 x 107 red cells/ml) were added to each monolayer,
centrifuged for 4 min at 30g and incubated for 30 min at 22°C (room temperature). Non-adherent
erythrocytes were removed by gentle washing with HBSS and the coverslips dipped into 1%
formal-HBSS to prevent red cell lysis. Triplicate coverslips were used and on each coverslip 200
macrophages were counted. Results were expressed as the percentage of macrophages binding two
or more erythrocytes.
Phagocytosis of latex. The macrophage monolayers were overlaid with 1 ml of HBSS and 20 p\
of latex suspension (Difco Laboratories, Surrey, UK) (adjusted to read 192 at 540 nm on a
spectrophotometer) and incubated for 1 h at 37°C. Non-phagocytosed particles were removed by
repeated washing with HBSS. Triplicate coverslips were used and on each coverslip 200
macrophages counted. The results were expressed as the percentage ofcells that had taken up five or
more latex particles.
Inhibition studies. Cell monolayers were incubated with I ml of alginate at physiological
concentrations (Ohman & Chakrabarty, 1982), diluted in HBSS for 30 min at 37°C. The cells were
washed and assays performed as described above. In other assays the alginate was added with the
indicator cells to the macrophage monolayers.
Calculations. Percentage inhibition was calculated as the difference between control (C) and test
(E) divided by the control x 100:
C-E
-x 100.
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Fig. 1. Inhibition of phagocytosis of non-mucoid Ps. aeruginosa by alginate. O O = pre-treatment of
macrophages with alginate; • • = addition of alginate with bacteria. Each point represents the mean of four
experiments +1 s.e.
Table 1. Effect of alginate on the phagocytosis of S. albus
Inhibition of phagocytosis (%)± 1 s.e.
Concentration Pre-treatment of macrophages Addition of alginate
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Table 2. Effect of alginic acid on phagocytosis of Ps. aeruginosa 492a Rev 1
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Inhibition of phagocytosis (%) + 1 s.e.
Concentration Pre-treatment of macrophages Addition of alginic
(mg/ml) with alginic acid acid with bacteria
0-3 29 + 6 34-8+11
0-6 37+10 44-8 + 7
1-25 41 + 11 56-7 + 6
2-5 63 + 7 77-3 + 4
5 78-7 + 5-2 92-7 + 0-3
10 86-6 + 3-3 95-5 + 4-5
20 100 + 0 100 + 0
I I I I 1
012 0 25 0-5 I 2
Alginate concentration (mg/mU
Fig. 2. Inhibition of bacterial opsonisation by alginate. • • = non-mucoid Ps. aeruginosa; O O = S.
albus. Each point represents the mean of five experiments (Ps. aeruginosa) or three experiments (S. albus) ± 1 s.e.
RESULTS
The effect of alginate on phagocytosis
For phagocytosis to occur Ps. aeruginosa required to be opsonized with hyperimmune serum,
whereas 5. albus could be opsonised with heat-inactivated normal serum presumably because of the
presence of anti-staphylococcal antibody. It is not possible to use mucoid Ps. aeruginosa in this
assay as the washing procedure after opsonisation causes removal of the alginate, so that the
bacteria are no longer mucoid.
Pseudomonas alginate inhibited the phagocytosis (P < 0 05) of non-mucoid Ps. aeruginosa (Fig.
1) and 5. albus (Table 1) when pre-incubated with the macrophage monolayer for 30 min. This
inhibitory effect was reduced by 50% if the macrophages were vigorously washed five times after
alginate treatment. The phagocytic capacity of the macrophages returned to normal when these
macrophages were re-incubated in Eagles MEM alone for 30 min. Inhibition reached a maximum of
90% when the alginate was added to the macrophage monolayer together with the opsonized
bacteria (Fig. 1).
Alginic acid, isolated from Macroystis pysifera kelp (Sigma) inhibited the phagocytosis of the
non-mucoid revertant in a dose-dependent fashion (Table 2) indicating that the effect of alginate
was not due to bacterial derived toxic impurities in the preparation.
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Fig. 3. Inhibition of rosette formation by sensitized sheep erythrocytes by alginate. O O = pre-treatment of
macrophages with alginate: • • = addition of alginate with sheep erythrocytes. Each point represents the
mean of four experiments + 1 s.e.
Fig. 4. Inhibition of phagocytosis of latex particles by alginate. O O = pre-treatment of macrophages with
alginate; • • = addition of alginate with latex. Each point represents the mean of three experiments + 1 s.e.
Effect of alginate on opsonization
Opsonization of the non-mucoid revertant by hyperimmune serum was inhibited (P < 0 05) at 0-12
mg/ml and 0-25 mg/ml and almost totally inhibited (P< 0-001) at concentrations over 0-5 mg/ml
(Fig. 2). The inhibitory effect was not due to inadequate pelleting of the bacteria in the alginate and
serum mixture during the washing procedure as colony counts showed that there was no difference
in the control and experimental bacterial concentrations of the pellets. Inhibition of opsonisation of
S. albus was less than that observed with Ps. aeruginosa. This may be due to the fact that
unopsonized 5. albus are phagocytosed by alveolar macrophages.
100
0-25 0-5 10 20
Alginate concentration (mg/ml)
Effect of alginate on Fc receptors
The effect of alginate on Fc receptors was studied with an antibody dilution that gave 30-40%
binding of sensitized sheep erythrocytes to the alveolar macrophages.
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Alginate reduced (P<0 05) the binding of sensitized sheep erythrocytes to the macrophages
(Fig. 3). This inhibition was greater when the alginate was incubated together with the sheep
erythrocytes than when the macrophages were pre-treated for 30 min.
The effect of alginate on phagocytosis of latex particles
Alginate inhibited phagocytosis of latex particles in a dose-dependent fashion. When the
macrophages were pre-incubated for 30 min, phagocytosis was inhibited (P < 0-05) at 1 mg/ml and 2
mg/ml (Fig. 4). Inhibition was increased at all concentrations used when the alginate was added
with the latex to the macrophages (F<0-05) at 0-25 mg/ml and 0-5 mg/ml and FcOOl at 1 mg/ml
and 2 mg/ml (Fig. 4).
DISCUSSION
Chronic lung infection is a major problem in patients with CF, although systemic infection is rare.
The fact that these patients are immunologically competent and have high levels of circulating
antibody against the infective bacteria (di Sant'Agnese & Davis, 1976; Hoiby & Wilk, 1975)
suggests the possibility of local impairment of immunity in the lung. Studies on alveolar
macrophages from CF patients have been contradictory. Thomassen et ai (1980) showed that there
was no intrinsic cellular defect of alveolar macrophages, while other reports showed them to have a
decreased capacity to phagocytose Candida (Cole, 1979; Sordelli et a!., 1982) or an increased
phagocytic capacity (Cassino et at., 1980). It has been claimed that the pathophysiology of lung
disease in cystic fibrosis is the result of a genetically inherited metabolic defect in the
monocyte/macrophage population (Wilson & Fudenberg, 1982).
The respiratory tract in CF offers an environment conducive to the production of mucoid Ps.
aeruginosa (Macone et al., 1981). As mucoid strains are rarely eliminated production of alginate
may confer a selective advantage by protecting the bacteria from the host's immune response. It has
been reported that mucoid Ps. aeruginosa survive more effectively in the pulmonary environment
than their non-mucoid revertants (Govan, Fyfe & Baker, 1983) and that non-mucoid forms are
more susceptible to phagocytosis than mucoid forms (Gosciniak et al., 1980). Alginate has been
shown to inhibit phagocytosis of bacteria by rabbit neutrophils (Schwartzmann & Boring, 1971)
and similar results have been obtained with guinea-pig alveolar macrophages (Ruhen et al., 1980).
An important function of alveolar macrophages is the elimination of foreign particles from the
lung by phagocytosis (Green & Kass, 1964). Our studies show that phagocytosis is inhibited when
the macrophages are pre-incubated with alginate. Inhibition was increased when alginate was
added with the bacteria and decreased when the cells were vigorously washed to remove excess
alginate. This suggests that the alginate was coating the macrophage and acting as a barrier to
prevent attachment and phagocytosis. It is unlikely that the effect is due to impurities in the
preparation. Alginic acid, a chemically similar compound showed a similar inhibitory effect.
Further evidence for the barrier effect of the alginate comes from our studies on the binding of
sensitized sheep erythrocytes to Fc receptors and phagocytosis of latex particles. Both binding and
phagocytosis were inhibited by the alginate supporting the view that the alginate binds
non-specifically to the macrophage and prevents particle attachment. Greater inhibition was
observed when the alginate was added along with the indicator cells. The test particles may be
trapped by the mucoid material and prevented from coming into contact with the macrophage as a
result of its viscous nature.
Opsonization of bacteria facilitates phagocytosis and any impairment of this immune defence
mechanism would be advantageous to the bacteria. The alginate from mucoid Ps. aeruginosa was
shown to inhibit opsonization by specific antibody of the non-mucoid revertant. In fact at high
concentrations of alginate opsonization was almost totally blocked. This result conflicts with the
work of Baltimore & Mitchell (1980), who found that opsonization of two non-mucoid strains,
which required antibody for opsonization was not inhibited by the addition of mucoid material.
However, they used a different technique for alginate separation and measurement ofopsonization,
which was not distinguished from phagocytosis.
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Pseudomonas alginate has recently been shown to be immunogenic (Pier, Matthews & Eardley,
1983; Bryan, Kureishi & Robin, 1983). However, the evidence suggests that mucoid bacteria are not
effectively opsonized and that such antibody may even be harmful if it forms immune complexes in
CF sera (Berdischewsky et al., 1980; Moss & Hsu, 1982).
If the in vitro inhibitory effect of alginate on phagocytosis and opsonization, reported in this
study, occurs in vivo, it may partly explain the predominance ofmucoid Ps. aeruginosa in CF. These
effects are likely to exacerbate chronic infection with Ps. aeruginosa by protecting the bacteria from
the host's immune defences.
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